{
  "documents": [
    "i An update to this article is included at the end Kidney Disease Outcomes Quality Initiative CLINICAL PRACTICE GUIDELINE FOR NUTRITION IN chronic kidney disease: 2020 UPDATE T. Alp Ikizler, Jerrilynn D. Burrowes, Laura D. Byham-Gray, Katrina L. Campbell, Juan-Jesus Carrero, Winnie Chan, Denis Fouque, Allon N. Friedman, Sana Ghaddar, D. Jordi Goldstein-Fuchs, George A. Kaysen, Joel D. Kopple, Daniel Teta, Angela Yee-Moon Wang, and Lilian Cuppari Abstract TheNationalKidneyFoundationsKidneyDiseaseOutcomesQualityInitiative(Kidney Disease Outcomes Quality Initiative)hasprovidedevidence-based guidelinesfornutritioninkidneydiseasessince1999. SincethepublicationofthefirstKDOQInutritionguideline, there hasbeenagreataccumulationofnewevidenceregardingthemanagementofnutritionalaspectsofkidneydiseaseand sophisticationintheguidelinesprocess. The2020updatetotheKDOQIClinicalPracticeGuidelineforNutritionin CKDwasdevelopedasajointeffortwiththeAcademyofNutritionandDietetics(Academy). Itprovidescomprehensive up-to-dateinformationontheunderstandingandcareofpatientswithchronickidneydisease(chronic kidney disease), especiallyinterms oftheirmetabolicandnutritionalmilieuforthepracticingclinicianandalliedhealthcareworkers. Theguidelinewas expandedtoincludenotonlypatientswithend-stagekidneydiseaseoradvancedCKD, butalsopatientswithstages15CKDwhoarenotreceivingdialysisandpatientswithafunctionalkidneytransplant. Theupdatedguidelinestatements focuson6primaryareas: nutritionalassessment, medicalnutritiontherapy(MNT), dietaryproteinandenergyintake, nutritionalsupplementation, micronutrients, andelectrolytes. Theguidelinesprimarilycoverdietarymanagementrather thanallpossiblenutritionalinterventions. TheevidencedataandguidelinestatementswereevaluatedusingGradingof Recommendations, Assessment, Development and Evaluation (GRADE) criteria. As applicable, each guideline statement is accompanied by rationale/background information, a detailed justification, monitoring and evaluation guidance, implementationconsiderations, specialdiscussions, andrecommendationsforfutureresearch. In citing this document, the following format should be used: Ikizler TA, Burrowes JD, Byham-Gray LD, et al; Kidney Disease Outcomes Quality Initiative NutritioninCKD GuidelineWorkGroup. KDOQIclinicalpracticeguidelinefornutritioninCKD: 2020 update. Am J Kidney Dis. 2020; 76(3)(suppl 1): S1-S107. AstheyaredesignedtoreflecttheviewsandrecommendationsoftheresponsibleKDOQIWorkGroup, based ondatafromanindependentevidencereviewteam, andbecausetheyundergobothinternalandpublicreview, Kidney Disease Outcomes Quality Initiative guidelines are not peer reviewed by AJKD. AJKD Vol76Iss3Suppl1September2020 S1 Disclaimer SECTION I: USE OF THE CLINICAL PRACTICE GUIDELINE ThisClinicalPracticeGuidelinedocumentisbaseduponthebestinformationavailableasofApril2017. Itisdesignedto provide information and assist decision making. It is not intended to define a standard of care and should not be construed as one, nor should it be interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, andlimitationsuniquetoaninstitutionortypeofpractice. Everyhealthcareprofessionalmakinguseofthese recommendations is responsible for evaluating the appropriateness of applying them in the setting of any particular clinical situation. The recommendations for research contained within this document are general and do not imply a specific protocol. SECTION II: DISCLOSURE Kidney Disease Outcomes Quality Initiative (Kidney Disease Outcomes Quality Initiative) and The Academy of Nutrition and Dietetics (Academy) make every effort to avoid any actual or reasonably perceived conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the work group. All members of the work group are required to complete, sign, and submit a disclosure and attestation form showing all such relationships that mightbeperceivedoractualconflictsofinterest. AllreportedinformationisprovidedintheBiographicandDisclosure Information section of this journal supplement and is on file at the National Kidney Foundation (National Kidney Foundation). Commissionedevidencereviewincludedarticlespublishedthrough April 2017. Consensus opinion statements use literature published thoughAugust2018.",
    "Commissionedevidencereviewincludedarticlespublishedthrough April 2017. Consensus opinion statements use literature published thoughAugust2018. S2 AJKD Vol76Iss3Suppl1September2020 Work Group Membership Work Group Co-Chairs T. Alp Ikizler, MD Lilian Cuppari, PhD Vanderbilt University Medical Center Oswaldo Ramos Foundation-Hrim Nashville, TN, USA Federal University of Sao Paulo Sao Paulo, Brazil Work Group Jerrilynn D. Burrowes, PhD, RD, CDN Laura D. Byham-Gray, PhD, RD Long Island University Rutgers University Brookville, NY, USA Newark, NJ, USA Katrina L. Campbell, PhD Juan-Jesus Carrero, Pharm, PhD Pharm, PhD Med Griffith University Karolinska Institutet Brisbane, Queensland, Australia Stockholm, Sweden Winnie Chan, PhD, RD Denis Fouque, MD, PhD University of Birmingham University Claude Bernard Lyon Birmingham, United Kingdom Lyon, France Allon N. Friedman, MD Sana Ghaddar, PhD, RDN, RN Indiana University School of Medicine DaVita Healthcare Indianapolis, IN, USA San Francisco, calcium, USA D. Jordi Goldstein-Fuchs, DSc, CNN-NP, NP-C, RD George A. Kaysen, MD, PhD Lucile Packard Childrens Hospital Stanford University of California-Davis Palo Alto, calcium, USA Davis, calcium, USA Joel D. Kopple, MD Daniel Teta, MD, PhD Lundquist Institute for Biomedical Innovation Lausanne University Hospital and Hospital of Sion Harbor-UCLA Medical Center and UCLA Lausanne, Switzerland Torrance, calcium, USA Angela Yee-Moon Wang, MD, PhD, FRCP Queen Mary Hospital The University of Hong Kong Hong Kong Special Administrative Region, China Evidence Review Team Deepa Handu, PhD, RD, LDN Mary Rozga, PhD, RDN Academy of Nutrition and Dietetics Academy of Nutrition and Dietetics Chicago, IL, USA Chicago, IL, USA AJKD Vol76Iss3Suppl1September2020 S3 Kidney Disease Outcomes Quality Initiative and Academy Guideline Development Staff Kerry Willis, PhD Jessica Joseph, MBA National Kidney Foundation National Kidney Foundation New York, NY, USA New York, NY, USA Laura Brereton, MSc Debra Taylor, MPH National Kidney Foundation National Kidney Foundation New York, NY, USA New York, NY, USA Tom Manley, RN, BSN Alison Steiber, PhD, RDN National Kidney Foundation Academy of Nutrition and Dietetics New York, NY, USA Chicago, IL, USA Mary Rozga, PhD, RDN Deepa Handu, PhD, RDN, LDN Academy of Nutrition and Dietetics Academy of Nutrition and Dietetics Chicago, IL, USA Chicago, IL, USA S4 AJKD Vol76Iss3Suppl1September2020 Organizational Leadership Academy of Nutrition and Dietetics Kidney Disease Outcomes Quality Initiative Alison Steiber, PhD, RDN Michael Rocco, MD, MSCE Chief Science Officer Kidney Disease Outcomes Quality Initiative Chair Holly Kramer, MD Vice Chair, Research President, National Kidney Foundation Bernard Jaar, MD, MPH Vice Chair, Education Michael J. Choi, MD Vice Chair, Policy Past President, National Kidney Foundation A special thanks to the International Society of Renal Nutrition and Metabolism (ISRNM) who provided critical intellectual and scientific support throughout the process. ISRNM Guideline Review Panel Kamyar Kalantar-Zadeh, MD, MPH, PhD (Chair) Csaba P. Kovesdy, MD Debbie Benner, MS, RD, CSR Anita Saxena, MD, PhD Mona Boaz, RD, PhD Pieter ter Wee, MD, PhD Jing Chen, MD, PhD Amanda Brown-Tortorici, MS, RD, CSCS Christiane Drechsler, MD Giacomo Garibotto, MD Fitsum Guebre-Egziabher, MD, PhD Linda Moore, RD, PhD Mary Kay Hensley, MS, RDN, CSR Stephen Russ Price, PhD Kunitoshi Iseki, MD AJKD Vol76Iss3Suppl1September2020 S5 Table of Contents ABBREVIATIONS AND ACRONYMS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S8 FOREWORD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . S17 Draft Report With Supporting Rationale. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S17 Peer Review Process. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S17 SUMMARY OF GUIDELINE STATEMENTS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S18 Kidney Disease Outcomes Quality Initiative CLINICAL PRACTICE GUIDELINE FOR NUTRITION IN chronic kidney disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S24 GUIDELINE 1: NUTRITIONAL ASSESSMENT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S24 1. 0 Statements on Usual Care. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S24 1. 1 Statement on Technical Devices and Anthropometric Measurements to Assess Body Composition. . . . S24 1. 2 Statements on Assessment With Laboratory Measurements. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S30 1. 3 Statement on Handgrip Strength. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S33 1. 4 Statement on Methods to Assess Energy Requirements. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S34 1. 5 Statements on Composite Nutritional Indices. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S35 1. 6 Statements on Tools/Methods Used to Assess Protein and Calorie Intake. . . . . . . . . . . . . . . . . . . . S38 GUIDELINE 2: MEDICAL NUTRITION THERAPY. . . . . . . . . . . . . . . . . . . . . . . . . .",
    ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S39 2. 1 Statements on Medical Nutrition Therapy (MNT). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S39 GUIDELINE 3: Protein AND ENERGY INTAKE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S43 3. 0 Statements on Protein Amount. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S43 3. 1 Statement on Energy Intake. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S43 3. 2 Statement on Protein Type. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S48 3. 3 Statements on Dietary Patterns. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S50 GUIDELINE 4: NUTRITIONAL SUPPLEMENTATION. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S52 4. 1 Statement on Oral, Enteral, and Intradialytic Parenteral Nutrition Supplementation. . . . . . . . . . . . . . S52 4. 2 Statement on Nutrition Supplementation Dialysate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S56 4. 3 Statement on Long Chain Omega-3 Polyunsaturated Fatty Acids (LC n-3 PUFA). . . . . . . . . . . . . . . S58 GUIDELINE 5: MICRONUTRIENTS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S61 5. 0 Statements for General Guidance. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S61 5.",
    ". . . . . . . . . . . . . . . . . . S61 5. 1 Statements on Folic Acid. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S63 5. 2 Statement on Vitamin C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S64 5. 3 Statements on Vitamin D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S66 5. 4 Statement on Vitamins A and E. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S68 5. 5 Statement on Vitamin potassium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S71 5. 6 Statement on Trace Minerals Selenium and Zinc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S72 GUIDELINE 6: ELECTROLYTES. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S74 6. 1 Statements on Acid Load. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S74 6. 2 Statements on Calcium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S77 6. 3 Statements on Phosphorus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S78 6. 4 Statement on Potassium. . . . . . . .",
    ". . . . . . . S78 6. 4 Statement on Potassium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S82 6. 5 Statements on Sodium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S83 BIOGRAPHIC AND DISCLOSURE INFORMATION. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S87 REFERENCES. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S93 S6 AJKD Vol76Iss3Suppl1September2020 Tables Table 1. Key Questions for Evidence Review. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S13 Table 2. Evidence Review Inclusion and Exclusion Criteria. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S14 Table 3. Quality of Evidence Grades. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S16 Table 4. Implications of Strong and Weak Recommendations for Different Users of Guidelines. . . . . . . . . . . . S16 Table 5. Measuring Body Weight. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S30 Figures Figure 1. Flow diagram of identified studies for assessment questions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . S15 Figure 2. Flow diagram of identified studies for intervention questions. . . . . . . . . . . . . . . . . . . . . . . . . . . .",
    ". . . . . . . . . . . . . . . . . . . . S15 AJKD Vol76Iss3Suppl1September2020 S7 Abbreviations and Acronyms 25(OH)D 25-HydroxyvitaminD 1, 25(OH) D 1, 25-DihydroxyvitaminD 2 Academy AcademyofNutritionandDietetics ACE Angiotensin-convertingenzyme AGREE AppraisalofGuidelinesforResearchandEvaluation ALA α-Linolenicacid APD Animal-basedproteindiet AV Arteriovenous BF Bodyfat BIA Bioelectricalimpedanceanalysis body mass index Bodymassindex blood pressure Bloodpressure BPI Bodyproteinindex BW Bodyweight continuous ambulatory peritoneal dialysis Continuousambulatoryperitonealdialysis CI Confidenceinterval CK Creatinekinase chronic kidney disease Chronickidneydisease chronic kidney disease-EPI ChronicKidneyDiseaseEpidemiologyCollaboration chronic Kidney disease-mineral and bone disorder Chronickidneydiseasemineralandbonedisorder cPENS CompositescoreofProteinEnergyNutritionStatus CRIC ChronicRenalInsufficiencyCohort CRP C-Reactiveprotein cardiovascular disease Cardiovasculardisease DASH DietaryApproachestoStopHypertension DBP Diastolicbloodpressure DHA Docosahexaenoicacid diabetic kidney disease Diabetickidneydisease DOPPS DialysisOutcomesandPracticePatternsStudy DXA Dual-energyx-rayabsorptiometry estimated glomerular filtration rate Estimatedglomerularfiltrationrate EAAs Essentialaminoacids EPA Eicosapentaenoicacid ERT EvidenceReviewTeam end-stage kidney disease End-stagekidneydisease FGF-23 Fibroblastgrowthfactor23 FM Fatmass FFM Fat-freemass FSA Four-siteskinfoldanthropometry glomerular filtration rate Glomerularfiltrationrate GNRI GeriatricNutritionRiskIndex GRADE GradingofRecommendations, Assessment, DevelopmentandEvaluation hemodialysis Hemodialysis HDL-C High-densitylipoproteincholesterol HGS Handgripstrength heart rate Hazardratio hsCRP High-sensitivityC-reactiveprotein IBW Idealbodyweight IDPN Intradialyticparenteralnutrition IL-6 Interleukin6 IMT Intimamediathickening IOM InstituteofMedicine IPAA Intraperitonealaminoacids ISRMN InternationalSocietyofRenalNutritionandMetabolism IV Intravenous ketoanalogue Ketoacidanalogue Kidney Disease: Improving Global Outcomes KidneyDisease: ImprovingGlobalOutcomes KDQOL-SF KidneyDiseaseQualityofLifeShortForm Kidney Disease Outcomes Quality Initiative KidneyDiseaseOutcomesQualityInitiative LBM Leanbodymass LCn-3PUFA Longchainomega-3polyunsaturatedfattyacids LDL-C Low-densitylipoproteincholesterol Low protein diet Low-proteindiet MAMC Midarmmusclecircumference MDRD ModificationofDietinRenalDisease MF-BIA Multifrequencybioelectricalimpedanceanalysis MGP MatrixGlaprotein S8 AJKD Vol76Iss3Suppl1September2020 MHD Maintenancehemodialysis MHDE MaintenanceHemodialysisEquation myocardial infarction Myocardialinfarction MIS MalnutritionInflammationScore MNA MiniNutritionAssessment MNA-SF Mini-NutritionAssessment-ShortForm MNT Medicalnutritiontherapy MST MalnutritionScreeningTool MUST MalnutritionUniversalScreeningTool NAM NationalAcademyofMedicine NEAAs Nonessentialaminoacids NEAP Netendogenousacidproduction NF-κB Nuclearfactor-κB NHANES NationalHealthandNutritionExaminationSurvey NIS NutritionImpactSymptoms National Kidney Foundation NationalKidneyFoundation NPV Negativepredictivevalue NRCT Nonrandomizedcontrolledtrial nPCR Normalizedproteincatabolicrate nPNA Normalizedproteinnitrogenappearance NS Nonsignificant NST NutritionScreeningTool ONS Oralnutritionalsupplement OR Oddsratio protein-creatinine ratio Proteincatabolicrate peritoneal dialysis Peritonealdialysis protein-energy wasting Protein-energywasting PIVKA-II ProteininducedbyvitaminKabsence/antagonist-II PNA Proteinnitrogenappearance PNI ProteinNutritionIndex PPV Positivepredictivevalue PRISMA PreferredReportingItemsforSystematicReviewsandMeta-analyses parathyroid hormone Parathyroidhormone QoL Qualityoflife red blood cell Redbloodcell RCTs Randomizedcontrolledtrials RDA RecommendedDietaryAllowance RDN Registereddietitiannutritionist REE Restingenergyexpenditure REIN RamiprilEfficacyinNephropathy R-NST Renal-NutritionScreeningTool respiratory rate Riskratio RRT Renalreplacementtherapy SBP Systolicbloodpressure SD Standarddeviation SGA SubjectiveGlobalAssessment SKF Skinfoldthickness SMD Standardizedmeandifference TBF Total-bodyfat TC Totalcholesterol TG Triglycerides TNF-α Tumornecrosisfactorα TPN Totalparenteralnutrition TSF Tricepsskinfoldthickness VPD Vegetableproteindiet very Low protein diet Verylow-proteindiet vs Versus WHO WorldHealthOrganization AJKD Vol76Iss3Suppl1September2020 S9 FOREWORD It has been 20 years since the National Kidney Foundapatients with chronic kidney disease. Finally, the guideline was expanded tion (National Kidney Foundation) published the first Kidney Disease Outto include not only patients with end-stage renal disease comes Quality Initiative (Kidney Disease Outcomes Quality Initiative) nutrition guideline for or advanced chronic kidney disease, as presented in the 2000 guideline, patients with end-stage renal disease. The treatment of but also patients with stages 1-5 chronic kidney disease who are not chronic Kidney disease (chronic kidney disease) has changed dramatically receiving Dialysis and patients with a functional Kidney since the original nutrition guideline was published. This transplant. Thus, the guideline provides a comprehenguideline update reflects the many changes in both guidesive assessment of nutrition in all adult patients with line development and the management of nutritional aschronic kidney disease. pects of chronic kidney disease during that period. Implementation activities are a critical part of maxiThere are several firsts with the Kidney Disease Outcomes Quality Initiative Clinical Practice mizing the value of a clinical practice guideline. ImpleGuideline for Nutrition in chronic kidney disease: 2020 Update. First, this mentation activities will include both patient and guideline was developed as a joint effort with the professional educational resources and tools. Patient reAcademy of Nutrition and Dietetics (Academy).",
    "Patient reAcademy of Nutrition and Dietetics (Academy). The sources include the National Kidney Diet (developed by Academy served as the Evidence Review Team (ERT) for the National Kidney Foundation Council on Renal Nutrition and the Academys this guideline; this group had previously developed a Renal Practice Group), as well as the nutrition component chronic kidney disease guideline in 2010 and has developed an extensive of the National Kidney Foundation Kidney Pathways. Professional education opevidence analysis library in nutrition. The ERT conportunities will include sessions at professional conferducted 2 comprehensive literature reviews that identiences, onlinelearning, andaspeakersguide. Additionally, fied more than 15, 000 studies for possible inclusion ongoing research activities are being done to understand into the guideline. After conducting a thorough review the barriers and facilitators related to implementation of of these studies, the ERT provided the review results in the guidelines and their impact on outcomes. systematic form for the work group to evaluate and This document is the culmination of a 5-year process incorporate into the guideline document. Second, the that included members of both the ERT and work group, evidence data and guideline statements were evaluated as well as public reviews by a number of individuals and using Grading of Recommendations, Assessment, groups, including the International Society of Renal Development and Evaluation (GRADE) criteria, an eviNutritionandMetabolism. BoththeNKFandtheAcademy dence review process that did not exist when the are deeply appreciative of the work performed by these original guideline was published in 2000. The GRADE volunteers who helped craft the final guideline document. criteria have been adopted by most organizations that We would like to specifically recognize the work group write guidelines on a regular basis and are considered a chairs, T. Alp Ikizler, MD, and Lilian Cuppari, PhD, for state-of-the-art method to grade guideline statements. their tireless efforts to lead the work group in performing Third, this extensively rewritten guideline has been thisextensiveupdate. Itisthecommitmentanddedication reorganized into 6 primary topics, namely nutritional of these volunteers to the Kidney Disease Outcomes Quality Initiative process that has made assessment, medical nutrition therapy, dietary Protein this guideline document possible. and energy intake, nutritional supplementation, microAlisonSteiber, PhD, RDN nutrients, and electrolytes. This grouping should make it ChiefScienceOfficer, Academy easier for the practitioner to identify best standards of Michael V. Rocco, MD, MSCE care in particular aspects of nutritional management of Chair, National Kidney Foundation Kidney Disease Outcomes Quality Initiative 2020NationalKidneyFoundation, Inc. andtheAcademyofNutritionandDietetics. PublishedbyElsevierInc. Allrightsreserved. 0272-6386/36. 00 S10 AJKD Vol76Iss3Suppl1September2020 INTRODUCTION Background continuum and decided to include patients with chronic kidney disease During progression of chronic Kidney disease (chronic kidney disease), the stages 1-5, including those receiving maintenance Dialysis requirements and utilization of different nutrients change and Kidney transplant recipients. However, it was recogsignificantly. These changes ultimately place patients with nized that patients with acute Kidney injury represented a Kidney disease at higher risk for nutritional and metabolic significantly different nutritional and metabolic profile abnormalities. Understanding the applicable nutritional such that they were excluded from the updated guideline. principles, the available methods for assessing nutritional Inaddition, weelectednottoproviderecommendationsin status, establishing patient-specific dietary needs, and certainguidelinesforpatientswithstages1-2CKD, mainly preventing or treating potential or ongoing nutritional due to lack of clinical relevance and limited data. deficiencies and derangements is therefore essential for Several important caveats need to be considered when optimal care of the patients with chronic kidney disease. The original sodiuminterpreting and implementing the 2020 updated clinical tional Kidney Foundation (National Kidney Foundation)Kidney Disease Outpractice guideline for nutrition in chronic kidney disease.",
    "There are no comes Quality Initiative (Kidney Disease Outcomes Quality Initiative) clinical practice guideline statements provided in this update on certain guidelinefornutrition in CKDwaspublishedin 2000and nutritional management aspects of patients with chronic kidney disease, provided in-depth information regarding these principles. includingbutnotlimitedtoobesity, exercise, andanabolic Since then, there have been significant improvements in pharmacotherapy. We hope that these areas of significant the understanding and care of patients with chronic kidney disease, especlinical importance can be covered soon. We would also cially in terms of their metabolic and nutritional milieu. note that the guideline does not stratify patients based on This 2020 update of theKDOQI clinical practice guideline their ethnic or racial backgrounds, which could have fornutritioninCKDisaimedatprovidingthemostup-toobvious implications. It is our expectation that this muchdateinformationontheseissuesforthepracticingclinician needed adjustment and consideration is taken upon by and allied health care workers. researchers and clinicians for more personalized and preThe 2020 guideline differs from the previous publicacise guidelines. Finally, it is important that the uptake and tion in multiple ways. The development process included implementation of these guidelines is continuously surinvolvement of multiple groups, including National Kidney Foundation, the veilled. Thesedataaremuchneededforfurtherrefinement Academy of Nutrition and Dietetics (Academy), and the and recalibration for the best care of patients with chronic kidney disease. International Society of Renal Nutrition and Metabolism Thisguidelineistheresultofmorethan5yearsofwork (ISRNM), with each entity contributing in a different but with a substantial amount of voluntary commitment from significant fashion. The initiative was funded solely by many dedicated individuals. We believe it is a muchresourcesprovidedthroughNKFandtheAcademy. ISRNM needed update given the advancements in the care of paprovidedintellectualand scientificsupportthroughoutthe tients with chronic kidney disease during the last 2 decades. We are also process. The work group members were chosen through aware that this is a dynamic process and there is much an application and review process and specific attention more that needs to be accomplished, especially given the was paid to geographic spread and diversity in the final pace of advancements in science and technology that we selectionofworkgroupmembers. Thesystematicevidence are experiencing. We still hope that the guideline will be review and grading were completed by the Academy Evhelpful to our colleagues in its current format so that they idence Review Team (ERT). can implement these guideline recommendations in the The updated guideline statements focus on 6 primary mosteffectivewaytoimprovethelivesofthosewithCKD. areas: nutritional assessment, medical nutrition therapy (MNT), dietary Protein and energy intake, nutritional The Guideline Development Process supplementation, micronutrients, and electrolytes. The primary emphasis in the updated guideline is to provide According to the National Academy of Medicine (NAM; information on dietary management rather than covering formerly the Institute of Medicine IOM), Clinical all possible nutritional intervention strategies. The ratiopractice guidelines are statements that include recomnale for having specific areas of emphasis was that nutrimendations intended to optimize patient care that are tion is a vast subject, comprising many components of informed by a systematic review of evidence and an dietary intake. It is not possible to cover every single assessment of the benefits and harms of alternative care component of diet and we are aware that the guideline options. 1(p4) This chapter describes the process and does not cover certain areas that might be important to methods used to conduct comprehensive systematic remany patients and caregivers. The work group members views and how the findings from these systematic reviews thought that this long-waited update should be more were used to develop clinical practice nutrition guidelines focusedandcouldbefollowedbyadditionalguidelinesfor for patients with chronic kidney disease. This guideline was developed before mealsothercomponentsofnutritionalcareofpatientswithCKD.",
    "This guideline was developed before mealsothercomponentsofnutritionalcareofpatientswithCKD. cording to the Standards for Developing Trustworthy The work group members also recognized that chronic kidney disease is a Clinical Practice Guidelines as stated by the NAM. AJKD Vol76Iss3Suppl1September2020 S11 Introduction Development of these guidelines was a collaborative evaluated each candidate based on set criteria. HigherprocessbetweentheNKFandtheAcademy. Nutritionandits scoring candidates were considered for the position of managementareanintegralaspectofcareforpatientswith work group chair/co-chair. A total of 15 work group kidneydisease. Duetorecentdevelopmentsintheliterature members were selected to develop these guidelines. Two regarding treatment and assessment of chronic kidney disease, the Academy co-chairswereappointed, andtheworkgroupconsistedof and National Kidney Foundation collaborated to merge, update, and expand the physicians, registered dietitians or nutritionists, recurrent2010EvidenceAnalysisLibraryCKDguidelinesand searchers, and methodologists with expertise in the renal theKDOQInutritionguideline. Hence, theobjectiveofthis nutrition field. According to their experiences and skill initiativeistoprovideMNTguidelinesforpatientswithCKD sets, theselectedmemberswereassignedtocorresponding toassess, prevent, andtreatprotein-energywasting(protein-energy wasting), subtopics. The work group participated in all steps of the mineral and electrolyte disorders, and other metabolic cosystematic review process, which included developing morbidconditionsassociatedwithCKD. research questions, agreeing on inclusion and exclusion criteria, developing the search plan, evaluating the evidence, and approving and grading the evidence and Overview of the Guideline Development Process developing recommendation statements. All work group Guideline development is a detailed and comprehensive members and the ERT met twice for 2-day face-to-face process. Thestepsfollowedtodevelopthisguidelineareas meetings, as well as teleconference calls once a month follows (some steps were completed concurrently): for the duration of the project. 1. Selecttheworkgrouporexpertpanelthatworkswith the ERT. Guideline Focus 2. Orienttheworkgrouptothe5-stepsystematicreview Duringthefirstmeetingtheworkgroupdefinedthescope process of the Academy Evidence Analysis Center. fortheguideline. Theco-chairsdevelopedthefirstdraftof 3. Develop research questions, inclusion and exclusion the scope, which was discussed and refined by the work criteria, and a detailed search plan, as well as identify group members. It was determined that the guideline interventions and outcomes of interest. wouldfocusonnutritioninallstagesofCKDinadultsand 4. Search multiple databases based on search plan. would cover the subtopics of macronutrient, micro5. Screen abstracts and full-text articles based on a priori nutrient, and electrolyte management in chronic kidney disease. Both eligibility criteria. assessment and intervention questions under these sub6. Extractdataandcriticallyassessthequalityofincluded topicswereproposed. Threeworkgroupsweredeveloped, studies (risk of bias of studies). with 5 members assigned to each work group and a Chair 7. Synthesize evidence narratively (evidence summary appointed to help lead the work group. andconclusionstatements)andintableformat. Grade the quality of evidence for each outcome and provide Grading of Recommendations, Assessment, DevelopSystematic Review Process ment and Evaluation (GRADE) tables. This guideline followed the Academys systematic review 8. Developrecommendationstatementsbasedonthefindmethodology. An analytical framework was developed by ings of the systematic review and other important conthe ERT and refined by the work group members to help siderationsandassignstrengthofrecommendation. guide question development. During the initial telecon9. Write a guideline manuscript. ferencecallsandfirstface-to-facemeeting, theworkgroup 10. Conduct internal, external, and public review of the developed a list of questions that were deemed important guideline. for clinicians and patients (Table 1). The work group 11. Respond to reviewer comments and update the developed the a priori inclusion and exclusion criteria as guideline before publication. listed in Table 2. Acomprehensivesearchoftheliteraturewasconducted using PubMed, MEDLINE, EMBASE, and CINAHL search Work Group Selection Process engines. A first literature search was conducted to identify The Academy led the process of work group member studies addressing assessment questions and a second recruitment. To ensure appropriate expertise and limit search was conducted to identify studies addressing bias, the Evidence Based Practice Committee Work Group intervention questions to identify studies that answered Selection subcommittee followed a transparent process of more than 1 question. Inclusion criteria included in the selecting work group members. An open recruitment searchplanincludedhumanadultswithCKDaged19years messagewithalinktoonlineapplicationwascirculatedvia and older published between 1985 and December 2016. stakeholders for experts in the topic area of chronic kidney disease.",
    "Search terms included terms to identify relevant nutrition Interested candidates provided signed disclosure and interventions assessment tools in adult patients with chronic kidney disease. conflict-of-interest forms, curriculum vitae, and personal The first literature search focused on assessment quesstatementsindicatinginterestandqualificationsthatrelated tions identified 4, 857 potential studies. The Preferred to the topic. The work group selection committee then Reporting Items for Systematic Reviews and Meta-analyses S12 AJKD Vol76Iss3Suppl1September2020 Introduction Table1. KeyQuestionsforEvidenceReview Topics Questions Assessment: nutritional Whatcompositenutritionalindicesshouldbeusedtoassessnutritionalstatusand/orPEWinadults status withCKD1-5D, nondialysisandtransplant? Whattechnicaldevicesandanthropometricmeasuresshouldbeusedtoassessbodycompositionin adultswithCKD1-5D, nondialyzedandtransplant? WhatlaboratorymeasuresshouldbeusedtoassessnutritionalstatusinadultswithCKD1-5D, nondialysisandtransplant? Isthereevidencetosupporttheuseofhandgripstrengthforassessingnutritionalstatusinadults withCKD1-5D, nondialysisandtransplant? Assessment: WhatmethodsshouldbeusedtoassessdietaryintakeofenergyandproteininadultswithCKD1macronutrients 5D, nondialysisandtransplant? WhatmethodsshouldbeusedassessenergyandproteinrequirementsinadultswithCKD1-5D, nondialysisandtransplant? Assessment: micronutrients WhatmethodsshouldbeusedtoassessmicronutrientintakeinadultswithCKD1-5D, nondialysis andtransplant? WhatmethodsshouldbeusedtoassessmicronutrientneedsinadultswithCKD1-5, nondialysis andtransplant? WhatmethodsshouldbetoassessmicronutrientstatusinadultswithCKD1-5, nondialysisand transplant? Assessment: electrolytes WhatmethodsshouldbeusedtoassessdietaryelectrolyteintakeinadultswithCKD1-5D, nondialysisandtransplant? WhatmethodsshouldbeusedtoassesselectrolyteneedsinadultswithCKD1-5, nondialysisand transplant? WhatmethodsshouldbeusedtoassesselectrolytestatusinadultswithCKD1-5, nondialysisand transplant? MNT WhatistheeffectofMNTprovidedbyaregistereddietitianorinternationalequivalentonoutcomesin adultpatientswithCKD1-5D, nondialysisandtransplant? Macronutrient: Protein Whatistheeffectofproteinrestriction, withorwithoutketoanaloguesofaminoacids, intakeon restrictionandtype outcomesinadultswithCKD1-5D, nondialysisandtransplant? Whatistheeffectofproteintype(animalvsplant)intakeonoutcomesinadultswithCKD1-5D, nondialysisandtransplant? Macronutrient: dietary WhatistheeffectofspecificdietarypatternsonoutcomesinpatientswithCKD1-5, nondialysisand patterns transplant? Macronutrient: omega-3supplementation Whatistheeffectofomega3supplementationonoutcomesinadultswithCKD1-5D, nondialysis andtransplant? Macronutrient: oralnutritionsupplements WhatistheeffectoforalnutritionalsupplementationonoutcomesinadultswithCKD1-5, nondialysisandtransplant? Macronutrient: dialysatesupplements WhatistheeffectofnutritionalsupplementationviadialysateonoutcomesinadultswithCKD1-5D, nondialysisandtransplant? Macronutrient: IDPNsupplements WhatistheeffectofnutritionalsupplementationviaIDPNonoutcomesinadultswithCKD1-5D, nondialysisandtransplant? Micronutrients: interventionquestions Whatistheeffectofmicronutrientintake(Bvitamins; vitaminsC, D, E, andK; selenium; andzinc)on outcomesinadultswithCKD1-5D, nondialysisandtransplant? Electrolytes: interventionquestions Whatistheeffectofdietaryintakeof(acid-base, calcium, phosphorus, Potassium, magnesium, and Sodium)on(electrolyte)biomarkersandotherhealthoutcomesinadultswithCKD1-5D, nondialysis andtransplant? Abbreviations: chronic kidney disease, chronickidneydisease; IDPN, intradialyticparenteralnutrition; MNT, medicalnutritiontherapy; protein-energy wasting, Protein-energywasting. (PRISMA) diagram illustrating the study selection process After the search was completed, studies were systemispresentedinFigure1. Thesecondcomprehensivesearch atically screened based on additional a priori inclusion/ toansweralltheinterventionquestionsinorderidentified exclusion criteria. For intervention questions, only ran11, 017 potential studies. The PRISMA diagram illustrating domized controlled trials (RCTs) that had at least 6 instudy selection process for intervention questions is in dividuals per arm were included. Included studies Figure 2. investigated an intervention of interest (eg, Protein AJKD Vol76Iss3Suppl1September2020 S13 Introduction Table2. EvidenceReviewInclusionandExclusionCriteria Inclusion Exclusion AssessmentResearchQuestions Age Adults(aged≥18y) Youngadultsaged≤18y, infants, children, andadolescents Setting Clinicaloroutpatient Otherthanclinicaloroutpatient Healthstatus CKDofanystage, nephroticsyndrome, maintenanceHD, Canceroranyotherterminalconditionorseriouscondition long-termPD, andkidneytransplantwithdifferentCKD stages, withorwithoutdyslipidemiaanddiabetes; Kidney transplantrecipients Nutrition-related chronic kidney disease None problem/condition Studydesign (cid: 1) Diagnostic, validity, reliability studies, prediction, and/ (cid: 1) Reviewarticle; meta-analysis(pertinentreviewarticleswill preferences orcorrelationstudies behandsearched) (cid: 1) Studies need to have a comparative tool/method (cid: 1) Notaresearchstudy: postersession, commentary, letter included toeditor, greyliterature: technicalreportsfromgovernmentagenciesorscientificresearchgroups, workingpapersfromresearchgroupsorcommittees, whitepapers, positionpapers, abstracts, conferencereports, or preprints Outcomes (cid: 1) Evaluates validity, agreement, and reliability of the (cid: 1) No evaluation of validity, agreement, or reliability of the screeningtool screeningtool (cid: 1) Reports≥1ofthefollowingoutcomes: (cid: 1) Doesnotreportonatleast1oftheoutcomesofinterest - Validity(eg, constructconvergent, divergentcrite- (cid: 1) Tools evaluated as predictors of morbidity and mortality rionconcurrentorpredictive) outcomes - Reliability(eg, inter-orintrarater) - Sensitivity/specificity - Positiveand/ornegativepredictivevalue - Agreement(κ) Studydropoutrate 20%forstudies1yand30%forstudies1y 20%forstudies1yand30%forstudies1y Yearrange 1985toDecember2016 Publishedbefore1985 Authorship (cid: 1) Ifanauthorisincludedon1primaryresearcharticle Studiesbysameauthorsimilarincontent thatissimilarincontent, themostrecentreviewor articlewillbeaccepted, andearlierversionswillbe rejected (cid: 1) Ifanauthorisincludedon1reviewarticleorprimary researcharticleandthecontentisdifferent, bothreviewsmaybeaccepted Language LimitedtoarticlesinEnglish LanguagesotherthanEnglish Subjects Humans Animals Publication Publishedinpeer-reviewedjournal Notpublishedinpeer-reviewedjournal InterventionResearchQuestions Age Adults(aged≥18y) Youngadultsaged≤18y, infants, children, andadolescents Setting Clinicaloroutpatient Otherthanclinicaloroutpatient Healthstatus CKDofanystage, nephroticsyndrome, maintenanceHD, Canceroranyotherterminalconditionorseriouscondition long-termPD, andkidneytransplantwithdifferentCKD stages, withorwithoutdyslipidemiaanddiabetes; Kidney transplantrecipients Nutrition-related chronic kidney disease None problem/condition Studydesign RCTorclinicalcontrolledstudies (cid: 1) Observationalstudies preferences (cid: 1) Reviewarticle; meta-analysis(pertinentreviewarticleswill behandsearched) (cid: 1) Notaresearchstudy: postersession, commentary, letter toeditor, greyliterature: technicalreportsfromgovernmentagenciesorscientificresearchgroups, workingpapersfromresearchgroupsorcommittees, whitepapers, positionpapers, abstracts, conferencereports, or preprints (Continued) S14 AJKD Vol76Iss3Suppl1September2020 Introduction Table2(Contd). EvidenceReviewInclusionandExclusionCriteria Inclusion Exclusion Outcomes Mortality, renalreplacementtherapy, qualityoflife, (cid: 1) Doesnotreportonatleast1oftheoutcomesofinterest nutritionalstatusoutcomes, dietaryintakeoutcomes, inflammationoutcomes, anthropometrics, micronutrient biomarkers, electrolytebiomarkers, CKDprogression, comorbidconditionoutcomes(lipidprofile, Blood Hypertension) Sizeofstudygroups Forcontrolledtrials, atleast6participantsineacharm 6individualsforeachstudygroup Studydropoutrate 20%forstudies1yand30%forstudies1y 20%forstudies1yand30%forstudies1y Yearrange 1985toDecember2016 Publishedbefore1985 Authorship (cid: 1) Ifanauthorisincludedon1primaryresearcharticle Studiesbysameauthorsimilarincontent thatissimilarincontent, themostrecentreviewor articlewillbeaccepted, andearlierversionswillbe rejected (cid: 1) Ifanauthorisincludedon1reviewarticleorprimary researcharticleandthecontentisdifferent, bothreviewsmaybeaccepted. Language LimitedtoarticlesinEnglish LanguagesotherthanEnglish Subjects Humans Animals Publication Publishedinpeer-reviewedjournal Notpublishedinpeer-reviewedjournal Abbreviations: chronic kidney disease, chronickidneydisease; hemodialysis, hemodialysis; peritoneal dialysis, peritonealdialysis; RCT, randomizedcontrolledtrial. Records identified through database searching Additional records identified through other sources (n 4, 784) (n 73) Records after duplicates removed (n 3147) Records screened (n 3147) Records excluded (n 2759) Full-text articles assessed for eligibility Full-text articles excluded, (n 388) with reasons (n 263) Studies included in qualitative synthesis (n 125) Figure1. Flowdiagramofidentifiedstudiesforassessmentquestions.",
    "Flowdiagramofidentifiedstudiesforassessmentquestions. Records identified through database searching Additional records identified through other sources (n 10, 974) (n 43) Records after duplicates removed (n 10, 309) Records screened (n 10, 309) Records excluded (n 9508) Full-text articles assessed for eligibility Full-text articles excluded, (n 801) with reasons (n 247) Studies included in qualitative synthesis (n 225) Studies included in quantitative analysis (n 126) Figure2. Flowdiagramofidentifiedstudiesforinterventionquestions. AJKD Vol76Iss3Suppl1September2020 S15 Introduction Table3. QualityofEvidenceGrades information, year of publication, type of study design, Grade Definition details of intervention (type of intervention, intervention High(A) Weareveryconfidentthatthetrueeffectliescloseto duration, who delivered the intervention, setting, and thatoftheestimateoftheeffect. number of centers), participant information (sample size, Moderate(B) Wearemoderatelyconfidentintheeffectestimate: mean age, age range, sex, study inclusion and exclusion Thetrueeffectislikelytobeclosetotheestimateof criteria, and comorbid conditions), intervention infortheeffect, butthereisapossibilitythatitis mation (intervention details, comparison group details, substantiallydifferent. and medication use), outcome information (reported Low(C) Ourconfidenceintheeffectestimateislimited: the primary and secondary outcomes and time points of retrueeffectmaybesubstantiallydifferentfromthe ported outcomes), and other details such as funding estimateoftheeffect. source. Verylow(D) Wehaveverylittleconfidenceintheeffectestimate: All included studies were critically appraised for risk thetrueeffectislikelytobesubstantiallydifferentfrom of bias. Two independent reviewers assessed the theestimateofeffect. quality of studies using the Academys online risk-ofTable 2013 GRADE Working Group; reproduced from the GRADE bias tool, the Quality Criteria Checklist. The questions handbook3; withpermissionofthecopyrightholder. of the Quality Criteria Checklist are based on quality constructs and risk of bias domains identified by the restrictions, phosphorus intake, and Sodium intake) in Cochrane Collaboration and the Agency for Healthcare comparisonwithnointerventionorminimalintervention. Research and Quality. Questions examine sampling For assessment questions, only studies that tested the valbias, performance bias, detection bias, attrition bias, idity, reliability, or relationship of an assessment tool and reporting bias. Any discrepancies between the 2 against a comparative tool (reference standard) or morreviewers were resolved by consensus or by a third tality were included in this review. reviewer. The list of titles and abstracts was independently reviewed and marked for inclusion or exclusion (along Data Synthesis and Grading the Evidence with the reason) and any differences were resolved by discussion with a third reviewer. The full text of articles Descriptive synthesis of evidence was conducted for all meeting inclusion criteria were ordered and reviewed for identifiedoutcomesforwhichtherewereincludedstudies. inclusion: 225 studies met the inclusion criteria for When possible, meta-analysis was conducted using a intervention questions, and 125, for assessment articles. A random-effects model. For continuous data, results were list of excluded articles with reason for exclusion was also summarizedasmeandifferencebetweentreatmentgroups created to maintain transparency (available on the Acad- (intervention vs control/placebo) with 95% confidence emy Evidence Analysis Center website). intervals (CIs) or standardized mean difference (SMD). Dichotomous outcomes were reported as odds ratio (OR) orriskratio(respiratory rate)with95%CI. TheI2statisticwasusedto Data Extraction and Study Quality Assessment determine the degree of heterogeneity in the calculated Relevant data were extracted from the included articles effectsize, and25%, 50%, and75%wereconsideredlow, using a standardized online data extraction tool. Key inmoderate, and High, respectively. Subgroup analysis was formation extracted from each study included author conductedasappropriatetomanageclinicalheterogeneity. Table4. ImplicationsofStrongandWeakRecommendationsforDifferentUsersofGuidelines StrongRecommendation(level1werecommend) WeakRecommendation(level2wesuggest) Forpatients Mostindividualsinthissituationwouldwantthe Themajorityofindividualsinthissituationwouldwantthe recommendedcourseofactionandonlyasmallproportion suggestedcourseofaction, butmanywouldnot. wouldnot. Forclinicians Mostindividualsshouldreceivetherecommendedcourseof Recognizethatdifferentchoiceswillbeappropriatefor action. Adherencetothisrecommendationaccordingtothe differentpatientsandthatyoumusthelpeachpatientarrive guidelinecouldbeusedasaqualitycriterionorperformance atamanagementdecisionconsistentwithherorhisvalues indicator. Formaldecisionaidsarenotlikelytobeneededto andpreferences. Decisionaidsmaywellbeusefulhelping helpindividualsmakedecisionsconsistentwiththeirvalues individualsmakingdecisionsconsistentwiththeirvaluesand andpreferences. preferences. Cliniciansshouldexpecttospendmoretime withpatientswhenworkingtowardadecision. Forpolicymakers Therecommendationcanbeadaptedaspolicyinmost Policymakingwillrequiresubstantialdebatesand situations, includingfortheuseasperformanceindicators. involvementofmanystakeholders. Policiesarealsomore likelytovarybetweenregions. Performanceindicatorswould havetofocusonthefactthatadequatedeliberationabout themanagementoptionshastakenplace. Source: ReproducedwithpermissionfromtheGRADEhandbook. 3 S16 AJKD Vol76Iss3Suppl1September2020 Introduction After completion of the data extraction and data synWhen providing the level for the strength of the thesis, the ERT provided the systematic review results in 3 recommendation, a number of factors besides the formats for the work group to review, edit, and approve: quality of evidence are taken into consideration, including patient values and preferences, quality of ev1.",
    "Evidencesummary: anarrativesummaryofallincluded idence, benefits and harms, cost/resources to implement trials for each identified outcome was drafted for each the recommendation, acceptability, feasibility, and research question in the systematic review. A concluhealth equity. In addition to evidence-based recomsion statement was developed for each proposed quesmendations, in certain scenarios Opinion statements tion/outcome. The conclusion statement is a clear, were developed. These statements were developed when simple, and to-the-point answer to the proposed there was not enough evidence or evidence had too Low questions. of quality to write a graded recommendation, but the 2. Study characteristics provided information regarding work group determined it was important to provide study characteristics, sample size, population, intersome guidance to patients and practitioners. These recvention details, and quality of each included study (see ommendations are ungraded and usually refer to general Tables S1-S28). or routine practice. 3. Quality of evidence (strength of evidence): each of the When the full draft of recommendation statements was conclusion statements were assigned a GRADE2 to ready, it was reviewed and edited multiple times by all reflect the quality of studies, inconsistency of results, work group members and the ERT. The work group imprecision, indirectness of the evidence, and publiparticipated in a final blinded vote of recommendation cation bias. Using this method, the evidence for each statements, and a majority of votes approving the stateoutcome of interest was graded as A (High), B (modment wasnecessary foreachstatementto be acceptedinto erate), C (Low), or D (very Low). A GRADE table was the final guideline. generated using GradePro and demonstrated how the strength of evidence (GRADE) was derived for each outcome of interest. Draft Report With Supporting Rationale After the recommendation statements were developed, Guideline Development the work group members drafted a guideline manuscript The work group members drafted comprehensive recomthat included the supporting materials for each topic, mendationsfornutritioncareforadultswithCKD. During including rationale, detailed justification (evidence this phase, the role of the work group member was to summary), special discussions, implementation considtranslate the available evidence into action statements that erations, risks and harms, costs, and need for future were clear, concise, and ready to be implemented by research. In these sections the work group members also practitioners. The work group and ERT used the GRADE cited additional references important to the respective method for development of recommendations. The topic, including discussion of studies published after our GRADEmethodinvolves2majorcomponents: aratingfor search dates or other systematic reviews on the topic. the quality of evidence (described above) and a rating of thestrengthofrecommendations. Theevidencegradesare reportedattheendoftherecommendationstatements(eg, Peer Review Process A, B, C, or D) and reflect the confidence in the estimated These guidelines underwent a systematic peer review proeffects (Table 33). The second component is rating the cess. Thefirst phaseof reviewwasan internalreviewconstrength of the recommendation statement. This rating ducted by Kidney Disease Outcomes Quality Initiative leadership and the National Kidney Foundation Scientific reflects the extent to which one is confident that desirable Advisory Board. Feedback from this internal review was effects of an intervention outweigh undesirable effects. reviewedandincorporatedintheguidelineasappropriate. The grade for strength of the recommendation can be The second phase of the review was an external review assignedLevel1 orLevel2. Table4 shows theimplication conducted by 12 experts in this field. The AGREE II tool of each level for practitioners, clinicians, and policy (Appraisal of Guidelines for Research and Evaluation) makers. Level 1 recommendations use the terminology criteriawereusedtoassessthequalityofguidelinereport- Werecommend, whichmeansthatthiscourseofaction ing. The third phase was an open public review phase. should be applied to most people and practitioners can Reviewer comments from all phases were collated by staff have confidence that implementing this recommendation andsenttoworkgroupmembersfordiscussionandpossible has more benefit than risk. Level 2 recommendations use edits.",
    "Level 2 recommendations use edits. Work group chairs coordinated the final revision of the terminology We suggest. theguidelinedocumentbasedonreviewcomments. AJKD Vol76Iss3Suppl1September2020 S17 SummaryofGuideline Statements SUMMARYOF GUIDELINE STATEMENTS Guideline1: NutritionAssessment 1. 0StatementsonUsualCare Routine Nutrition Screening 1. 0. 1 InadultswithCKD3-5Dorposttransplantation, itisreasonabletoconsiderroutinenutritionscreeningatleastbiannually withtheintentofidentifyingthoseatriskofprotein-energywasting(OPINION). Nutrition Screening Tools 1. 0. 2 InadultswithCKD3-5Dorposttransplantation, thereislimitedevidencetosuggesttheuseofonetooloverothersfor identifyingthoseatriskofprotein-energywasting(protein-energy wasting)(2D). Routine Nutrition Assessment 1. 0. 3 In adults with chronic kidney disease 3-5D or posttransplantation, it is reasonable that a registered dietitian nutritionist (RDN) or an international equivalent conduct a comprehensive nutrition assessment (including but not limited to appetite, history of dietaryintake, bodyweightandbodymassindex, biochemicaldata, anthropometricmeasurements, andnutrition-focused physicalfindings)atleastwithinthefirst90daysofstartingdialysis, annually, orwhenindicatedbynutritionscreeningor providerreferral(OPINION). 1. 1StatementsonTechnicalDevicesandAnthropometricMeasurementstoAssessBodyComposition BioelectricalImpedanceforPatientsonMaintenanceHemodialysis(MHD) 1. 1. 1 InadultswithCKD5DonMHD, wesuggestusingbioimpedanceandpreferablymulti-frequencybioelectricalimpedance (MF-BIA)toassessbodycompositionwhenavailable. Bioimpedanceassessmentsshouldideallybeperformedaminimumof30minutesormoreaftertheendofthehemodialysissessiontoallowforredistributionofbodyfluids(2C). Bioelectrical Impedance for chronic kidney disease Patients Not on Dialysis or on Peritoneal Dialysis (peritoneal dialysis) 1. 1. 2 InadultswithCKD1-5orCKD5DonPD, thereisinsufficientevidencetosuggestusingbioelectricalimpedancetoassess bodycomposition(2D). Dual-Energy X-Ray Absorptiometry (DXA) for Body Composition Assessment 1. 1. 3 InadultswithCKD1-5Dorposttransplantation, itisreasonabletouseDXAwhenfeasibleasitremainsthegoldstandard formeasuringbodycompositiondespitebeinginfluencedbyvolumestatus(OPINION). Body Composition and Body Weight/body mass index 1. 1. 4 InadultswithCKD1-5Dorposttransplantation, itisreasonabletoconsiderassessingbodycompositionincombination withbodyweight/BMIatthefirstvisitandtomonitoroverallnutritionstatusperiodicallyovertime(OPINION). Frequency of Body Weight/body mass index and Body Composition Assessment 1. 1. 5 InadultswithCKD1-5Dorposttransplantationwhoareclinicallystable, itisreasonabletomeasurebodyweightandBMI andtomonitorforchangesinbodyweight/BMIandbodycompositionasneeded(OPINION): (cid: 1) AtleastmonthlyinMHDandPDpatients (cid: 1) Atleastevery3monthsinpatientswithCKD4-5orposttransplantation (cid: 1) Atleastevery6monthsinpatientswithCKD1-3 Assessment of Body Weight 1. 1. 6 InadultswithCKD1-5Dorposttransplantation, itisreasonableforregistereddietitiannutritionist(RDN)oraninternationalequivalentorphysicianstouseclinicaljudgmenttodeterminethemethodformeasuringbodyweight(eg, actual measuredweight; historyofweightchanges; serialweightmeasurements; adjustmentsforsuspectedimpactofedema, ascites, andpolycysticorgans)duetoabsenceofstandardreferencenorms(OPINION). body mass index as a Predictor of Mortality 1. 1. 7 InadultswithCKD5DonPD, wesuggestthatunderweightstatus(basedonBMI)canbeusedasapredictorofhigher mortality(2C). 1. 1. 8 InadultswithCKD5DonMHD, wesuggestthatoverweightorobesitystatus(basedonBMI)canbeusedasapredictorof lowermortality, whereas, underweightstatusandmorbidobesity(basedonBMI)canbeusedasapredictorofhigher mortality(2B). 1. 1. 9 In adultswith chronic kidney disease 1-5, it is reasonableto consider usingunderweight status (based onBMI) as a predictorof higher mortality, thoughthemortalityriskassociatedwithoverweightorobesitystatus(basedonBMI)isnotclear(OPINION). S18 AJKD Vol76Iss3Suppl1September2020 SummaryofGuidelineStatements 1. 1. 10 InadultswithCKDposttransplantation, itisreasonabletoconsiderusingunderweightandoverweightorobesitystatus (basedonBMI)asapredictorofhighermortality(OPINION). body mass index and protein-energy wasting 1. 1. 11 InadultswithCKD1-5Dorposttransplantation, BMIaloneisnotsufficienttoestablishadiagnosisofPEWunlessthe BMIisverylow(18kg/m2)(OPINION). Skinfold Thickness 1. 1. 12 In adults with chronic kidney disease 1-5D (1B) or posttransplantation (OPINION), in the absence of Edema, we suggest using skinfold thicknessmeasurementstoassessbodyfat. Waist Circumference 1. 1. 13 InadultswithCKD5D, wesuggestthatwaistcircumferencemaybeusedtoassessabdominalobesity, butitsreliabilityin assessingchangesovertimeislow(2C). Conicity Index 1. 1. 14 InadultswithCKD5DonMHD, wesuggestthattheconicityindexmaybeusedtoassessnutritionalstatus(OPINION)andas apredictorofmortality(2C). Creatinine Kinetics 1. 1. 15 InadultswithCKD5D, wesuggestthatcreatininekineticsmaybeusedtoestimatemusclemass, thoughveryhighorvery lowdietaryintakeofmeatand/orcreatinesupplementswillinfluenceaccuracyofthismeasurement(2C). 1. 2StatementsonAssessmentWithLaboratoryMeasurements Single Biomarker Measurements 1. 2. 1 In adults with chronic kidney disease 1-5D or posttransplantation, biomarkers such as normalized Protein catabolic rate (nPCR), serum albumin, and/or serum prealbumin (if available) may be considered complementary tools to assess nutritional status. However, theyshouldnotbeinterpretedinisolationtoassessnutritionalstatusastheyareinfluencedbynon-nutritional factors(OPINION). Serum Albumin Levels 1. 2. 2 InadultswithCKD5DonMHD, serumalbuminmaybeusedasapredictorofhospitalizationandmortality, withlowerlevels associatedwithhigherrisk(1A). 1. 3StatementonHandgripStrength 1. 3. 1 InadultswithCKD1-5D, wesuggestthathandgripstrengthmaybeusedasanindicatorofprotein-energystatusandfunctional statuswhenbaselinedata(priormeasures)areavailableforcomparison(2B). 1. 4StatementsonMethodstoAssessEnergyRequirements Assessment of Resting Energy Expenditure 1. 4. 1 InadultswithCKD1-5Dorposttransplantation, itisreasonabletouseindirectcalorimetrytomeasurerestingenergy expenditurewhenfeasibleandindicated, asitremainsthegoldstandardfordeterminingrestingenergyexpenditure (OPINION). Resting Energy Expenditure Equations 1. 4. 2 In adults with chronic kidney disease 5D who are metabolically stable, we suggest that in the absence of indirect calorimetry, diseasespecific predictive energy equations may be used to estimate resting energy expenditure as they include factors that mayinfluencethemetabolicrateinthispopulation(2C). 1. 5StatementsonCompositeNutritionalIndices 7-Point Subjective Global Assessment (SGA) 1. 5. 1 InadultswithCKD5D, werecommendtheuseofthe7-pointSubjectiveGlobalAssessmentasavalidandreliabletoolfor assessingnutritionalstatus(1B). Malnutrition Inflammation Score (MIS) 1. 5. 2 InadultswithCKD5DonMHDorposttransplantation, MalnutritionInflammationScoremaybeusedtoassessnutritional status(2C). 1. 6StatementsonTools/MethodsUsedtoAssessProteinandCalorieIntake Considerations When Assessing Dietary Intake 1. 6. 1 InadultswithCKD3-5Dorposttransplantation, itisreasonabletoassessfactorsbeyonddietaryintake(eg, medication use, knowledge, beliefs, attitudes, behavior, accesstofood, depression, cognitivefunction)toeffectivelyplannutrition interventions(OPINION). AJKD Vol76Iss3Suppl1September2020 S19 SummaryofGuideline Statements 3-Day Food Records to Assess Dietary Intake 1. 6. 2 In adults with chronic kidney disease 3-5D, we suggest the use of a 3-day food record, conducted during both Dialysis and nondialysis treatmentdays(whenapplicable), asapreferredmethodtoassessdietaryintake(2C). Alternative Methods of Assessing Dietary Intake 1. 6. 3 InadultswithCKD3-5(OPINION)orCKD5D(2D), 24-hourfoodrecalls, foodfrequencyquestionnaires, andnPCRmaybe consideredasalternativemethodsofassessingdietaryenergyandproteinintake(2D). Guideline2: MedicalNutritionTherapy 2. 0StatementsonMedicalNutritionTherapy(MNT) MNT to Improve Outcomes 2. 1. 1 InadultswithCKD 1-5D, werecommendthataregistereddietitiannutritionist(RDN)oraninternational equivalent, in closecollaborationwithaphysicianorotherprovider(nursepractitionerorphysicianassistant), provideMNT. Goalsareto optimizenutritionalstatus, andtominimizerisksimposedbycomorbidconditionsandalterationsinmetabolismonthe progressionofkidneydisease(1C)andonadverseclinicaloutcomes(OPINION). MNT Content 2. 1. 2 InadultswithCKD1-5Dorposttransplantation, itisreasonabletoprescribeMNTthatistailoredtotheindividualsneeds, nutritionalstatus, andcomorbidconditions(OPINION). MNT Monitoring and Evaluation 2. 1. 3 InadultswithCKD 3-5Dorposttransplantation, itis reasonableforthe registereddietitiannutritionist(RDN)oraninternationalequivalenttomonitorandevaluateappetite, dietaryintake, bodyweightchanges, biochemicaldata, anthropometricmeasurements, andnutrition-focusedphysicalfindingstoassesstheeffectivenessofMNT(OPINION). Guideline3: ProteinandEnergyIntake 3.",
    "MNT Monitoring and Evaluation 2. 1. 3 InadultswithCKD 3-5Dorposttransplantation, itis reasonableforthe registereddietitiannutritionist(RDN)oraninternationalequivalenttomonitorandevaluateappetite, dietaryintake, bodyweightchanges, biochemicaldata, anthropometricmeasurements, andnutrition-focusedphysicalfindingstoassesstheeffectivenessofMNT(OPINION). Guideline3: ProteinandEnergyIntake 3. 0StatementsonProteinAmount Protein Restriction, chronic kidney disease Patients Not on Dialysis and Without Diabetes 3. 0. 1 InadultswithCKD3-5whoaremetabolicallystable, werecommend, undercloseclinicalsupervision, proteinrestriction withorwithoutketoacidanalogs, toreduceriskforend-stagekidneydisease(end-stage kidney disease)/death(1A)andimprovequalityof life(QoL)(2C): (cid: 1) alow-proteindietproviding0. 550. 60gdietaryprotein/kgbodyweight/day, or (cid: 1) averylow-proteindietproviding0. 280. 43gdietaryprotein/kgbodyweight/daywithadditionalketoacid/aminoacidanalogstomeet proteinrequirements(0. 550. 60g/kgbodyweight/day) Protein Restriction, chronic kidney disease Patients Not on Dialysis and With Diabetes 3. 0. 2 IntheadultwithCKD3-5andwhohasdiabetes, itisreasonabletoprescribe, undercloseclinicalsupervision, adietary proteinintakeof0. 6-0. 8g/kgbodyweightperdaytomaintainastablenutritionalstatusandoptimizeglycemiccontrol (OPINION). Dietary Protein Intake, MHD and peritoneal dialysis Patients Without Diabetes 3. 0. 3 InadultswithCKD5DonMHD(1C)orPD(OPINION)whoaremetabolicallystable, werecommendprescribingadietary proteinintakeof1. 0-1. 2g/kgbodyweightperdaytomaintainastablenutritionalstatus. Dietary Protein Intake, Maintenance Hemodialysis and Peritoneal Dialysis Patients With Diabetes 3. 0. 4 InadultswithCKD5Dandwhohavediabetes, itisreasonabletoprescribeadietaryproteinintakeof1. 0-1. 2g/kgbody weightperdaytomaintainastablenutritionalstatus. Forpatientsatriskofhyper-and/orhypoglycemia, higherlevelsof dietaryproteinintakemayneedtobeconsideredtomaintainglycemiccontrol(OPINION). 3. 1StatementonEnergyIntake 3. 1. 1 InadultswithCKD1-5D(1C)orposttransplantation(OPINION)whoaremetabolicallystable, werecommendprescribing anenergyintakeof25-35kcal/kgbodyweightperdaybasedonage, sex, levelofphysicalactivity, bodycomposition, weightstatusgoals, CKDstage, andconcurrentillnessorpresenceofinflammationtomaintainnormalnutritionalstatus. 3. 2StatementonProteinType 3. 2. 1 InadultswithCKD1-5D(1B)orposttransplantation(OPINION), thereisinsufficientevidencetorecommendaparticular proteintype(plantvsanimal)intermsoftheeffectsonnutritionalstatus, calciumorphosphoruslevels, ortheblood lipidprofile. S20 AJKD Vol76Iss3Suppl1September2020 SummaryofGuidelineStatements 3. 3StatementsonDietaryPatterns Mediterranean Diet 3. 3. 1 InadultswithCKD1-5notondialysisorposttransplantation, withorwithoutdyslipidemia, wesuggestthatprescribinga MediterraneanDietmayimprovelipidprofiles(2C). Fruits and Vegetables 3. 3. 2 InadultswithCKD1-4, wesuggestthatprescribingincreasedfruitandvegetableintakemaydecreasebodyweight, Blood Hypertension, andnetacidproduction(NEAP)(2C). Guideline4: NutritionalSupplementation 4. 1StatementsonOral, Enteral, andIntradialyticParenteralNutritionSupplementation Oral Protein-Energy Supplementation 4. 1. 1 InadultswithCKD3-5D(2D)orposttransplantation(OPINION)atriskoforwithprotein-energywasting, wesuggesta minimumofa3-monthtrialoforalnutritionalsupplementstoimprovenutritionalstatusifdietarycounselingalonedoes notachievesufficientenergyandproteinintaketomeetnutritionalrequirements. Enteral Nutrition Supplementation 4. 1. 2 In adults with chronic kidney disease 1-5D, with chronically inadequate intake and whose Protein and energy requirements cannot be attainedbydietarycounselingandoralnutritionalsupplements, itisreasonabletoconsideratrialofenteraltubefeeding (OPINION). Total Parenteral Nutrition (TPN) and Intradialytic Parenteral Nutrition (IDPN) Protein-Energy Supplementation 4. 1. 3 InadultswithCKDwithprotein-energywasting, wesuggestatrialofTPNforCKD1-5patients(2C)andIDPNforCKD5D onMHDpatients(2C), toimproveandmaintainnutritionalstatusifnutritionalrequirementscannotbemetwithexisting oralandenteralintake. 4. 2StatementonNutritionSupplementationDialysate Dialysate Protein-Energy Supplementation 4. 2. 1 InadultswithCKD5DonPDwithprotein-energywasting, wesuggestnotsubstitutingconventionaldextrosedialysate withaminoaciddialysateasageneralstrategytoimprovenutritionalstatus, althoughitisreasonabletoconsideratrialof aminoaciddialysatetoimproveandmaintainnutritionalstatusifnutritionalrequirementscannotbemetwithexisting oralandenteralintake(OPINION). 4. 3StatementsonLongChainOmega-3PolyunsaturatedFattyAcids(LCn-3PUFA) LC n-3 PUFA Nutritional Supplements for Mortality and Cardiovascular Disease 4. 3. 1 InadultswithCKD5DonMHDorposttransplantation, wesuggestnotroutinelyprescribingLCn-3PUFA, includingthose derivedfromfishorflaxseedandotheroils, tolowerriskofmortality(2C)orcardiovascularevents(2B). 4. 3. 2 InadultswithCKD5DonPD, itisreasonabletonotroutinelyprescribeLCn-3PUFA, includingthosederivedfromfishor flaxseedandotheroils, tolowerriskofmortalityorcardiovascularevents(OPINION). LC n-3 PUFA Nutritional Supplements for Lipid Profile 4. 3. 3 InadultswithCKD5DonMHD, wesuggestthat1. 3-4g/dLCn-3PUFAmaybeprescribedtoreducetriglyceridesandLDL cholesterol(2C)andraiseHDLlevels(2D). 4. 3. 4 InadultswithCKD5DonPD, itisreasonabletoconsiderprescribing1. 3-4g/dLCn-3PUFAtoimprovethelipidprofile (OPINION). 4. 3. 5 InadultswithCKD3-5, wesuggestprescribingw2g/dLCn-3PUFAtolowerserumtriglyceridelevels(2C). LC n-3 PUFA Nutritional Supplements for Arteriovenous (AV) Graft and Fistula Patency 4. 3. 6 InadultswithCKD5DonMHD, wesuggestnotroutinelyprescribingfishoiltoimproveprimarypatencyratesinpatients withAVgrafts(2B)orfistulas(2A). LC n-3 PUFA Nutritional Supplements for Kidney Allograft Survival 4. 3. 7 In adults with chronic kidney disease posttransplantation, we suggest not routinely prescribing LC n-3 PUFA to reduce the number of rejectionepisodesorimprovegraftsurvival(2D). AJKD Vol76Iss3Suppl1September2020 S21 SummaryofGuideline Statements Guideline5: Micronutrients 5. 0StatementsforGeneralGuidance Dietary Micronutrient Intake 5. 0. 1 InadultswithCKD 3-5Dorposttransplantation, itis reasonableforthe registereddietitiannutritionist(RDN)oraninternational equivalent to encourage eating a diet that meets the recommended dietary allowance (RDA) for adequate intakeforallvitaminsandminerals(OPINION). Micronutrient Assessment and Supplementation 5. 0. 2 InadultswithCKD 3-5Dorposttransplantation, itis reasonableforthe registereddietitiannutritionist(RDN)oraninternational equivalent, in close collaboration with a physician or physician assistant, to assess dietary vitamin intake periodicallyandtoconsidermultivitaminsupplementationforindividualswithinadequatevitaminintake(OPINION). Micronutrient Supplementation, Dialysis 5. 0. 3 InadultswithCKD5Dwhoexhibitinadequatedietaryintakeforsustainedperiodsoftime, itisreasonabletoconsider supplementationwithmultivitamins, includingallthewater-solublevitamins, andessentialtraceelementstopreventor treatmicronutrientdeficiencies(OPINION). 5. 1StatementsonFolicAcid Folic Acid Supplementation for Hyperhomocysteinemia 5. 1. 1 In adults with chronic kidney disease 3-5D or posttransplantation who have hyperhomocysteinemia associated with Kidney disease, we recommend not to routinely supplement folate with or without B-complex since there is no evidence demonstrating reductioninadversecardiovascularoutcomes(1A). Folic Acid Supplementation for Folic Acid Deficiency and Insufficiency 5. 1. 2 In adults with chronic kidney disease 1-5D (2B) or posttransplantation (OPINION), we suggest prescribing folate, vitamin B12, and/or BcomplexsupplementtocorrectforfolateorvitaminB12deficiency/insufficiencybasedonclinicalsignsandsymptoms (2B). 5. 2StatementonVitaminC Vitamin C Supplementation 5. 2. 1 InadultswithCKD1-5DorposttransplantationwhoareatriskofvitaminCdeficiency, itisreasonabletoconsidersupplementationtomeettherecommendedintakeofatleast90mg/dformenand75mg/dforwomen(OPINION). 5. 3StatementsonVitaminD Vitamin D Supplementation for Vitamin D Deficiency and Insufficiency 5. 3. 1 InadultswithCKD1-5D(2C)orposttransplantation(OPINION), wesuggestprescribingvitaminDsupplementationinthe formofcholecalciferolorergocalciferoltocorrect25-hydroxyvitaminD(25(OH)D)deficiency/insufficiency. Vitamin D Supplementation With Proteinuria 5. 3. 2 InadultswithCKD1-5withnephrotic-rangeproteinuria, itisreasonabletoconsidersupplementationofcholecalciferol, ergocalciferol, orothersafeandeffective25(OH)Dprecursors(OPINION). 5. 4StatementonVitaminsAandE Vitamins A and E Supplementation and Toxicity 5. 4. 1 InadultswithCKD5DonMHDorCKD5DonPD, itisreasonabletonotroutinelysupplementvitaminAorEbecauseofthe potentialforvitamintoxicity. However, ifsupplementationiswarranted, careshouldbetakentoavoidexcessivedoses, andpatientsshouldbemonitoredfortoxicity(OPINION). 5. 5StatementonVitaminK Anticoagulant Medication and Vitamin potassium Supplementation 5. 5. 1 InadultswithCKD1-5Dorposttransplantation, itisreasonablethatpatientsreceivinganticoagulantmedicinesknownto inhibitvitaminKactivity(eg, warfarincompounds)donotreceivevitaminKsupplements(OPINION). 5. 6StatementonTraceMineralsSeleniumandZinc Selenium and Zinc Supplementation 5. 6.",
    "5. 1 InadultswithCKD1-5Dorposttransplantation, itisreasonablethatpatientsreceivinganticoagulantmedicinesknownto inhibitvitaminKactivity(eg, warfarincompounds)donotreceivevitaminKsupplements(OPINION). 5. 6StatementonTraceMineralsSeleniumandZinc Selenium and Zinc Supplementation 5. 6. 1 In adultswith chronic kidney disease 1-5D, we suggest tonot routinelysupplement selenium or zinc since there is little evidencethat it improvesnutritional, inflammatory, ormicronutrientstatus(2C). S22 AJKD Vol76Iss3Suppl1September2020 SummaryofGuidelineStatements Guideline6: Electrolytes 6. 1StatementsonAcidLoad Dietary Management of Net Acid Production (NEAP) 6. 1. 1 InadultswithCKD1-4, wesuggestreducingnetacidproduction(NEAP)throughincreaseddietaryintakeoffruitsand vegetables(2C)inordertoreducetherateofdeclineofresidualkidneyfunction. Bicarbonate Maintenance 6. 1. 2 InadultswithCKD3-5D, werecommendreducingnetacidproduction(NEAP)throughincreasedbicarbonateoracitric acid/sodiumcitratesolutionsupplementation(1C)inordertoreducetherateofdeclineofresidualkidneyfunction. 6. 1. 3 InadultswithCKD3-5D, itisreasonabletomaintainserumbicarbonatelevelsat24-26mmol/L(OPINION). 6. 2StatementsonCalcium Total Calcium Intake 6. 2. 1 InadultswithCKD3-4nottakingactivevitaminDanalogs, wesuggestthatatotalelementalcalciumintakeof800-1, 000 magnesium/d (including dietary calcium, calcium supplementation, and calcium-based phosphate binders) be prescribed to maintainaneutralcalciumbalance(2B). 6. 2. 2 InadultswithCKD5D, itisreasonabletoadjustcalciumintake(dietarycalcium, calciumsupplements, orcalcium-based binders)withconsiderationofconcurrentuseofvitaminDanalogsandcalcimimeticsinordertoavoidhypercalcemiaor calciumoverload(OPINION). 6. 3StatementsonPhosphorus Dietary Phosphorus Amount 6. 3. 1 InadultswithCKD3-5D, werecommendadjustingdietaryphosphorusintaketomaintainserumphosphatelevelsinthe normalrange(1B). Dietary Phosphorus Source 6. 3. 2 In adults with chronic kidney disease 1-5D or posttransplantation, it is reasonable when making decisions about phosphorus restriction treatmenttoconsiderthebioavailabilityofphosphorussources(eg, animal, vegetable, additives)(OPINION). Phosphorus Intake With Hypophosphatemia 6. 3. 3 For adults with chronic kidney disease posttransplantation with hypophosphatemia, it is reasonable to consider prescribing Highphosphorusintake(dietorsupplements)inordertorepleteserumphosphate(OPINION). 6. 4StatementsonPotassium Dietary Potassium Amount 6. 4. 1 In adults with chronic kidney disease 3-5D or posttransplantation, it is reasonable to adjust dietary Potassium intake to maintain serum potassiumwithinthenormalrange(OPINION). Dietary and Supplemental Potassium Intake for Hyperkalemia or Hypokalemia 6. 4. 2 InadultswithCKD3-5D(2D)orposttransplantation(OPINION)witheitherhyperkalemiaorhypokalemia, wesuggestthat dietaryorsupplementalpotassiumintakebebasedonapatientsindividualneedsandclinicianjudgment. 6. 5StatementsonSodium Sodium Intake and Blood Hypertension 6. 5. 1 InadultswithCKD3-5(1B), CKD5D(1C), orposttransplantation(1C), werecommendlimitingsodiumintaketolessthan 100mmol/d(or2. 3g/d)toreducebloodpressureandimprovevolumecontrol. Sodium Intake and Proteinuria 6. 5. 2 In adultswith chronic kidney disease 3-5 wesuggest limitingsodiumintaketo lessthan 100mmol/d(or 2. 3g/d) toreduceproteinuria synergisticallywithavailablepharmacologicinterventions(2A). Sodium Intake and Dry Body Weight 6. 5. 3 In adults with chronic kidney disease 3-5D, we suggest reduced dietary Sodium intake as an adjunctive lifestyle modification strategy to achievebettervolumecontrolandamoredesirablebodyweight(2B). AJKD Vol76Iss3Suppl1September2020 S23 Guideline 1: Nutritional Assessment Kidney Disease Outcomes Quality Initiative CLINICAL PRACTICE GUIDELINE FOR NUTRITION IN chronic kidney disease Guideline 1: Nutritional Assessment remains the gold standard for measuring body 1. 0 Statements on Usual Care composition despite being influenced by volume status (OPINION). Routine Nutrition Screening 1. 0. 1 InadultswithCKD3-5Dorposttransplantation, itis Body Composition and Body Weight/body mass index reasonable to consider routine nutrition screening 1. 1. 4 InadultswithCKD1-5Dorposttransplantation, it at least biannually with the intent of identifying is reasonable to consider assessing body compothose at risk of Protein-energy wasting (OPINION). sition in combination with body weight/body mass index at the first visit and to monitor overall nutrition Nutrition Screening Tools status periodically over time (OPINION). 1. 0. 2 In adults with chronic kidney disease 3-5D or posttransplantation, there is limited evidence to suggest the use of one Frequency of Body Weight/body mass index and Body Composition Assessment tool over others for identifying those at risk of 1. 1. 5 In adults with chronic kidney disease 1-5D or posttransplantation Protein-energy wasting (protein-energy wasting) (2D). who are clinically stable, it is reasonable to measure body weight and body mass index and to monitor for Routine Nutrition Assessment changes in body weight/body mass index and body composi1. 0. 3 InadultswithCKD3-5Dorposttransplantation, itis tion as needed (OPINION): reasonable that a registered dietitian nutritionist (cid: 1) At least monthly in MHD and peritoneal dialysis patients (RDN) or an international equivalent conduct a (cid: 1) Atleastevery3monthsinpatientswithCKD4comprehensive nutrition assessment (including but 5 or posttransplantation not limited to appetite, history of dietary intake, (cid: 1) Atleastevery6monthsinpatientswithCKD1-3 body weight and body mass index, biochemical data, anthropometricmeasurements, and nutritionAssessment of Body Weight focusedphysicalfindings)atleastwithinthefirst90 1. 1. 6 InadultswithCKD1-5Dorposttransplantation, it days of starting Dialysis, annually, or when indiis reasonable for registered dietitian nutritionist cated by nutrition screening or provider referral (RDN)oraninternationalequivalentorphysicians (OPINION).",
    "to use clinical judgment to determine the method for measuring body weight (eg, actual measured weight; history of weight changes; serial weight 1. 1 Statement on Technical Devices and measurements; adjustments for suspected impact Anthropometric Measurements to Assess Body of Edema, ascites, and polycystic organs) due to Composition absence of standard reference norms (OPINION). Bioelectrical Impedance for Patients on Maintenance Hemodialysis (MHD) body mass index as a Predictor of Mortality 1. 1. 1 InadultswithCKD5DonMHD, wesuggestusing 1. 1. 7 In adults with chronic kidney disease 5D on peritoneal dialysis, we suggest that bioimpedance and preferably multi-frequency underweightstatus(basedonBMI)canbeusedas bioelectrical impedance (MF-BIA) to assess body a predictor of higher mortality (2C). composition when available. Bioimpedance as1. 1. 8 In adults with chronic kidney disease 5D on MHD, we suggest that sessments should ideally be performed a minioverweight or obesity status (based on body mass index) can mum of 30 minutes or more after the end of the beusedasapredictoroflowermortality, whereas, hemodialysissessiontoallowforredistributionof underweight status and morbid obesity (based on body fluids (2C). body mass index) can be used as a predictor of higher mortality (2B). Bioelectrical Impedance for chronic kidney disease Patients Not on Dialysis or on Peri1. 1. 9 In adults with chronic kidney disease 1-5, it is reasonable to toneal Dialysis (peritoneal dialysis) considerusingunderweightstatus(basedonBMI) 1. 1. 2 InadultswithCKD1-5orCKD5DonPD, thereis as a predictor of higher mortality, though the insufficient evidence to suggest using bioelectrical mortality risk associated with overweight or impedance to assess body composition (2D). obesity status (based on body mass index) is not clear (OPINION). Dual-Energy X-Ray Absorptiometry (DXA) for Body Composition 1. 1. 10 InadultswithCKDposttransplantationadults, itis Assessment reasonable to consider using underweight and 1. 1. 3 InadultswithCKD1-5Dorposttransplantation, it overweight or obesity status (based on body mass index) as a is reasonable to use DXA when feasible as it predictor of higher mortality (OPINION). S24 AJKD Vol76Iss3Suppl1September2020 Guideline 1: Nutritional Assessment Regardless of the method selected to assess body body mass index and protein-energy wasting composition, noneareperfect, andtheerrorssurrounding 1. 1. 11 In adults with chronic kidney disease 1-5D or posttransplantation, them should not be ignored. Errors may have clinical body mass index alone is not sufficient to establish a diagnosis relevance, especially if the individual is treated and of protein-energy wasting unless the body mass index is very Low (18 kg/m2) observed over time. 5 Moreover, the results of the mea- (OPINION). sures are only as useful as the availability of suitable referencedatafromagroupofpersonsofatleastthesame Skinfold Thickness age, race, sex, and disease status. 1. 1. 12 In adults with chronic kidney disease 1-5D (1B) or posttransplantation (OPINION), in the absence of Detailed Justification Edema, we suggest using skinfold thickness meaTechnical Devices to Measure Body Composisurements to assess body fat. tion. MultifrequencyBIA. Twelve studies reported on the use of multifrequency BIA (MF-BIA) to assess fat mass Waist Circumference (FM) and fat-free mass (FFM) in maintenance hemodial1. 1. 13 In adults with chronic kidney disease 5D, we suggest that waist ysis(MHD), peritonealdialysis(peritoneal dialysis), andCKDpatientsnot circumference may be used to assess abdominal receiving Dialysis. Four of these studies were validity/ obesity, butitsreliabilityinassessingchangesover reliabilitystudies: 2inMHDpatients, 6, 71inPDpatients, 8 time is Low (2C). and 1 in chronic kidney disease patients not receiving Dialysis. 9 Threewerepredictionstudies: 2inMHDpatientsand1 Conicity Index in MHD and peritoneal dialysis patients. 10-12 1. 1.",
    "9 Threewerepredictionstudies: 2inMHDpatientsand1 Conicity Index in MHD and peritoneal dialysis patients. 10-12 1. 1. 14 In adults with chronic kidney disease 5D on MHD, we suggest that Eight were correlation studies; 5 in MHD pathe conicity index may be used to assess nutritients, 6, 8, 13-16 1 in peritoneal dialysis patients, 1 in MHD and peritoneal dialysis pational status (OPINION) and as a predictor of tients, 17 and 1 in chronic kidney disease patients not receiving Dialysis. 9 mortality (2C). MHD patients. FM and FFM measured using MF-BIA had Good agreement with DXA in 2 studies, 6, 7 had High Creatinine Kinetics correlations with several markers of nutritional status in 4 1. 1. 15 In adults with chronic kidney disease 5D, we suggest that Creatinine studies, 6, 15-17andpredictedhardoutcomesin3studies. 10kinetics may be used to estimate muscle mass, 12 Furstenberg and Davenport concluded that MF-BIA was though very High or very Low dietary intake of a more robust tool than DXA for measuring body meat and/or creatine supplements will influence composition in MHD patients. 7 Donadio et al found that accuracy of this measurement (2C). MF-BIA yielded a smaller prediction error in MHD patients. 6 BodycompositiondeterminedusingMF-BIAwasfound Rationale/Background to be predictive of hospitalization11 and survival. 10-12 In Methods of assessing body composition, including Rodriguesetal, BIAunderestimatedFMandoverestimated anthropometric measurements, are components of the FFM when compared with air displacement plethysmognutrition assessment in chronic kidney disease. Anthropometric measureraphy in MHD patients. 16 protein-energy wasting determined using MF-BIA ments are practical, inexpensive, and noninvasive techwas positively related to body mass index (body mass index) and niques that describe body mass, size, shape, and levels of negatively associated with serum albumin level. 15 In fatness and leanness; they are the most basic and indirect Mancini et al, bioimpedance vector analysis was predicted methods of assessing body composition. These include by normalized Protein catabolic rate (nPCR) and albumin height, weight, skinfolds, circumferences, bioelectrical level in MHD patients with normal nutritional status, but impedance analysis (BIA), Creatinine kinetics, and nearthe predictive effects were not accurate in undernourished infrared. Dual-energy x-ray absorptiometry (DXA) is a patients. 14 In MHD patients, a body Protein index (BPI) direct method that is considered the gold standard for score calculated from MF-BIA Protein mass and height assessing body composition in patients with chronic kidney disease; howsignificantly correlated with Blood Protein levels in men ever, this measure is labor intensive, invasive, and receiving MHD, but there was no relationship in women expensive and can be influenced by a number of chronic kidney diseasereceiving MHD. 17 related factors such as hydration status. peritoneal dialysis patients. FM and FFM measured using MF-BIA Timing of body composition assessments is important showed wide limits of agreement with DXA in 1 study, in chronic kidney disease because assumptions of hydration are required for which was affected by hydration status, 8 and was an inaccurate interpretation of the results, and fluid/electrolyte dependent risk factor for survival in another study. 10 In balance is likely to be altered significantly in patients with continuous ambulatory peritoneal dialysis (continuous ambulatory peritoneal dialysis) patients, lean body chronic kidney disease. For these reasons, in adults undergoing Dialysis, asmass (LBM) measured using MF-BIA and the Creatinine sessments are best obtained after treatment when body kinetic method were highly correlated but there was no fluid compartments levels are balanced. 4, 5 difference in LBM using BIA in patients with or without AJKD Vol76Iss3Suppl1September2020 S25 Guideline 1: Nutritional Assessment peritoneal dialysate. 13 A BPI score calculated from MF-BIA method of skinfold thickness measurement is very useful proteinmassandheightsignificantlycorrelatedwithblood for assessing BF in patients on long-term MHD therapy.",
    "talityinmorethan150, 000adultswithCKDwithakidney (cid: 1) Therearenopotentialrisksorharmsassociatedwiththe transplant. The authors conclude that compared with application of the guideline for body mass index. participantswithnormalweightstatusatbaseline, those (cid: 1) The standard weight status categories that have been who were underweight (heart rate, 1. 09 95% CI, 1. 02-1. 20) defined by the World Health Organization (WHO) before mealsor overweight/obese (heart rate, 1. 20 95% CI, 1. 14-1. 23) cording to body mass index ranges for adults should be used in the were at increased hazard of mortality. 65 chronic kidney disease population; these include 18. 5 kg/m2 for unNear-Infrared. Evidence examining the validity of derweight, 18. 5to24. 9kg/m2fornormalweight, 25. 0 near-infrared radiation as a measure of body composition to 29. 9 kg/m2 for overweight, and ≥30 kg/m2 for was too limited to make recommendations. obese. Population-specific body mass index cutoffs to define weight status may be lower for Asian populations. Special Discussions (cid: 1) Limited evidence suggested that obesity (body mass index ≥ 30 kg/ The guidelines for MF-BIA, DXA, and skinfold measurem2) may be a risk factor for higher mortality in inments require specialized equipment. dividuals who are receiving Dialysis and younger than Bioelectrical impedance or DXA is not routinely avail65 years. Therefore, practitioners should consider paable at all facilities and could cause undo financial burden tient age when determining mortality risk according to on the client and the facility. body mass index. Good-quality calipers are needed to obtain an accurate (cid: 1) In patients receiving Dialysis, weight to calculate body mass index measurement of SKF. However, the measurer must be should be measured following Dialysis treatment to trained to obtain accurate results. To obtain waist improve accuracy. S28 AJKD Vol76Iss3Suppl1September2020 Guideline 1: Nutritional Assessment (cid: 1) For certain patients, such as those with polycystic kidmust be used because each norm has significant drawney disease, nutrition screening using standard body mass index backs (Table 566-71). (and waist circumference) measurements is not (cid: 1) Ideal body weight (IBW) is the body weight associated suitable. with the lowest mortality for a given height, age, sex, SkinfoldMeasurements. and frame size and is based on the Metropolitan Life (cid: 1) The guideline for skinfold measurements applies to all Insurance Height and Weight Tables. (Caution: not adult patients with chronic kidney disease, including posttransplant. generalizable tothe CKDpopulation and data-gathering However, for the measurements to be useful to the methods were not standardized. ) practitioner, longitudinal assessments must be done to (cid: 1) The Hamwi method can be used to estimate IBW. provide meaningful information about changes in BF (Caution: a quick and easy method for determining percent for that patient. optimal body weight but has no scientific data to sup- (cid: 1) Therearenopotentialrisksorharmsassociatedwiththe port its use. ) application of the guideline for skinfold measurements (cid: 1) Standard body weight as used in the original Kidney Disease Outcomes Quality Initiative in all adult patients with chronic kidney disease. nutrition guideline is the median body weight of (cid: 1) Skinfold measurements may not be accurate for obese average Americans from 1976 to 1980 for height, age, patients because calipers may have upper limits that do sex, and frame size as determined by the Second sodiumnot accommodate High levels of adiposity. tional Health and Nutrition Examination Survey (NHANESII). (Caution: Althoughdataarevalidatedand Creatinine Kinetics. standardized and use a large database of ethnically (cid: 1) The guideline for using Creatinine kinetics to measure diverse groups, data are provided only on what inmuscle mass applies to all adult patients with chronic kidney disease. dividuals weigh, not what they should weigh to reduce However, the procedure requires the patient to collect morbidity and mortality. )",
    "his or her Urine for a 24-hour period and preferably to (cid: 1) body mass index often defines generalized obesity in the general keep the collection on ice, which may make the propopulation. Studiesinmaintenancedialysispatientshave cedure inconvenient for some patients. Furthermore, identified that patients at higher body mass index have lower morintake of meat or Protein supplements containing cretality risk. (Caution: the researchers may not have staatinemaycontributetourinarycreatinineexcretionand tisticallyadjustedforallconfoundersrelatedtocomorbid this must be considered when calculating Creatinine conditions occurring in chronic kidney disease on maintenance Dialysis kinetics. In MHD patients, Creatinine kinetics based on Diabetes, malignancy, etcanditisunclearhowitmay preand post-hemodialysis serum Creatinine measurements is relatetopatientswithCKDnotreceivingdialysis. ) more reliable for patients who are anuric. (cid: 1) Adjusted body weight is based on the theory that 25% (cid: 1) Therearenopotentialrisksorharmsassociatedwiththe of the excess body weight (adipose tissue) in obese application of the guideline for Creatinine kinetics in patients is metabolically active tissue. (Caution: this has adult patients with chronic kidney disease. not been validated for use in CKDand mayeither overor underestimate energy and Protein requirements. ) Dual-Energy X-rayAbsorptiometry. (cid: 1) DXA is a valid technique for measuring body compoMonitoring and Evaluation sition in adult patients with chronic kidney disease, including posttrans- (cid: 1) Anthropometric measurements for assessment of body plant patients. In MHD and peritoneal dialysis patients, this is despite composition should be done routinely in patients with the measurement being influenced by overhydration. chronic kidney disease; these include skinfold measurements, waist (cid: 1) DXA is associated with very small amounts of radiation circumference, and Creatinine kinetics. and this should be considered when weighing the (cid: 1) body mass index should be used routinely to assess weight status in benefits and risks of this method for a particular indipatients with chronic kidney disease because it is useful in predicting vidual. Ten screenings with DXA result in a similar mortality. However, inisolation, BMIisnotsufficientto amount of radiation exposure as 1 chest x-ray. establish a diagnosis of protein-energy wasting unless it is very Low (18 Measuring Body Weight. Body weight is a complikg/m2). cated measurement in chronic kidney disease and requires careful clinical (cid: 1) However, because of the cost associated with some of interpretation. Regardless of stage of chronic kidney disease, body weight these measures (eg, MF-BIA and DXA), there is insufshould be measured serially, and any sudden changes in ficientevidencefortheworkgrouptosuggesttheuseof body weight (eg, unintentional weight loss or weight these measurements on a routine basis in clinical gain) can indicate serious changes in health status. A practice. patients weight history and comparison to his or her (cid: 1) Although absolute body weight and body mass index are useful inusual body weight over time assists in determining risk dicators of nutritional status, percent change in usual for protein-energy wasting, as well as establishing optimal health goals. body weight (dry weight in maintenance Dialysis paWhen using published weight norms in the anthropotients)maybe amorereliablemeasure fordetermining metric assessment of adult patients with chronic kidney disease, caution risk for protein-energy wasting. AJKD Vol76Iss3Suppl1September2020 S29 Guideline 1: Nutritional Assessment Table5. MeasuringBodyWeight IdealBW66(Hamwi (cid: 1) Women: 100lb(45. 36kg)forfirst50(127cm)andadd5lb(2. 27kg)foreachadditionalinch(25. 4cm)50 methoda) (cid: 1) Men: 106lb(48. 08kg)forfirst50(127cm)andadd6lb(2. 72kg)foreachadditionalinch(25. 4cm)50 StandardBW67 (cid: 1) Average50thpercentileweightsformenandwomenbyage, height, andframesizeintheUS(basedonNHANESII date). TablesarepublishedinKDOQI2000NutritionGuideline. 67 DesirableBW68 (cid: 1) Basedonbodymassindex AdjustedBW69 (cid: 1) AdjustedBWidealBW(actualBWidealBW)0. 25 (cid: 1) ItisrecommendedthatBWshouldbeadjustedforcalculationofnutrientrecommendationifpatientsweightis95%or 115%ofideal/standardBW: adjustedBWEdema-freeBW(standardBWEdema-freeBW)0. 25 Edema-freeBW70 (cid: 1) Analogoustoestimateddryweightinthepatientbeingtreatedbyrenalreplacementtherapies PercentofusualBW71 (cid: 1) PercentusualBW(usualBWcurrentBW)/usualBW)100 Abbreviations: BW, bodyweight; Kidney Disease Outcomes Quality Initiative, KidneyDiseaseOutcomesQualityInitiative; NHANESII, SecondNationalHealthandNutritionExamination Survey; ultrasound, UnitedStates. aCansubtract10%forsmallframeandadd10%forlargeframe. Future Research (cid: 1) Obtain a reference data set for maintenance Dialysis patients of the same age, race, and sex. Multifrequency BIA.",
    "Multifrequency BIA. (cid: 1) Determine the frequency with which MF-BIA mea- (cid: 1) Define the criteria or threshold of waist circumference surements should be performed in patients with chronic kidney disease, in the chronic kidney disease population in defining obesity/overweight particularly in individuals who are nondialyzed, treated and whether the criteria in the general population also with peritoneal dialysis, or posttransplant. apply to patients with chronic kidney disease and Dialysis and transplant (cid: 1) Determine the validity and reliability of these meapatients. surements compared with DXA and anthropometric markers of nutritional status in peritoneal dialysis patients, posttrans1. 2 Statements on Assessment With Laboratory plant patients, and chronic kidney disease patients not receiving Dialysis. Measurements (cid: 1) Determine how to use the data from body composition to assist daily clinical practice and treatment alterations. Single Biomarker Measurements (cid: 1) Determinehowdatafrombodycompositionassessment 1. 2. 1 In adults with chronic kidney disease 1-5D or posttransplantation, and serial changes over time may predict clinical biomarkers such as normalized Protein catabolic outcomes. rate (nPCR), serum albumin, and/or serum prealbumin (if available) may be considered complementary tools to assess nutritional status. However, BodyMassIndex. (cid: 1) ExaminethepredictivevalueofBMIwithmortalityand they should not be interpreted in isolation to assess nutritional status as they are influenced by nonother markers of nutritional status in maintenance nutritional factors (OPINION). Dialysis patients of different racial and ethnic backgrounds. Determine whether the body mass index categories for Serum Albumin Levels Dialysis patients are similar to the general population. 1. 2. 2 In adults with chronic kidney disease 5D on MHD, serum albumin may be used as a predictor of hospitalization and Creatinine Kinetics. (cid: 1) Determinethefrequencywithwhichcreatininekinetics mortality, with lower levels associated with higher risk (1A). should be measured and monitored. SkinfoldMeasurements. (cid: 1) Determine the frequency with which skinfold measurements should be obtained and monitored in the Background/Rationale chronic kidney disease population. AssessmentsofnutritionalstatusinpatientswithCKDhave traditionally relied on biochemical or other related calcu- (cid: 1) Obtain a reference data set for maintenance Dialysis lated indices such as serum albumin, prealbumin, and patients of the same age, race, and sex. nPCR as diagnostic tools. Albumin is a major circulating Protein that plays a number of biological roles, such as WaistCircumference. maintainingosmoticpressureandtransportingavarietyof (cid: 1) Determine the frequency with which waist circumfermolecules. Serum prealbumin, also known as transence should be measured and monitored in the chronic kidney disease thyretin, is another circulating Protein produced by the population. Liver with a shorter half-life than albumin; it is therefore S30 AJKD Vol76Iss3Suppl1September2020 Guideline 1: Nutritional Assessment moresensitive to rapidchanges in nutritionalstatus. nPCR peritoneal dialysis patients. Of the 2 studies in peritoneal dialysis, one was a is a common tool used to estimate Protein intake and is prospective cohort study38 and the other was a retrocalculated using the intradialytic increase in serum urea spective cohort study. 78 Leinig et al78 demonstrated that nitrogenlevelinMHDpatientsandfromurinaryureafrom hypoalbuminemia was a significant independent predic24-hour Urine collection in chronic kidney disease patients not receiving tor of mortality (heart rate, 2. 3 95% CI, 1. 1-5. 0) after 24 Dialysis. The advantages of such markers include the fact months of follow-up. Churchill et al38 described that for that they are easily quantifiable and available for each paevery 1-g/L increase in serum albumin level, there was a tient. However, these markers are known to be heavily 2-year relative mortality risk of 0. 94 (95% CI, 0. 90influenced by inflammation, illness, Liver failure, volume 0. 97). expansion, and urinary or dialysate Protein losses (or in MHD and peritoneal dialysis patients. Both MHD and peritoneal dialysis patients thecaseofnPCR, proteinbalanceandotherfactors). Serum were evaluated in 2 prospective cohort studies.",
    "73, 75 In the study by de Roij van with stages 2-4 chronic kidney disease (P 0. 05). 85 Zuijdewijnetal, 34normalizedproteinnitrogenappearance In summary, serum prealbumin concentration was (nPNA nPCR) was a significant predictor of all-cause associated with nPCR, inflammatory marker levels, lean mortality (Harrell C statistic 0. 56; P 0. 01), but the and fat tissue indices, mortality, and hospitalizations in authorsreportedthatMISandserumalbuminlevelhadthe MHD patients. However, there were no studies examining best predictive value. 34 Jones et al73 and Molfino et al75 thevalidityand/orreliabilityof thismeasurecomparedto found that nPCR was a significant predictor of serum ala gold standard. bumin and prealbumin levels. peritoneal dialysis patients. Both prospective and cross-sectional Special Discussions studieswereconductedinPDpatients. Theformershowed The biochemical markers must be obtained predialysis for that nPCR was negatively correlated with anthropometric maintenance Dialysis patients. measures of body composition and positively correlated with composite nutritional index scores (r 0. 32; P Implementation Considerations 0. 001), but there was no relationship between nPCR and (cid: 1) A number of considerations must be made on the serum albumin level. 87 The latter study demonstrated that unique situation of patients with chronic kidney disease for appropriate Protein catabolic rate (protein-creatinine ratio) was not correlated with LBM screening and assessment of their nutritional status. measured using the Creatinine kinetic method or MFSome of these include fluid status, which could alter BIA. 13 body composition and biochemical markers; the presMHD and peritoneal dialysis patients. A cross-sectional study ence of systemic inflammation, which could change demonstratedthatSGAscorewasassociatedwithnPCR(r serum concentrations of acute-phase proteins; the 0. 29; P 0. 027) in a group of MHD and peritoneal dialysis patients. 88 presenceandextentofproteinuria, amajordeterminant chronic kidney disease patients not receiving Dialysis. A crossof serum albumin concentrations; and level of residual sectional study by Cigarran et al indicated that nPNA Kidney function, which could influence serum S32 AJKD Vol76Iss3Suppl1September2020 Guideline 1: Nutritional Assessment concentrations of some biochemical markers, such as Detailed Justification prealbumin, that are cleared by the kidneys. Five studies examined relationships between HGS and (cid: 1) The guideline for serum albumin applies to all adult comparative measures in patients with chronic kidney disease, including 1 patients with chronic kidney disease receiving maintenance Dialysis. study with chronic kidney disease patients not receiving Dialysis, 89 1 study (cid: 1) There are no potential risks or harms associated with with incident Dialysis patients, 83 2 studies with MHD paapplication of the guideline for measuring/monitoring tients, 90, 91 and 1 study with peritoneal dialysis patients. 8 Overall, HGS serum albumin levels in adult patients with chronic kidney disease was a valid measure of nutritional status compared to MIS receiving maintenance Dialysis. in MHD patients (sensitivity, 70%-87%; specificity, 43%- (cid: 1) The gold-standard method for measuring serum albu66%)91 and was negatively associated with MIS in chronic kidney disease min is nephelometry, which is not commonly used in patients not receiving Dialysis (r 0. 42; P 0. 001), 89 but practice due to cost and time. In patients with chronic kidney disease 3results may vary according to confounding variables. HGS 5D, the bromocresol green method should be used to was correlated with LBM assessed using other methods, estimate albumin level, whereas in patients without but there was no correlation with other markers of body chronic kidney disease or chronic kidney disease 1-2, the bromocresol purple method is composition or nutritional status in peritoneal dialysis patients. 8 In incimore accurate. dent Dialysis patients, HGS had higher correlations with nutritional status and inflammatory marker levels and was Future Research more predictive of mortality than muscle mass measured General. using DXA.",
    "4. 2 InadultswithCKD5Dwhoaremetabolicallystable, HemodialysisEquation(MHDE)moreaccuratelypredicted we suggest that in the absence of indirect caloREE than the Mifflin-St. Joer equation. Vilar et al98 also rimetry, disease-specific predictive energy equafound that their created equation for REE was the best tions may be used to estimate resting energy predictor of REE when compared with traditional predicexpenditure as they include factors that may influtive energy equations. Generally, agreement between ence the metabolic rate in this population (2C). equations and methods was Low to moderate. Special Discussions Among patients with stage 5 chronic kidney disease receiving MHD or peritoneal dialysis, Rationale/Background there are several factors that may influence energy Achieving energy balance is critical in persons diagnosed expenditurebeyondthetraditionaldeterminants(age, sex, with chronic kidney disease so that Protein-energy malnutrition and protein-energy wasting and FFM), such as hyperparathyroidism, hyperglycemia, can be prevented or treated in susceptible persons. Thus, and chronic inflammation, that should be considered in obtaining reliable data regarding dietary energy intake, as the overall energy prescription. Energy needs will be varwell as having a valid measure for energy expenditure, is iable depending on the health status of the patient (eg, paramount. acutely vs chronically ill) and overall health goals (eg, Indirect calorimetry remains as the best-practice meaweightmaintenance, repletion, orloss). Energyneedsmay sure for determining resting energy expenditure (REE) in be different depending on the stage of chronic kidney disease and its adults diagnosed with chronic kidney disease stages 1-5, including renal respectivetreatment(Dialysis vs transplant). In the context replacement therapy (RRT) patients (MHD or peritoneal dialysis patients of these recommendations, metabolically stable inor transplant recipients). More research is needed to dicates the absence of any active inflammatory or infecdemonstrate whether handheld indirect calorimetric detious diseases, no hospitalization within 2 weeks, absence vices may be a suitable alternative in this population. of poorly controlled Diabetes and consumptive diseases In the absence of indirect calorimetry, there are more such as cancer, absence of antibiotics or immunosupthan200predictiveenergyequationsavailablethatmaybe pressivemedications, andabsenceofsignificantshort-term able to estimate REE in patients diagnosed with chronic kidney disease. loss of body weight. Several have been shown to either overor underestimate Implementation Considerations REEinearlierstagesofCKD, aswellaspatientstreatedwith maintenance Dialysis. There have been several cross- (cid: 1) The registered dietitian nutritionist (RDN) should sectional studies that suggest that the energy requirements consider a number of factors when determining the of patients with earlier stages of chronic kidney disease may not be subenergy requirements for adults diagnosed with chronic kidney disease, stantiallydifferentthanforhealthyadults, buttheevidence andtheseincludethepatientsoverallhealthstatus, chronic kidney disease is limited. Recent research has shown that predictive endiagnosis and associated therapies, level of physical ergy equations specifically designed for patients with chronic kidney disease activity, age, sex, weight status, disease-specific dereceivingmaintenancedialysishavelowerbiasandgreater terminants, metabolic stressors, and treatment goals. precision. (cid: 1) Disease-specificequationsshouldbeusedwhenestimating Even the best predictive models designed for chronic kidney disease do energyrequirementsforthedifferentpatientpopulations, not account for the contribution of physical activity or suchasthosetreatedbyHDorPD(ie, MHDE). structured exercise. Reliance on current estimates for (cid: 1) Thermaleffectsoffoodmaybedecreasedinindividuals physical activity may not determine total energy rewho are nondialyzed compared with dialyzed due to quirements accurately in this population. lower Protein intake. S34 AJKD Vol76Iss3Suppl1September2020 Guideline 1: Nutritional Assessment Monitoring and Evaluation Detailed Justification Patients should be monitored routinely to assess whether Composite Nutritional Indices: Screening energy requirements are being met satisfactorily. Changes Tools. Geriatric Nutrition Risk Index. Three studies rein nutritional status should be treated and the energy ported on the use of the Geriatric Nutrition Risk Index prescription modified accordingly. (GNRI) to assess nutritional status, including 2 validity/ reliabilitystudies99, 100and1predictionstudyinMHDpaFuture Research tients. 34 In 1 study, GNRI had the greatest area under the (cid: 1) Determinetheenergyrequirementsacrossthespectrum curve(usingMISasareference)ofthenutritionscreening of Kidney disease and evaluate for the contribution of tools.",
    "100 GNRI showed a significantly negative correlation exercise and physical activity; that is, indexing total withtheMIS(r0. 67; P0. 0001), andthemostaccurate energy expenditure in chronic kidney disease. GNRIcutofftoidentifyamalnourishedpatientaccordingto (cid: 1) Uncover thekey determinants of energy expenditure in the MIS was 91. 2. The GNRIs sensitivity, specificity, and chronic kidney disease, enabling practitioners to account for them in the accuracy of a score of 91. 2 in predicting malnutrition before mealsenergy prescription. cordingtotheMISwere73%, 82%, and79%, respectively. (cid: 1) Develop and test predictive energy equations in chronic kidney disease AnotherstudyreportedthatGNRIhadahighinterobserver that can more accurately or precisely determine the agreement score (κ 0. 98) and High intraobserver reproindividuals unique energy requirements. ducibility (κ 0. 82). 99 In another study, GNRI was a significantpredictorformortalityat2. 97years(P0. 001)but 1. 5 Statements on Composite Nutritional Indices hadlowerpredictivevalueforall-causemortalitycompared withMISandalbuminlevels. 34 7-Point Subjective Global Assessment (SGA) Malnutrition Universal Screening Tool/Malnutrition 1. 5. 1 In adults with chronic kidney disease 5D, we recommend the use of Screening Tool. Two validity/reliability studies reported the 7-point Subjective Global Assessment as a valid on the use of Malnutrition Universal Screening Tool and reliable tool for assessing nutritional status (MUST) and Malnutrition Screening Tool (MST) to assess (1B). nutritional status in MHD patients. 100, 101 A study by Lawson et al101 reported on the validity and reliability of Malnutrition Inflammation Score (MIS) both MUST and MST in MHD patients. The sensitivity of 1. 5. 2 InadultswithCKDonMHDorposttransplantation, both the MUST and MST was Low (53. 8% for MUST; Malnutrition Inflammation Score may be used to 48. 7% for MST), indicating that they are not particularly assess nutritional status (2C). sensitive at identifying individuals with malnutrition in this group, compared to SGA. Both tools have High specificity (MUST, 78. 3%; MST, 85. 5%), so they are Good at Rationale/Background excluding individuals who are not malnourished. Reliabilityassessedusingκwas0. 58forMUST(95%CI, 0. 20Assessment of nutritional status in adults diagnosed with 0. 80) and 0. 33 for MST (95% CI, 20. 03-0. 54). Both tools chronic kidney disease stages 1-5D must occur on a routine basis to prevent hadanegativepredictivevalue(NPV)of60%, andpositive and/ortreatmalnutritionand wasting. TheNutritionCare predictive value (PPV) for MUST was 73. 7% and for MST Process begins with a nutrition screening, whereby key was78. 7%. Thoughthesetoolsarenotsensitiveenoughto nutritional indicators may trigger further assessment and identify all malnourished renal in-patients, they are still intervention. There are several nutrition screening mechfairlyreliableandrelatedtoothernutritionstatusmarkers. anismsinclinicalpractice, butfewarespecifictoCKDand In Yamada et al, 100 the authors compared results from therearelimiteddatafortheirvalidityandreliability. Most various malnutrition assessment tools to the reference oftheexistingtoolsfocusonidentificationofmalnutrition standard of MIS. MUST and MST scores were both signifrisk; only 1 currently screens for protein-energy wasting. Regardless of the icantly associated with MIS (P 0. 0001 for each). The mechanism used, the nutritional assessment conducted receiver operation characteristic curves of the MUST and subsequent to thescreening shouldbecomprehensiveand MST compared to MIS were the smallest of the tools includetheroutinemonitoringofnutritioncareoutcomes. measured, and sensitivity, specificity, and accuracy to The main components of the comprehensive nutrition detect hypoalbuminemia were among the lowest of all assessment comprise anthropometric measurements, biotoolsconsidered, indicatingthatthesemaynotbethebest markers, clinical symptoms exhibited on physical examitools to discriminate nutritional risk in patients on MHD. nation, dietary intake assessment, and medical/ psychosocial history. The availability of composite nutriMiniNutritionAssessment. Four studies reported on the use of Mini Nutrition Assessment (MNA) to assess tional indices (eg, the SGA or MIS) that collect such data nutritional status in MHD patients: 3 were validity/reliand therefore assist the clinician in deciding about the abilitystudies100, 102, 103and1wasacorrelationalstudy. 104 individuals nutritional status and eventual plan of care. Afsar et al102 reported on the reliability of the MNA tool Therefore, these nutritional indices are specific to the compared to the SGA 3-point scale.",
    "Four studies reported on the use of MIS as a predictor Other measures. Blumberg Benyamini et al116 of mortality. 11, 34, 103, 110 Three of the studies reported compared the integrative score with the SGA 7-point that in patients receiving MHD, MIS is a significant scaleinMHDpatients. Integrativeclinicalnutritiondialysis AJKD Vol76Iss3Suppl1September2020 S37 Guideline 1: Nutritional Assessment score is based on biochemical measures of albumin, plan prescribed and re-assess and change the plan Creatinine, urea, cholesterol, CRP, Dialysis adequacy, and accordingly to achieve the goals established. weight change. With every unit increase in integrative Future Research. score, the odds of death were significantly decreased (heart rate, 0. 929; 95% CI, 0. 885-0. 974; P 0. 002). SGA and inte- (cid: 1) More research is needed in trying to standardize the grative scores were significantly correlated (n 69; r methods for nutrition screening so that early identifi0. 853; P 0. 01), and according to the author, this is a cation and referral can result. (cid: 1) Additional investigations should focus on what comuseful prognostic tool to detect early nutrition positenutritionalindices, ifany, canbeusedreliablyin deterioration. earlier stages of chronic kidney disease. A prediction study investigated which nutritional (cid: 1) More research is needed to examine which composite composed scoring system best predicts all-cause mortality in MHD patients. 110 This study indicated that SGA score nutritional indices are appropriate for nutrition screening or assessment in people with chronic kidney disease who are andMISarebetterpredictorsofall-causemortalityat15. 5 nondialyzed. months in this study and ISRNM criteria were not able to (cid: 1) More research is needed examining the validity and predict mortality in this sample. reliability of the GNRI and SGA tools in elderly people One correlation study investigated the relationship bewith chronic kidney disease. tween body adiposity index, BIA, anthropometrics, and DXA. 117 The correlation coefficient was higher between (cid: 1) Furtherevaluationofscreeningandassessmenttoolsfor DXA versus anthropometric measurements (r 0. 76) and protein-energy wasting are necessary, especially in terms of response to body adiposity index (r 0. 61) when comparedwith BIA nutritional interventions. (r 0. 57) in the adjusted analysis (P 0. 0001). Results suggestthatBIAestimatesBFwithlimitedaccuracyinCKD 1. 6 Statements on Tools/Methods Used to Assess patients not receiving Dialysis compared with DXA. Protein and Calorie Intake SpecialDiscussions. Thelarge body of literature on Considerations When Assessing Dietary Intake nutritional assessment and composite nutritional indices 1. 6. 1 InadultswithCKD3-5Dorposttransplantation, itis has been completed in chronic kidney disease 5D. Although some of these reasonable to assess factors beyond dietary intake tools may be relevant and can be translated to earlier (eg, medication use, knowledge, beliefs, attitudes, stages(1-4)ofCKD, thereisaneedforthepractitionerto behavior, access to food, depression, cognitive conduct a comprehensive nutritional assessment function) to effectively plan nutrition interventions comprising the main domains of the Nutrition Care (OPINION). Process. protein-energy wasting, a term supported by the ISRNM, describes the 3-Day Food Records to Assess Dietary Intake complexity of nutritional and metabolic alterations that 1. 6. 2 InadultswithCKD3-5D, wesuggesttheuseofa3existinCKD. AlthoughPEWdefinitionisusefultoidentify day food record, conducted during both Dialysis patientswithovertnutritionalabnormalities, itssensitivity and nondialysis treatment days (when applicable), is Low given its strict criteria. Although comprehensive as a preferred method to assess dietary intake (2C). nutritional indices have been validated for the recognition ofapoornutritionalstatus(eg, malnutrition), itisunclear Alternative Methods of Assessing Dietary Intake how well some of these same tools may be applied in the 1. 6. 3 InadultswithCKD3-5(OPINION)orCKD5D(2D), early identification of protein-energy wasting. 24-hour food recalls, food frequency questionImplementation Considerations. naires, and nPCR may be considered as alternative (cid: 1) Routine nutrition screening of adults diagnosed with methods of assessing dietary energy and Protein chronic kidney disease stages 1-5D should occur to allow for the identiintake (2D).",
    "fication and further assessment and treatment of nutritional concerns. (cid: 1) A comprehensive nutrition assessment, using a comRationale/Background posite nutritional index, should be conducted at the Poor nutritional intake and obesity are prevalent among initial visit and completed whenever there is suspicion patients diagnosed with chronic kidney disease and therefore it is important of any change in health status or as per institutional or to monitor dietary intake that provides information on regulatory policies. total energy and macroand micronutrients, as well as Monitoring and Evaluation. The comprehensive overall food/liquid servings and eating patterns. In this nutrition assessment will guide the nutrition intervention context, it is important to identify reliable methods for prescribed. Theclinicianshouldmonitorkeynutritioncare estimating dietary intake in diverse care settings. Underoutcomes, such as dietary nutrient intake, body composiand overreporting of intake are a concern in this tion, and serum biomarker levels, based on the treatment population. S38 AJKD Vol76Iss3Suppl1September2020 Guideline 2: MedicalNutrition Therapy Detailed Justification estimates of dietary Protein intake, Sodium, and A total of 6 studies reported on the use of methods to Potassium. assess Protein and energy intake in individuals with Dietary intake methods may need to be simplified, chronic kidney disease. 118-124 modified, or combined with a few strategies to obtain reliable dietary intake data, with emphasis on them being Food Records/Diary. Based on the findings of 4 culturally appropriate. studies, food records/diary for assessing dietary intake of Protein and calories were reliable and correlated with Implementation Considerations reference standards. Food records can provide accurate (cid: 1) Routine dietary assessment among adults diagnosed information if patients are instructed and trained and food intake is recorded for at least 7 days. 120-122 Two with chronic kidney disease stages 1-5D should occur to allow for identification and treatment of nutritional concerns related studies used food diary/3-day food records to deterto nutrient intake. mine underreporting of energy intake in nondialyzed and peritoneal dialysis patients. 118, 119 Underreporting was noticed in (cid: 1) Assessing dietary intake using multiple complementary methods, such as food frequency questionnaire 72. 5% of chronic kidney disease patients not receiving Dialysis and 52. 5% and 24-hour Urine collection to measure urinary urea of peritoneal dialysis patients. Both studies indicated that undernitrogen, Sodium, and Potassium, may be useful to reporting was more pronounced in overweight patients. confirm the accuracy of dietary intake estimates. Shapiro et al compared energy intake measured using 3day food record (dietitian interviewassisted) and REE (cid: 1) Dietary assessment should be conducted at the initial visit and completed whenever there is a change in measured using indirect calorimetry. Energy intake rehealth status or as per institutional or regulatory ported by interview-assisted food records was lower than measured REE. 124 policies. Food Frequency Questionnaires. Delgado et al conducted a validation study comparing Block Brief 2000 Monitoring and Evaluation food frequency questionnaire against 3-day food diary A thorough assessment of dietary intake will guide the records125 and found that the Block Brief 2000 food frenutrition intervention prescribed. The clinician should quency questionnaire underestimated energy and macromonitor key nutrition care outcomes based on the treatnutrient intake in patients receiving hemodialysis. However, simple mentplanandre-assessandchangetheplanaccordinglyto calibration equations can be used to obtain intake similar achieve the goals established. to 3-day food diary records. Future Research Protein Catabolic Rate. Three studies examined (cid: 1) Identifythebest methodsfordietaryassessmentamong the use of protein-creatinine ratio to assess Protein intake in patients with CKD123, 126, 127 and found significant correlations with adults diagnosed with chronic kidney disease stages 1-5D and those receiving a Kidney transplant. reference standards for measuring dietary intake (eg, (cid: 1) Focus on how to better determine instances of underfood records).",
    "reference standards for measuring dietary intake (eg, (cid: 1) Focus on how to better determine instances of underfood records). However, protein-creatinine ratio overestimated Protein intake when daily Protein intake was 1 g/kg, and and overreporting of dietary intake in this population. when daily Protein intake was 1 g/kg, it was (cid: 1) Further development and testing of dietary assessment tools that integrate technology to patient care and assist underestimated using protein-creatinine ratio. In peritoneal dialysis patients, Protein individuals with limited literacy and vision and are nitrogen appearance (PNA) (protein-creatinine ratio) normalized to culturally appropriate. desirable body weight was correlated better with Blood urea nitrogen level (r 0. 702) and dialysis adequacy measure (r 0. 348). 127 Guideline 2: Medical Nutrition Therapy Special Discussions 2. 1StatementsonMedicalNutritionTherapy(MNT) Despite the food record/diary being the most reliable MNT to Improve Outcomes and valid measure of dietary intake among patients 2. 1. 1 In adults with chronic kidney disease 1-5D, we recommend that a diagnosed with chronic kidney disease, it relies on accurate reporting registered dietitian nutritionist (RDN), or an ininclusive of portion sizes. The food record may be seen ternational equivalent, in closecollaborationwith a as cumbersome to complete for several days and is physician, or other provider (nurse practitioner or limited to individuals who are able to read and record physician assistant), provide MNT. Goals are to intake reliably. With the generation of smartphone optimize nutritional status, and to minimize risks applications, there has been a burgeoning interest in imposed by comorbid conditions and alterations recording dietary intake using technology, with limited in metabolism on the progression of Kidney success in its adoption among certain subgroups (eg, disease (1C) and on adverse clinical outcomes the elderly). In chronic kidney disease patients not receiving Dialysis, 24- (OPINION). hour Urine collection to measure urinary urea nitrogen, Sodium, and Potassium is more reliable to yield AJKD Vol76Iss3Suppl1September2020 S39 Guideline 2: MedicalNutrition Therapy (cid: 1) providing individualized meal plans and follow-up on MNT Content adherenceandsuccessfulimplementation. Interventions 2. 1. 2 InadultswithCKD1-5Dorposttransplantation, itis include but are not limited to weight management and reasonable to prescribe MNT that is tailored to the maintenance/repletion of patient nutritional status; individualsneeds, nutritionalstatus, andcomorbid (cid: 1) addressing inflammation, obtaining a euvolemic state, conditions (OPINION). contributing to correction of electrolyte abnormalities, assisting in anemia management, and managing bone MNT Monitoring and Evaluation disease through nutrition assessment and dietary in2. 1. 3 InadultswithCKD3-5Dorposttransplantation, itis terventions including individualized meal plans; reasonable for the registered dietitian nutritionist (cid: 1) assisting in identifying medication errors and need for (RDN) or an international equivalent to monitor adjustment in collaboration with nephrology provider and evaluate appetite, dietary intake, body weight (medical doctor, nurse practitioner, or physician changes, biochemical data, anthropometric meaassistant); surements, and nutrition-focused physical findings (cid: 1) providing and updating nutrition therapy as new to assess the effectiveness of MNT (OPINION). knowledge emerges. Detailed Justification Rationale/Background MNT requires nutrition screening and assessment of Individualized management of nutritional intake is a nutritional status to provide individualized treatment for crucial aspect of care for individuals diagnosed with any specific disease states. Patients with chronic kidney disease are on a dynamic stage of chronic kidney disease, including those receiving maintenance nutrition trajectory according to their disease stage and Dialysis and those who have received a Kidney transplant. MNT is needed at each stage of chronic kidney disease. Metabolic abnorThesepatientsarevulnerablefornutritionalabnormalities, malities and acid-base and fluid and electrolyte balances which are associated with higher risk for morbidity, oftenchangeasCKDprogresses. Forexample, apatientcan mortality, and length of hospital stay.",
    "Forexample, apatientcan mortality, and length of hospital stay. Nutritional needs be hypokalemic during stage 2 chronic kidney disease, requiring Potassium change throughout the disease course, from the earlier supplementation and a High-Potassium diet. Months or stages of chronic kidney disease to the posttransplant period. The metabolic years later, this same patient during stage 4 chronic kidney disease might abnormalitiesandcomorbiddiseasesthatoftenaccompany become hyperkalemic, requiring medication adjustment chronic kidney disease further emphasize the need for specialized nutrition and dietary Potassium restriction rather than supplemenhealth care. Therefore, it is essential that such individuals tation. Shouldthissamepatientreceiveakidneytransplant, receivetailorednutritionassessmentandcounselinginthe he or she might stabilize Potassium balance and have no form of MNT. MNT is a collaborative approach that typineed for Potassium supplementation or dietary Potassium cally requires the medical expertise and prescription of restriction. This type of complicated patient with chronic kidney disease MNT by a physician or other provider (nurse practitioner requires specialized nutrition health care and ongoing or physician assistant) and implementation by an RDN or monitoring by a nephrology RDN. international equivalent). These roles are not mutually SixteenRCTsexaminingtheeffectofMNTonnutritionexclusive and involve ongoing team-patient analysis and related outcomes were identified in the systematic review discussion. Participating providers and RDNs are recom- (Table S7). However, these studies wereheterogeneous in mended to have received specialized education and terms of the populations (5 studies included patients who training in nutrition and chronic kidney disease in accordance with the rewere nondialyzed, 9 included patients receiving MHD, 1 quirements set forth by local regulations. included patients receiving continuous ambulatory peritoneal dialysis, and 1 included patients Medical Nutrition Therapy. In 2002, the American posttransplant), interventions (eg, RDNs used various Dietetic Association published a nutrition care model that methodsofnutritionalcounselingamongthestudies), and provided evidence-based High-quality standardized care outcomes (ex: Protein intake, serum phosphate level, for patients with chronic kidney disease, nondialyzed and posttransplant. 128 serumalbuminlevel, body mass index, anddyslipidemia). Intervention The document was later revised in 2010, which reported durations ranged from 4 weeks to 2 years. that nutrition care provided by a registereddietician up to chronic kidney disease Progression. In4ofthestudiesrangingfrom4 twice monthly over a 1-year period can have a valuable weeksto4months, theauthorsfoundnoeffectofMNTon role in the medical care of patients with chronic kidney disease by: chronic kidney disease progression in chronic kidney disease patients not receiving Dialysis (cid: 1) providing nutrition assessment and interventions to compared with participants receiving standard nutrition delay Kidney disease progression in addition to coeducation for chronic kidney disease, which may or may not have also been morbid conditions such as Diabetes mellitus, cardioprovidedbyanRDN. Interventionsrangedfrom1in-person vascular disease (cardiovascular disease), dyslipidemia, gout, and contactplustelephonecontactswiththeRDNfor12weeks nephrolithiasis; (stage 4 chronic kidney disease)129 to a multidisciplinary intervention (cid: 1) using behavioral methods to individualize the approach including 4 weeks of weekly counseling with an RDN and minimize barriers to individualized goals; (stages 3-4 chronic kidney disease)130 to two 2-hour cooking classes and a S40 AJKD Vol76Iss3Suppl1September2020 Guideline 2: MedicalNutrition Therapy shoppingtour(stages2-4CKD)131tonutritioncounseling on arm and waist circumference, as well as body plusnutritioneducationfor4months(stages3-5CKD). 132 composition, were limited and unclear. SGA Scores. Three RCTs, including 2 study popPhosphate Levels. Eight studies examined the effect ulations, reported on the effect of MNT on SGA scores. of MNTonphosphorus/phosphate levelsinMHD patients Campbell et al demonstrated that malnourished patients for durations ranging from 8 weeks to 6 months. In with stage 4 chronic kidney disease had SGA scores that significantly Ashurst Ide and Dobbie135 and Lou et al, 136 phosphorusimproved in the intervention group compared with the focused education, provided once and monthly for 6 control group, for whom malnutrition by SGA score months, respectively, significantly improved (decreased) increased. 129 The intervention consisted of nutritional mean serum phosphate levels.",
    "There was a sigwhich consisted of a Low glycemic index and moderate nificant increase in mean Low-density lipoprotein cholesenergydeficit. MNTcounselingwasbasedontheStagesof terol (LDL-C) and a significant decrease in mean HighChange Model. 134 There was no difference in change in density lipoprotein cholesterol (HDL-C) levels in both body mass index between groups after 2 years. groups during the 4-month study period (P 0. 001 for In a meta-analysis of 2 studies, participants who each measure). Between-group analysis was not reported. received MNT had a greater mean decrease in body mass index BothHowdenetal130andFlesheretal131examinedthe comparewiththecontrolgroups(0. 8995%CI, 1. 52to effect of MNT in participants with stages 3-4 chronic kidney disease. In 0. 25kg/m2. 132, 134ResultsregardingtheeffectofMNT Howden et al, 130 intervention participants received a AJKD Vol76Iss3Suppl1September2020 S41 Guideline 2: MedicalNutrition Therapy multidisciplinary lifestyle intervention for 12 months. It protocols, and analyses. Therefore, this section included 4 weeks of group behavioral and lifestyle modiincluded recommendations that are mostly opinion fication by an RDN and a psychologist. No significant based. changeswereobservedinTG, TC, HDL-C, orLDL-Clevels MNT facilitates the delivery of Nutrition Practice betweenthe2groups. InFlesheretal, 131inadditiontothe Guidelines through a systemic approach of delivery that is standard nutrition care for chronic kidney disease, the intervention group based on scientific evidence and expert opinion. The edreceived cooking classes over 4 weeks for 2 hours per ucation, content, and practice expertise for the provision sessionandashoppingtourledbyanRDN. Nosignificant of MNT individualized care is found within the scope of difference was observed in mean TC levels between the 2 practice of the RDN with expertise in nephrology. groups. PooledanalysisconfirmednoeffectofMNTonTC and TG levels. However, in pooled analysis, LDL-C levels Implementation Considerations were decreased by MNT (mean, 6. 022 95% CI, 7. 754 (cid: 1) Evidence-based protocols are inherent to MNT but also to 4. 290 milligrams per deciliter). There was no clear effect of MNT on require individualized modification. Blood Hypertension (blood pressure). (cid: 1) Implementation of MNT for patients with chronic kidney disease requires the formation of a fiscal structure that will ProteinIntake. Six RCTs examined the effect of MNT support the integration of MNT into routine medical on Protein intake in patients with chronic kidney disease. Two of those management of patients with chronic kidney disease. The interest level studiestargetedproteinintakeastheirprimaryoutcomeof to integrate MNT into clinical practice exists by many the MNT provided to the participants. nephrology and general medicine clinics; however, Paes-Barreto et al132 educated nondialysis patients on the lack of adequate reimbursement for RDN services eating a Low-Protein diet (Low protein diet), whereas Leon et al133 may preclude the opportunity to pursue counseled MHD participants on following a High-proimplementation. tein diet. Both studies showed High adherence to the (cid: 1) DemandforMNTisgrowingastheglobalprevalenceof recommended Protein intake among participants in the chronic kidney disease increases. Reimbursement policies for disease intervention group as compared with the control group. prevention need to include MNT. Legislation awareness The other 4 studies did not show any significant differisneededtodisseminatethevalueofMNTaspartofthe ences in Protein intake between the intervention and comprehensive chronic kidney disease care. control groups, but Protein intake was not the primary (cid: 1) MNT may be delivered through telehealth options to outcome. improve patient education and successful maintenance The use of MNT protocols has the potential to preserve of nutrition interventions and adherence to reduce nutritional status, modify risk factors for progression of health care manpower. kidneydisease, andassistwithlivingwithCKDfromadiet and lifestyle perspective through teaching patients healthy food choices in an individualized manner.",
    "kidneydisease, andassistwithlivingwithCKDfromadiet and lifestyle perspective through teaching patients healthy food choices in an individualized manner. Monitoring and Evaluation MonitoringandevaluationofMNTonpatientsnutritional Special Discussions parameters is an essential component of treatment and The full utility and value of MNT provided by the includes assessment of patients clinical status (body RDN on both nutrition outcomes and risk for weight is the most straightforward and least costly and morbidity, mortality, and hospitalizations has not yet readily available test), laboratory tests, nutritional status, been fully identified. The impact of the RDN in many cause of Kidney disease, lifestyle (stress, exercise, evaluadisease states and the value of repeated contacts with tion of smoking and alcohol use, etc), and patient-idenan RDN on specific nutrition parameters has been tified nutrition goals. documented in the literature. 143 This is particularly true for patients with chronic kidney disease, as well as in other disease Future Research states and metabolic phenotypes such as obesity that (cid: 1) Development of an MNT database is imperative to the affect chronic kidney disease risk and exacerbation of chronic kidney disease progression. formalization of MNT outcomes research. Although MNT outcomes research is still in its infancy, (cid: 1) EvaluationoftheimpactofMNTcareonprogressionof the studies that exist exhibit important relationships Kidney disease by analysis of association with risk facon nutrition parameters and other outcomes. An MNT tors of comorbid conditions is necessary. database that monitors MNT intervention effectiveness (cid: 1) Patient outcomes pertaining to the individualized on nutrition and overall outcome parameters would nutrition plan formulated for patients and/or enable the formalization of this analysis. Studies that group classes to evaluate the effectiveness and prove causality or significant association between MNT adherence of the therapy should be explored in application and patient outcomes are currently in future studies. progress. In addition, the strength of the evidence in (cid: 1) Research examining access to MNT, as well as methods the studies reviewed prohibits strong recommenda- (fiscal, referral, etc) that support MNT access for intions due to the variability in study populations, dividuals with chronic kidney disease worldwide. S42 AJKD Vol76Iss3Suppl1September2020 Guideline 3: Protein andEnergyIntake Guideline 3: Protein and Energy Intake Rationale/Background Proteinmetabolisminthebodyisresponsibleforadequate 3. 0 Statements on Protein Amount growthinchildrenandmaintenanceofbodyproteinmass ProteinRestriction, CKDPatientsNotonDialysisandWithoutDiabetes such as muscle mass in adults. Every day, approximately 3. 0. 1 In adults with chronic kidney disease 3-5 who are metabolically sta250 g of Protein are catabolized, leading to Protein catable, we recommend, under close clinical supervibolic products such as urea and many other known or sion, Protein restriction with or without keto acid unidentified compounds. Most of these degradation analogs, to reduce risk for end-stage Kidney disease products are normally cleared bythe kidneys and excreted (end-stage kidney disease)/death (1A) and improve quality of life in Urine. When Kidney function declines, there will be an (QoL) (2C): accumulation of these by-products into the Blood, which (cid: 1) a Low-Protein diet providing 0. 550. 60 g dietary will progressively impair organ function. 144 This has been Protein/kg body weight/day, or clearly identified for compounds such as p-cresyl sulfate, (cid: 1) a very Low-Protein diet providing 0. 280. 43 g diindoxyl sulfate, trimethyl aminoxide, and fibroblast etary Protein/kg body weight/day with additional growth factor 23 (FGF-23), which are now considered as keto acid/amino acid analogs to meet Protein reuremic toxins. Second, Protein intake is responsible for a quirements (0. 550. 60 g /kg body weight/day) major fraction of Kidney workload, and much experimentalandclinicalresearchhasconfirmedtherenaleffects Protein Restriction, chronic kidney disease Patients Not on Dialysis and With Diabetes of a Protein load and a deleterious role of the renal 3. 0.",
    "0. 2 In the adult with chronic kidney disease 3-5 and who has Diabetes, it hyperfiltration response associated with Protein intake. is reasonable to prescribe, under close clinical suTherefore, in a situation of nephron reduction such as pervision, adietaryproteinintakeof0. 6-0. 8g/kg chronic kidney disease, reducing Protein intake will reduce hyperfiltration, bodyweightperdaytomaintainastablenutritional with an additive effect to those of angiotensin-reducing status and optimize glycemic control (OPINION). drugs. 144 As a consequence of both actions, reducing uremia and uremic toxins on one hand and improving Dietary Protein Intake, MHD and peritoneal dialysis Patients Without Diabetes renal hemodynamics on the other hand, a reduction in 3. 0. 3 In adults with chronic kidney disease 5D on MHD (1C) or peritoneal dialysis proteinintakemayreduceclinicalsymptomsandpostpone (OPINION) who are metabolically stable, we the need to start maintenance Dialysis treatment. recommend prescribing a dietary Protein intake of In the context of these recommendations, metaboli1. 0-1. 2 g/kg body weight per day to maintain a cally stable indicates the absence of any active inflamstable nutritional status. matory or infectious diseases, no hospitalization within 2 weeks, absence of poorly controlled Diabetes and DietaryProteinIntake, MaintenanceHemodialysisandPeritonealDialysis consumptive diseases such as cancer, absence of antibiotic Patients With Diabetes or immunosuppressive medications, and absence of sig3. 0. 4 In adultswith chronic kidney disease 5D and who have Diabetes, it is nificant short-term loss of body weight. Another considreasonable to prescribe a dietary Protein intake of eration is determination of body weight for diet 1. 0-1. 2 g/kg body weight per day to maintain a prescription. Becausethebodyweightsuggested(whether stable nutritional status. For patients at risk of hyIBW, body mass index, usual or current, or adjusted) depends on perand/or hypoglycemia, higher levels of dietary clinician judgment related to the patients health goals Protein intake may need to be considered to (Guideline Statement 1. 1. 6), the specific weight formula maintain glycemic control (OPINION). usedforprescriptionshouldbepersonalizedtothepatient. Detailed Justification Energy Intake. Energy metabolism may be impaired inpatientswithCKD. Hence, maintainingadequateenergy intake is necessary to prevent protein-energy wasting. 3. 1 Statement on Energy Intake Evidence from 10 controlled trials in predialysis pop3. 1. 1 In adults with chronic kidney disease 1-5D (1C) or postulations andfrom3studies inMHDpatientsindicatesthat transplantation (OPINION) who are metabolically energyintakerangingfrom30to35kcal/kgperdayhelps stable, werecommendprescribinganenergyintake maintain neutral nitrogen balance and nutritional staof 25-35 kcal/kg body weight per day based on tus. 145-157 However, it is important to remember that age, sex, level of physical activity, body composimany other factors may influence energy expenditure tion, weightstatusgoals, CKDstage, andconcurrent beyondtraditionaldeterminantssuchasage, sex, andFFM. illness or presence of inflammation to maintain Some of these factors include hyperparathyroidism, hynormal nutritional status. perglycemia, and chronic inflammation that should be considered into the overall energy prescription; health AJKD Vol76Iss3Suppl1September2020 S43 Guideline 3: Protein andEnergyIntake status(eg, acutelyillvsmanagedlongterm); overallhealth cumulative incidences of death and Dialysis therapy start goals; and weight maintenance, repletion or loss. were unaffected by the diet regimen, and a Low-ProteinThereisstillapaucityofcontrolledmetabolicstudies, as intakegroup(0. 55g/kgperday)doesnotseemtoconfer well as long-term well-designed outpatient clinical trials, a survival advantage compared with a moderate-Proteinstudying energy intake in this population. Results from an intakegroup(0. 80g/kgperday)butmaybeexplainedby old metabolic study examining energy requirements in arelativelysmallsamplesize. Pooledtogether, resultsfrom MHD (sample size 6) indicated that mean energy intake the secondary analysis of the number of events of death/ of 35 kcal/kg per day helped maintain neutral nitrogen end-stage kidney disease combined from the 3 studies indicated a beneficial balanceandbodycomposition. 158Anothersimilarstudyin effect of Protein restriction on death/end-stage kidney disease (OR, 0. 621; 6 individuals indicated that average intake of 38 kcal was 95% CI, 0. 391-0. 985). 153, 161, 164 desirable to maintain neutral nitrogen balance. 159 Recent Qualityoflife.",
    "3-0. 5 g/kg Protein/kg per day) supplemented with KAs. cated a decrease in TC and TG levels only in the very Low protein diet group. Coggins et al171 indicated a significant decrease in Are LPDs/VLPDs plus KAs indicated for patients with chronic kidney disease with protein-energy wasting? This question cannot easily be answered TC, HDL-C, andLDL-ClevelsintheVLPDgroup. Garneata et al147 showed that cholesterol levels remained stable becauseitmaydependonthecauseofpatientwasting. For example, an acute catabolic state may induce protein-energy wasting despite during the entire duration of the study; however, patients nutrient intake that is normally considered adequate. were taking statins/fibrates as standard therapy. Therefore, priorityshouldbegiventothecorrectionofthe Dietary Protein intake and Diabetes mellitus. Nutrition cause of wasting and Protein and energy intake should be plays a significant role in the management of individuals increased until the wasting state improves. An Low protein diet/very Low protein diet with diabetic Kidney disease (diabetic kidney disease) in conjunction with plus ketoanalogue should not be started during a catabolic state in pharmacologic interventions. The goal is to maintain patients with chronic kidney disease and should be implemented only in optimal glycemic control and at the same time maintain metabolicallystablepatientswithout intercurrent illnesses. adequate Protein and energy intake to achieve optimal Do an Low protein diet and very Low protein diet plus KAs have an impact on nutritional status. There are some previous guidelines that nutritional status? In a post hoc analysis of the MDRD AJKD Vol76Iss3Suppl1September2020 S47 Guideline 3: Protein andEnergyIntake Study, 150 the authors compared the randomly assigned (cid: 1) Energy needs may be different depending on the stage groups (Low protein diet vs very Low protein diet plus KAs) for various outcomes of chronic kidney disease and its respective treatment (Dialysis vs related to nutritional status. Overall, the results demontransplantation). strate the safety of dietary Protein restriction over 2 to 3 years in patients with moderate to advanced chronic kidney disease. ProteinRestriction. However, there were small but significant changes from (cid: 1) Increase the training and number of specialized renal baseline in some nutritional indices and minimal differdietitians worldwide who could effectively and safely ences between the randomly assigned groups in some of implement LPDs and VLPDs. these changes. In both Low protein diet and very Low protein diet plus KAs, both (cid: 1) Promote Low-Protein products to simplify dietary Protein and energy intake declined. Serum albumin levels counseling and help achieve an Low protein diet. increased, while serum transferrin levels, body weight, (cid: 1) Be more aggressive with dietary interventions to percent BF, arm muscle area, and Urine Creatinine improve symptoms when maintenance Dialysis is not a excretion declined. In a longitudinal study looking at treatment option or needs to be postponed (vascular body composition, a very Low protein diet plus ketoanalogue induced a small access maturation or organizing a preemptive Kidney decline in LBM on the average of 1. 2 kg, with transplant). concomitant increase in FM, mainly in the first 3 months. (cid: 1) The need for food information is important to obtain These parameters subsequently stabilized and even Good adherence to the restricted Protein intake. Howimproved slightly thereafter. 193 Other short-term studies ever, therapeutic education can help patients improve did not show noticeable effects of LPDs and VLPDs plus personal motivation and can even become a personal KAs on nutritional parameters. Nevertheless, the small goal to achieve. Getting more interested in food haranthropometric measurement declines observed in some vesting, preparation, andcookingmayimproveQoL.",
    "Nevertheless, the small goal to achieve. Getting more interested in food haranthropometric measurement declines observed in some vesting, preparation, andcookingmayimproveQoL. In studies are of concern because in routine practice, LPDs addition, postponing initiation of Dialysis undoubtedly and VLPDs plus KAs are used in the long term and maintains a better QoL rather than undergoing mainbecause of the adverse effect of protein-energy wasting in patients with tenance Dialysis. 194 end-stage kidney disease. This is why physicians who prescribe LPDs must (cid: 1) Certain patient populations such as patients with polyregularly monitor patients Protein and energy intake, cystic Kidney disease do not benefit from an Low protein diet or body weight, and nutritional status. very Low protein diet. Individualdietaryplansshouldbeconsideredfor these patients. Implementation Considerations EnergyIntake. Monitoring and Evaluation (cid: 1) Energy intake of patients with chronic kidney disease should take into Adherencetodietsshouldbemonitoredfrequentlyduring account the patients overall metabolic state and cothe first year of dietary intervention using dietary inmorbid conditions. Accordingly, the recommended terviews (3 is optimal) and 24-hour Urine collection for range should be personalized to each patient. urinary urea nitrogen excretion to assist monitoring di- (cid: 1) The RDN should consider a number of factors when etary adherence. Then twice-yearly follow-up may be determining the energy requirements for adults diagrecommended until the start of maintenance Dialysis. nosed with chronic kidney disease, and these include the patients overall health status, chronic kidney disease diagnosis and associated therapies, Future Research level of physical activity, age, sex, weight status, (cid: 1) Determine whether an Low protein diet has an additive or a synermetabolic stressors, and treatment goals. gistic effect to that of renin-angiotensin aldosterone (cid: 1) Patients should be monitored routinely to assess system antagonists or newer nephroprotective agents whether energy requirements are being met satisfacto- (ie, Sodium-glucose transport Protein 2 inhibitors) on rily. Changes in nutritional status should be treated and proteinuria and nephroprotection through RCTs. the energy prescription modified accordingly. (cid: 1) Examine the impact of an Low protein diet and very Low protein diet with or (cid: 1) Among patients with stage 5 chronic kidney disease receiving maintewithout KAs on gut microbiota in patients with chronic kidney disease. nance Dialysis (hemodialysis or peritoneal dialysis), there are several factors that (cid: 1) Investigate at which chronic kidney disease stage it is best to initiate dimay influence energy expenditure beyond the tradietary Protein intake modification. tional determinants (age, sex, and FFM), such as hy- (cid: 1) Examine ways and strategies to improve adherence and perparathyroidism, hyperglycemia, chronic compliance with LPDs and VLPDs plus KAs. inflammation, infections, and other intercurrent illnessesthatshouldbeconsideredintotheoverallenergy prescription. 3. 2 Statement on Protein Type (cid: 1) Energy needs will be variable depending on the health status of the patient; for example, acutely versus 3. 2. 1 In adults with chronic kidney disease 1-5D (1B) or postchronically ill versus, overall health goals, and weight transplantation (OPINION), there is insufficient evmaintenance, repletion, or loss. idence to recommend a particular Protein type S48 AJKD Vol76Iss3Suppl1September2020 Guideline 3: Protein andEnergyIntake ProteinCatabolicRate. VPDsmaybeassociatedwith (plant vs animal) in terms of the effects on nutria decrease in protein-creatinine ratio after 6 months, but evidence was tional status, calcium or phosphorus levels, or the limited. InSorokaetal, 200PCRwassignificantly(P0. 05) Blood lipid profile. lowerafter6monthsofaVPDcomparedwiththeprestudy diet, buttherewerenochangesintheAPD. Inasecondary analysis, there was a mean difference of 0. 10 (95% CI, 0. 17to0. 03)g/kgperdayinPCRswiththeVPDversus theAPD. Thismighthavebeentheconsequenceofslightly Rationale/Background reduced absorption of Protein from vegetal source (estiVegetable Protein diets (VPDs) may have beneficial effects mated to be 90% of animal Protein). on health. A recent population-based study suggested that soy or soy isoflavones intake significantly reduced the risk Prealbumin Levels.",
    "However, the power to TC, LDL-C, HDL-C, and TG levels within or between discriminate might have been insufficient due to the small groups. However, in hyperlipidemic patients, soy Protein number of patients enrolled. In pooled analysis of 4 lead to a significant decrease in TC, LDL-C, and TG levels studies, there was no effect of Protein type on serum alcompared with milk Protein, whereas HDL-C levels bumin levels. AJKD Vol76Iss3Suppl1September2020 S49 Guideline 3: Protein andEnergyIntake significantlyincreased. Tabibietal202comparedtheimpact (cid: 1) Examine the impact of a very Low protein diet on the generation of of a soy Protein supplement versus control in peritoneal dialysis patients toxic middle molecules. and found no significant impact on TC, LDL-C, HDL-C, and TG levels in the intervention group. Soroka et al200 3. 3 Statements on Dietary Patterns found no significant differences after a VPD, APD, or prestudydietonTC, LDL-C, andTGlevelsinpatientswith Mediterranean Diet stage 4 chronic kidney disease. HDL-C level was significantly lower after a 3. 3. 1 In adults with chronic kidney disease 1-5 not on Dialysis or postVPD compared with the prestudy diet. transplantation, with or without dyslipidemia, we In pooled analysis of 3 studies, there was no mean suggest that prescribing a Mediterranean Diet may difference in TC, LDL-C, HDL-C, or TG levels between improve lipid profiles (2C). groups. Fruits and Vegetables Special Discussions 3. 3. 2 InadultswithCKD1-4, wesuggestthatprescribing VPDs have been studied to test metabolic hypotheses in increased fruit and vegetable intake may decrease patients with chronic kidney disease. In particular, phosphorus may be less body weight, Blood Hypertension, and net acid proabsorbed during a VPD, which may benefit calcium and duction (NEAP) (2C). phosphate metabolism. This becomes more important because currently processed food contains much added inorganic phosphorus as compared with a VPD. The fat content of a VPD possesses a healthier profile and may Rationale/Background benefit patients in long-term studies. Finally, toxic middle Dietary patterns reflect the variety of foods that represent molecules such as p-cresyl sulfate, indoxyl sulfate, and habitual dietary intake. 204 Particular dietary patterns, trimethylamine oxide, almost exclusively produced from including the Mediterranean diet, the Dietary Approach to animal source Protein, could be reduced by VPDs and this StopHypertension(DASH), andplant-basedanddietshigh hypothesis should be tested in long-term clinical trials in in fruits and vegetables (including vegetarian diets) are patients with chronic kidney disease. As demonstrated in other subtopics of examples of healthy dietary patterns that have been the this guideline, VPDs have shown reduction in acid load, subject of interest in nutritional epidemiology. 205 A increase in dietary fiber intake, and reduction of phosphatewhole-diet approach considers the synergistic effects of phorusandbodyweight. Thereisincreasinginterestinthe nutrients resulting in cumulative effects on health and role of VPDs in chronic kidney disease due to the benefits of this dietary disease. 205 pattern on cardiovascular disease risk factors in the general population. chronic kidney disease presents many challenges for nutrition manageHowever, current evidence from RCTs specifically ment, including increased risk for death and appreciable comparing benefits of a VPD versus an APD in patients cardiovascular disease burden among affected persons. Traditionally, with chronic kidney disease is limited. nutrition education has focused on individual nutrients, such as Protein, phosphorus, Potassium, and Sodium. Implementation Considerations Recent evidence has linked healthy dietary patterns with (cid: 1) Work with patients to help them meet their individureduced chronic cardiovascular disease and mortality risk in the healthy population. 206-208 However, these relationships have not alized dietary Protein and energy intake needs. (cid: 1) Based on the preference of the patient with chronic kidney disease for been explored conclusively with the chronic kidney disease population.",
    "209 from4to13yearsoffollow-up(respiratory rate, 0. 7395%CI, 0. 63However, 1 NRCT reported on the effect of the Medi0. 83). terranean dietary pattern on albuminuria in adults with A recent Cochrane review of 6 RCTs evaluated dietary patterns in chronic kidney disease (1 study n 191 of a carbohydratestages 2 and 3 chronic kidney disease, and both Mediterranean diet groups (normal and organic) had significant reductions in alburestrictedlow-ironpolyphenolenricheddiet, 2studiesn minuria values compared with the Low-Protein group. 210 355 of a Mediterranean diet, 2 studies n 181 of increasedfruitandvegetableintake, and1studyn12ofa High Fruit and Vegetable Dietary Pattern. chronic kidney disease High-Protein/Low-carbohydrate diet). From this review, progression. Inadultswithstages3-4CKD, thefruitsand dietary interventions had uncertain effects on all-cause vegetables dietary pattern has mixed effects on estimated glomerular filtration rate mortality and cardiovascular events. However, with Lowcompared with oral bicarbonate supplementation. 212, 213 qualityevidence, therewasreducedSBPandDBPandhigher Body weight. Two RCTs reported on the effect of a GFRsandalbuminlevelsfollowingdietaryinterventions. 216 fruit and vegetable dietary pattern on body weight in Although the intervention studies examining dietary adults with chronic kidney disease. Goraya et al213 reported that the group patterns in chronic kidney disease are limited, there is consistent evidence following the fruit and vegetable dietary pattern had from observational analyses on dietary patterns containing greater net body weight loss than both the oral-bicarfruits, vegetables, whole grains, lean meats, Low-fat dairy, bonate and standard-care groups (P 0. 05). Goraya et and Low added salt and improved clinical outcome al212 reported lower body weight in adults with chronic kidney disease (notably mortality) in chronic kidney disease. 215 A recent study confirmed stages 3-4 following a fruit and vegetable dietary pattern that intake of nuts, Low-fat dairy products, and legumes is compared with the oral bicarbonate supplementation protective against the development of chronic kidney disease. 217 There is groupatthe1-yearfollow-up(P0. 01; meandifference, therefore a need to undertake future trials to further 5. 09; 95% CI, 7. 73 to 2. 44 kg; I2 56%). investigate more holistic dietary interventions over singleBlood Hypertension. Three studies (2 RCTs and 1 nutrient approaches in these patients. Dietary pattern may NRCT) reported on the effect of increased fruit and improve additional outcomes not reported in the systemvegetable intake on blood pressure in adults with chronic kidney disease. All 3 atic review, including constipation. studies indicated that increased intake of fruit and vegetable had a significant effect on lowering SBP Implementation Considerations compared with the oral bicarbonate supplement intake group or standard-care group. 212-214 Goraya et al213 (cid: 1) The safety and acceptability of various dietary patterns, indicated reductions in SBPs in all groups; however, includingtheDASHandMediterraneandiets, withhigh the 3-year value for the fruits and vegetables group intakes of fruit and vegetables must be determined on was lower than those in bicarbonate and control. anindividualbasisinadvancedstagesofkidneydisease, Goraya et al212 showed that compared with the biespecially in regard to serum Potassium control and carbonate group, the fruit and vegetables group had adequacy of Protein and energy intake. AJKD Vol76Iss3Suppl1September2020 S51 Guideline 4: Nutritional Supplementation (cid: 1) Individualized support and follow-up may be required Rationale/Background to support patients in implementing and adhering to protein-energy wasting is common among patients with chronic kidney disease, especially complex dietary changes. those undergoing maintenance Dialysis therapy, 218 and is associated with increased morbidity and mortality. 219 The cause of protein-energy wasting in patients with chronic kidney disease is complex and Monitoring and Evaluation multifactorial and includes reduced energy and Protein Adherence to dietary patterns in clinical trials can be intake resulting from anorexia and dietary restrictions, challenging. Engagingaprocessofself-monitoringagainst inflammation, hypercatabolism, Protein losses during food group targets may assist with supporting adherence.",
    "Studydurationsrangedfrom12weeksto13. 5 oral and enteral intake. months. Seven of the RCTs included participants with S52 AJKD Vol76Iss3Suppl1September2020 Guideline 4: Nutritional Supplementation some level of malnutrition at baseline. 221-226, 230, 235 In 11 in patients receiving MHD of 3 to 13. 5 months contrast, 5 studies did not actively enroll malnourished duration, 1RCT227inpatientsreceivingMHDandPDof6 patients. 226-229, 231 Of the NRCTs, Sezer et al234 enrolled months duration, 2 RCTs225, 228 in patients receiving peritoneal dialysis malnourished patients as defined by serum albumin level of 6 months duration, and 1231 in patients with chronic kidney disease 3-4 or weight loss, Cheu et al232 enrolled patients with of 24 weeks duration. Overall, the literature suggested hypoalbuminemia, and Scott et al233 did not actively rethat Protein-energy ONS modestly improved serum albucruit patients with malnutrition. min levels, though the results should be interpreted with caution. A pooled analysis of 11 studies221-228, 231, 233, 234 Mortality, Hospitalizations, and QoL. One NRCT that included patients with chronic kidney disease 3-5D found that ONS examined the effect of ONS on mortality in 276 patients modestly improved serum albumin levels as compared receiving MHD who were treated with ONS for a Low with controls (mean difference, 0. 121 95% CI, 0. 006serum albumin level versus 194 similar patients who 0. 236 grams per deciliter). However, a subgroup analysis found the refused ONS or for whom treatment was deemed inapeffect to be significant only when using Protein-energy propriate. 232 No difference in mortality (heart rate, 0. 70 95% ONS223, 224, 226, 228, 233, 234(meandifference, 0. 1695%CI, CI, 0. 36-1. 35)wasnotedoveramediandurationof13. 5 0. 08-0. 24 grams per deciliter) and not energy221, 231 or Proteinmonths. based222, 225, 227 supplements. Heterogeneity of results in Two RCTs227, 230 and 1 NRCT232 evaluated the effect of the pooled analysis was High (I2 68. 3%; P 0. 001) so ONS on hospitalization over a period of 6 to 13. 5 months results should be interpreted cautiously. in patients receiving MHD or peritoneal dialysis. A pooled analysis of the One RCT in 86 patients receiving MHD reported that 2 RCTs227, 232 found no significant difference in the odds ONS did not influence serum prealbumin levels as of hospitalization by group assignment, but an NRCT232 compared with dietary advice. 224 Two RCTs of 3 to 6 reported a 34% reduction in risk of hospitalization (heart rate, months duration in patients receiving MHD reported 0. 66 95% CI, 0. 50-0. 86) by 12 months in patients conflicting effects of ONS on total-Protein levels, perhaps receiving ONS compared with controls. related to the type of ONS. 2211, 222 The first study of 30 Threestudies(2RCTs223, 224and1NRCT233), eachof3 patients reported a positive effect on total-Protein levels months duration, examined the effect of ONS on QoL using an amino acidbased ONS, 222 while a second of 21 measures in patients receiving MHD. One RCT223 and 1 patients found no effect of a 6-month energy-based ONS NRCT233 reported that patients receiving general223 or intervention. 221 Twostudies (an RCT221 and an NRCT233) renal-specific233 Protein-energy ONS had higher QoL in patients receiving MHD of 3 to 6 months duration scores in the domains of physical functioning223, 233 and found no effect of ONS on serum transferrin levels, either bodily pain223 compared to receiving dietary advice individually or in a pooled analysis. only223 or no supplementation, 233 but another RCT224 reported that renal-specific Protein-energy ONS did not Anthropometric Measurements. The effect of ONS influence QoL scores in any domain.",
    "The effect of ONS influence QoL scores in any domain. A pooled analysis of onanthropometricindicesvariedinlargepartaccordingto the 2 RCTs223, 233 found that ONS did not significantly the type of ONS used, with the greatest effects being seen influence bodily Pain, physical functioning, or general in 1 study221 that used an energy-based ONS. health QoL domain scores. Bodymassindex. Sevenstudies(6RCTs221-226and1 NRCT234) evaluated the effect of ONS on body mass index during a 3chronic kidney disease Progression. An RCT231 conducted for 24 to 6-month period. Six of the studies were conducted in weeks examined the effect of an energy-based ONS on patients receiving MHD221-224, 226, 234 and 1 in patients progression of chronic kidney disease in 109 patients with chronic kidney disease 3-4 who receivingPD. 225Apooledanalysisdemonstratednooverall were following an Low protein diet. Although no difference in serum effect of ONS on body mass index, though the study using an energyCreatinine levelsor eGFRswasobserved betweenONSand based ONS noted an increase in body mass index. 221 Overall, the hetcontrols, there was a comparativereduction in proteinuria erogeneity was moderate (I2 49. 8%; P 0. 06). in the ONS arm (P 0. 05). Body weight. Six studies (5 RCTs and 1 NRCT) Composite Nutritional Scores and Biochemical investigated theeffect of ONS on body weight over 3 to 6 Markers of Nutritional Status. A 3-month RCT in 18 months in patients receiving MHD221, 222, 229, 233 or PD228 patients receiving MHD examined the effect of a foodand patients with chronic kidney disease 3-4. 231 Overall, ONS was linked based ONS on SGA scores. 223 The authors describe a to increased body weight but mainly in patients receiving significantly greater SGA score improvement in patients MHD consuming an energy-based supplement. However, receiving ONS compared with patients receiving nutri1 RCT in patients receiving peritoneal dialysis that used a Protein-based tionalguidanceonly. OneNRCTfoundthatONSovera6ONSreportedincreasedbodyweight. 228Apooledanalysis monthperioddidnotinfluencetheMISascomparedwith of all 6 studies221, 222, 228, 229, 231, 233 found higher body dietary advice. 234 weight in the ONS group compared with the control arm Fifteen studies (12 RCTs221-225, 227-231, 236 and 3 (mean, 2. 7795%CI, 1. 19-4. 36kg)inpatientswithCKD NRCTs232-234) examined the effect of ONS on serum al3-5D. However, the difference was mainly driven by enbumin levels in patients with chronic kidney disease 3-5D. These included ergy-based ONS in patients on MHD. AJKD Vol76Iss3Suppl1September2020 S53 Guideline 4: Nutritional Supplementation Dialysistargetweight. Fourstudies(3RCTs223, 224, 235 studies222-225, 227, 228, 234 found that ONS significantly and 1 NRCT234) in patients receiving MHD223, 224, 234, 235 increased nPCR in patients receiving Dialysis (SMD, 0. 29 examined the effect of ONS on Dialysis target weight over 95% CI, 0. 04-0. 53), suggesting a potentially clinically a3-to6-monthperiod. Overall, noeffectofONSontarget relevant effect. However, a subgroup analysis found the weight was observed, though 1 NRCT234 reported an ineffect to be significant only in persons receiving Proteincreaseintargetweightusingarenal-specificprotein-energy based222, 225, 227 but not Protein-energybased ONS, 234 as did 1 RCT236 using a Protein-based ONS. A ONS. 223, 224, 228, 234 Similar results were noted in a pooled pooled analysis of 3 studies223, 224, 234 found no overall efanalysis of 3 studies224, 225, 228 examining the effects of fect. Hiroshigeetal236reportedresultsinafigureandcould ONS on reported Protein intake in which ONS increased notbeincludedinpooledanalysis. reported Protein intake in only 1 study that supplemented LBM/FFM/muscle mass. Seven trials (6 RCTs221egg albumin Protein. 225 223, 228, 229, 236 and 1 NRCT234) in patients receiving Energy. Six RCTs221, 224-226, 231, 236 with study duraMHD221-223, 229, 234, 236 or PD228 studied the effect of ONS tions of 3 to 6 months examined the effect of ONS on onmarkersofleanmassover3to6months.",
    "Overall, ONS energy intake in patients receiving MHD, 221, 224, 226, 236 increased LBM or FFM only in patients receiving MHD receiving peritoneal dialysis, 225 and with chronic kidney disease stages 3-4. 231 Overall, who received an energy-based ONS. In patients receiving ONSincreasedenergyintake, thoughtheeffectwaslimited MHD, theeffectofprotein-basedONSonLBMwasmixed. topatientsonMHDreceivingrenal-specificprotein-energy Inapooledanalysisof6studies, 221-223, 228, 229, 234ONSwas ONS. Four of 5 studies in patients receiving Dialysis reassociatedwithasignificantincreaseinLBMorFFM(mean ported that ONS increased energy intake. 221, 224-226, 236 difference, 1. 18 95% CI, 0. 16-2. 20 kg) compared with However, a subgroup analysis found the effect to be sigthe control arm, but a subgroup analysis found the effect nificantonlyforpatientsonMHDreceivingprotein-energy to be significant only in patients receiving MHD using ONS, 224, 226 but not receiving Protein-225 or energyenergy-based ONS. based231 ONS alone. The only study in patients with chronic kidney disease Bodyfat. Seven studies (6 RCTs221-223, 226, 229, 238 and 3-4 found no improvement in energy intake using a 1NRCT234)inpatientsreceivingMHDevaluatedtheeffect nonprotein calorie ONS. 231 of ONS on BF over a period of 3 to 6 months. A pooled Phosphorus and calcium. An RCT of 3 months analysis of 6 studies221-223, 226, 228, 234 reported no overall duration in patients receiving MHD found no effect on effect of ONS on body FM, though subgroup analyses phosphorus or calcium intake. 224 demonstrated that energy-221 and Protein-enerOther biochemical markers (CRP, anemia indices, gybased223, 226, 234 ONS significantly increased body FM electrolyte and lipid levels). Seven studies (6 RCTs222compared with controls with Protein-based ONS having 224, 226, 229, 231 and 1 NRCT234) of 3 to 6 months durano effect. tion in patients receiving MHD222-224, 226, 229, 234 and with Skinfold measurements. Five studies (4 chronic kidney disease 3-4232 found no effect of ONS on CRP levels. Seven RCTs221, 223, 225, 228 and 1 NRCT234) in patients with chronic kidney disease studies (5 RCTs221-223, 225, 229 and 2 NRCTs223, 234) in pareceiving MHD221, 223, 224 or PD225, 228 examined the effect tients receiving MHD221-223, 229, 234 or PD225 examined the of ONS on skinfold measurements over a 3to 6-month effect of ONS on markers of anemia over a 3to 6-month period. A pooled analysis of 4 studies221, 225, 228, 234 reperiod. Overall, ONS had no effect on these markers. Five ported that ONS significantly increased skinfold measurestudies (4 RCTs223, 225, 229, 231 and 1 NRCT233) examined ments (mean difference, 3. 91 95% CI, 0. 93-6. 90 mm) the effect of ONS on serum calcium, phosphate, and pocomparedwith dietarycounselingorno supplementation, tassiumlevelsover3 to6 months. Threeofthetrialswere but this effect was significant only in patients receiving in patients receiving MHD, 223, 229, 233 1 was in patients MHD using energy-based ONS. receiving peritoneal dialysis, 225 and 1 was in patients with chronic kidney disease 3-4. 231 Armormusclecircumference. Four RCTs in patients None of the studies found any effect on ONS on these receiving MHD221, 223 or PD225, 228 evaluated the effect of electrolyte levels. Five studies (4 RCTs221, 225, 226, 231 and 1 ONS on arm or muscle circumference over a 3to 6NRCT234) examined the effect of ONS on plasma lipid month period. None of the studies showed any effect. levels over 3 to 6 months. Findings from pooled analyses demonstrated no overall effect of ONS on lipid levels. Dietary Intake. Protein. Ten studies (9 RCTs221225, 227, 228, 231, 236 and 1 NRCT234) examined the effect of Intradialytic parenteral nutrition. This evidence reONSonproteinintakeasestimatedusingnPCR/nPNA, 24view encompassed 3 studies that examined the effects of hour dietary recall, or multiple-day food records with IDPN on nutritional status and clinical outcomes in MHD study durations of 3 to 6 months. Overall, Protein-based patients, including 1 NRCT235 and 2 RCTs.",
    "237 benefit over ONS. It was postulated that markers of nutriCompared with a standard IDPN formulation of both tional statusimproved irrespectiveof the route of nutrient EAAs and NEAAs, an IDPN formulation with EAAs did not administrationaslongasdietaryproteinandenergytargets affect percent of desirable body weight, skinfold meaare met. 237 However, a direct comparison between IDPN surements, or arm muscle area. and ONS is lacking; this would only imply that ONS is equally effective as IDPN when oral intake is possible. Laboratory markers of nutritional status (albumin, BecauseONSwasincludedintheinterventionarmaswell, prealbumin, and transferrin. Three studies235, 237, 238 theinferiorityofIDPNoverONScannotbeevaluated. examined the effect of IDPN on laboratory markers of A recently published RCT investigating the effect of nutritionalstatusinmalnourishedMHDpatients. Theresults IDPN therapy on levels of prealbumin and other fromthesestudiesconcludedthatIDPNinconjunctionwith biochemical and clinical nutritional markers in malnourdietarycounseling235 orONS237increased albumin, 235, 237 ished MHD patients239 demonstrated that IDPN therapy prealbumin, 237 or transferrin levels, 235 but similar imincreasedprealbuminlevelsandwassuperiortonutritional provements in albumin and prealbumin levels were counseling after 16 weeks. This study was not included in observed when adequate and comparable Protein and enthis evidence review because the date of publication was ergy were provided to patients receiving ONS only. 237 beyond the cutoff time for study inclusion. In this study, ComparedwithastandardIDPNformulationofbothEAAs patients randomly assigned to the intervention group and NEAAs, an IDPN formulation with EAAs only did not received standardized nutritional counseling plus IDPN 3 affectalbuminandtransferrinlevels. 238 times weekly for 16 weeks. There were no within-group Other laboratory markers (inflammation CRP, hechanges and between-group differences at week 16 in moglobin, lipid profile). One study evaluated and found other clinical and biochemical nutritional markers (body mass index, no effect of IDPN on inflammation in malnourished hemodialysis albumin, transferrin, protein-creatinine ratio, phase angle alpha, and SGA patients. Canoetal237 reportedno changein CRPlevelsin scores). AJKD Vol76Iss3Suppl1September2020 S55 Guideline 4: Nutritional Supplementation Implementation Considerations regularly throughout the supplementation period to eval- (cid: 1) ONS should be prescribed 2 to 3 times daily and pauate the effectiveness of ONS. Ongoing monitoring and evaluation of nutritional statients should be advised to take ONS preferably 1 hour tus during IDPN therapy is necessary. Serum glucose, blood pressure, after meals rather than as a meal replacement to maxiandvolumestatusshouldbecloselymonitoredduringand mize benefit. 218 (cid: 1) Monitored in-centerprovision ofhigh-proteinmealsor after MHD. In the case of new or additional insulin requirement, the use of insulin analogues should be choONS during MHD may be a useful strategy to increase sen individually tailored with consultation with an endototal Protein and energy intake. 240 Many of the crinologist to avoid postdialytic hypoglycemia. perceived negative effects of intradialytic feeding such Ultrafiltration rate should be adjusted accordingly to as postprandial hypotension, aspiration risk, infection remove the extra fluid provided by IDPN. control, and hygiene, as well as Diabetes and phosphatephoruscontrol, canbeavoidedwithcarefulmonitoring. Future Research (cid: 1) ONS prescription should take into account patient preference. The acceptability of ONS in terms of (cid: 1) Adequately powered RCTs are necessary to evaluate the appearance, smell, taste, texture, and type of preparaimpact of ONS on long-term survival, hospitalization, tion(milkshaketype, juicetype, puddingtype, Protein/ and QoL in patients throughout the range of chronic kidney disease. An energybar, orfortificationpowder)shouldbecarefully ongoing study will help address this unmet need considered. The tolerability of ONS should also be (NCT02933151). carefullymonitoredbecausesomepatientsmaydevelop (cid: 1) In addition, further research is needed to define the gastrointestinal symptoms with ONS. optimal composition and scheduling of ONS, as well as (cid: 1) Energy-dense and Low-electrolyte renal-specific ONS define the patient subgroups most likely to benefit. may be necessary to increase Protein and energy intake (cid: 1) Adequately powered and long-term clinical trials and avoid fluid overload and electrolyte derangements.",
    "comparingtheindependenteffectsofIDPNandONSon (cid: 1) Concern about infectious complications (particularly nutritional status, morbidity, mortality, and QoL are when infused through hemodialysis catheters) and the High cost required. ofIDPNarethegreatestbarriersforregularuseofIDPN. (cid: 1) MHD patients meeting all of the following 3 criteria 4. 2 Statement on Nutrition Supplementation may benefit from IDPN therapy: Dialysate 1) evidence of protein-energy wasting and inadequate dietary Protein Dialysate Protein-Energy Supplementation and/orenergyintake; 2)inabilitytoadministerortolerate 4. 2. 1 In adults with chronic kidney disease 5D on peritoneal dialysis with Protein-energy adequate oral nutrition, including food supplements or wasting, we suggest not substituting conventional enteral feeding; and 3) Protein and energy requirements dextrose dialysate with amino acid dialysate as a can be met when IDPN is used in conjunction with oral general strategy to improve nutritional status, intake or enteral feeding. althoughitisreasonabletoconsideratrialofamino (cid: 1) IDPN therapy should not be considered as a long-term acid dialysate to improve and maintain nutritional approach of nutritional support. It should be disstatus if nutritional requirements cannot be met continued and ONS should be attempted as soon as with existing oral and enteral intake (OPINION). improvements in nutritional status are observed and patients are capable of using the oral or enteral route. Specific criteria for improvement should be patient Rationale/Background specific. (cid: 1) IfIDPNtherapyinconjunctionwithoralintakedoesnot PEWiscommonamongpatientsreceivingmaintenancePD and is associated with increased morbidity and mortalachieve the nutritional requirements of the patient or ity. 242 Inflammation, acidosis, insulin resistance, insuffithe gastrointestinal tract is impaired, TPN given on a cient dietary intakes of Protein and energy as a result of daily basis should be considered. anorexia, andperitoneallossesofproteinsandaminoacids contribute to protein-energy wasting. 243 Intraperitoneal amino acid (IPAA) Monitoring and Evaluation supplementation was introduced to compensate for Low Gastrointestinal side effects can influence adherence to Protein intake and Protein losses. Substituting amino acids ONS, 241 and extended periods of monotonous suppleforglucoseinPDsolutionsshouldincreasetheaminoacid mentation can lead to flavor and taste Fatigue, as well as intake and decrease the net amino acid losses of the panonadherence to the prescribed ONS. Therefore, regular tient, thereby increasing the net intake of Protein premonitoring and evaluation during the supplementation cursors. 244 IPAA supplementation may also reduce periodarecrucialandadjustmentstotheONSprescription the infused carbohydrate load, thereby reducing the may be necessary to improve adherence and optimize risk for hyperglycemia and the tendency for effectiveness. Nutritional status should be monitored hypertriglyceridemia. 244 S56 AJKD Vol76Iss3Suppl1September2020 Guideline 4: Nutritional Supplementation Detailed Justification 0. 018) and bicarbonate levels (P 0. 002). In a secondary Thisevidencereviewincluded3studiesthatexaminedthe analysis, the IPAA groups in Jones et al245 and Misra et effect of IPAA supplementation on nutritional status in al247 demonstrated a mean difference of 0. 50 (95% CI, malnourished peritoneal dialysis patients, including 2 RCTs245, 246 and 1 0. 87 to 0. 13) mEq/Lin potassiumand 1. 10 (95%CI, nonrandomized crossover trial. 247 In the 2 RCTs, 245, 246 1. 43 to 0. 77) millimoles per liter in bicarbonate levels, respecresults were compared between those receiving traditively, when compared with the dextrose dialysate group. tional1. 5%dextrosedialysateversusthosewhoreplaced1 In pooled analysis, there was a mean difference of 0. 55 to 2daily exchangesof 1. 5%dextrosedialysatewith 1. 1% (95% CI, 0. 70 to 0. 41) milligrams per deciliter in phosphate levels in amino acid dialysate. Study durations ranged from 3 the IPAA group compared with the dextrose dialysate months245 to 3 years. 246 In the nonrandomized crossover group. trial, Misra et al247 used the same study design in which Dietary Intake (Protein and Energy Intake). One the participants were assigned to each exposure (amino RCTexaminedtheeffectofIPAAsupplementationontotal acid dialysate for 1 exchange per day or dextrose dialysate and oral Protein and energy intakes in malnourished peritoneal dialysis only) for 6 months.",
    "Accordingly, they have been tested in a evaluate the effects of IPAA therapy on nutritional status, variety of medical conditions. Of particular interest has patient survival, hospitalization, other clinical outcomes, been their putative effects on cardiac membrane stabiliand QoL in peritoneal dialysis patients at risk or with protein-energy wasting. zation, leading to possible reduction of malignant arrhythmias and sudden cardiac death. Patients with chronic kidney disease 4. 3 Statements on Long Chain Omega-3 have been documented to have some of the lowest Blood Polyunsaturated Fatty Acids (LC n-3 PUFA) levels of LC n-3 PUFAs in the literature, 248 thus making them potentially very suitable candidates for supplemenLCn-3PUFANutritionalSupplementsforMortalityandCardiovascular tation interventions. LC n-3 PUFA supplementation has Disease also been studied as possible therapy for a number of 4. 3. 1 In adults with chronic kidney disease 5D on MHD or postconditions commonly observed in patients with chronic kidney disease, transplantation, we suggest not routinely prescribincludingdyslipidemia, HDaccessfailure, cardiovascular disease, anddeath, ingLCn-3PUFA, includingthosederivedfromfish as well as for their immunomodulatory effects in patients orflaxseedandotheroils, tolowerriskofmortality with Kidney allografts. (2C) or cardiovascular events (2B). 4. 3. 2 InadultswithCKD5DonPD, itisreasonablenotto Detailed Justification routinely prescribe LC n-3 PUFA, including those Thirty-five RCTs studied the impact of LC n-3 PUFA supderivedfromfishorflaxseedandotheroils, tolower plementation on a variety of health biomarkers and outriskofmortalityorcardiovascularevents(OPINION). comes in adults with chronic kidney disease 2-5D and Kidney transplant. Twenty-four of these studies included patients receiving LC n-3 PUFA Nutritional Supplements for Lipid Profile MHD as the target population, though 1 study also 4. 3. 3 In adults with chronic kidney disease 5D on MHD, we suggest that included patients receiving peritoneal dialysis. 249 Nearly all the in1. 3-4 g/d LC n-3 PUFA may be prescribed to terventions used Fish oil as the main source of LC n-3 reduce triglycerides and LDL cholesterol (2C) and PUFAs, but flaxseed oil249 and ground flaxseed250 were raise HDL levels (2D). also studied. Study length (4 weeks to 2 years) and size 4. 3. 4 In adults with chronic kidney disease 5D on peritoneal dialysis, it is reasonable to (12-567 participants) varied widely. The heterogeneity of consider prescribing 1. 3-4 g/d LC n-3 PUFA to thisliteratureintermsoftheabsoluteandrelativeamounts improve the lipid profile (OPINION). of n-3 PUFAs supplemented, type of placebo used, and 4. 3. 5 In adults with chronic kidney disease 3-5, we suggest prescribing w study duration makes it more difficult to provide conclu2g/d LC n-3 PUFA to lower serum triglyceride sive evidence for or against the use of LC n-3 PUFAs as a levels (2C). treatment option. All-Cause Mortality and Cardiovascular Events. LC n-3 PUFA Nutritional Supplements for Arteriovenous (AV) Graft Despite the putative overall benefits of LC n-3 PUFAs and and Fistula Patency the elevated risk for death in patients with chronic kidney disease, 3 RCTs 4. 3. 6 In adults with chronic kidney disease 5D on MHD, we suggest not demonstrated no improvement in mortality with suppleroutinely prescribing Fish oil to improve primary mentation. However, the studies were heterogeneous in patency rates in patients with AV grafts (2B) or terms of study population (1 in patients with MHD, 251 2 fistulas (2A). in patients with chronic kidney disease with Kidney allografts252, 253), the dose of LC n-3 PUFAs (1. 44 g/d of EPA 0. 96 g/d LC n-3 PUFA Nutritional Supplements for Kidney Allograft Survival of DHA253; 1. 62 g/d of EPA 1. 08 g/d of DHA252; 4. 3. 7 In adults with chronic kidney disease posttransplantation adults, we 0. 77 g/d of EPA 0.",
    "42-0. 96 g/d of EPA and enced by physical activity, smoking status, and sex, the 0. 24-0. 6 g/d of DHA), flaxseed oil (2 g/d), or ground preponderance of these studies did not control for these flaxseed(40g/d), acounterintuitivefinding. Interestingly, factors. Of the 12 studies in patients receiving MHD, 6 positive results were more consistent in chronic kidney disease patients not reported negative results249, 265, 266, 268, 270, 272 and 6 found receiving Dialysis, 259, 261, 262, 264 in whom Fish oil supplethat HDL-C levels were increased. 249, 250, 255, 263, 271, 273 Efmentation (1. 8 g/d total or 0. 46-1. 44 g/d of EPA with fects were not clearly influenced by study quality or 0. 25-0. 96 g/d of DHA) for 8 to 12 weeks consistently duration. However, the positive studies tended to use lowered TG levels. lower doses of LC n-3 PUFA (0. 72-0. 96 g/d of EPA with Total cholesterol. The literature did not suggest a 0. 42-0. 6 g/d of DHA), flaxseed oil (2 g/d), or ground beneficial effect of LC n-3 PUFA supplementation on TC flaxseed(40g/d). Inapooledanalysisofall12studies, LC levels. Eleven of 13 studies in patients receiving MHD ren-3 PUFA supplementation was found to increase HDL-C ported no effect (0. 42-1. 8 g of EPA and 0. 24-1. 14 g of levels by a mean of 7. 1 (95% CI, 0. 52-13. 63) milligrams per deciliter. DHA per day for 4 weeks to 6 However, heterogeneity was High overall. Results were months), 249, 255, 263, 265, 266, 268-273 while the 2 studies mixedinthe4trialsofCKDpatientsnotreceivingdialysis, supplementing with flaxseed oil (2 g/d for 120 days)249 with 2 showing a benefit262, 264 and 2 reporting no efor ground flaxseed (40 g/d for 8 weeks)250 noted a sigfect. 259, 261 Again, the outcome was not clearly influenced nificant reduction in TC levels (though 1 study did not by quality of study, study duration, or dosage, and results compare differences between groups250). A pooled analcould not be pooled. Finally, the only study in patients ysis of all 13 studies did not find any effect on mean TC with chronic kidney disease with Kidney allografts showed no benefit. 258 levelbutnotedahighlevelofheterogeneityinthedata(I2 Inflammatory markers. The putative anti-inflamma- 95. 77%; P0. 001). Threeof4supplementationstudies tory effects of LC n-3 PUFA were tested on 2 established inCKDpatientsnotreceivingdialysisreportednoeffecton biomarkers of inflammation. TC levels, 251, 261, 264 whereas the fourth demonstrated a C-Reactive Protein. Fifteen RCTs studied the effect of reduction at 3 months (P 0. 05) with no difference beFish oil supplementation on circulating CRP levels. In chronic kidney disease tween arms. 259 Results could not be pooled for these 4 patients not receiving Dialysis, Fish oil either compared to studies. Although Ramezani et al274 reported lower placebo261, 275 or at varying doses264 had no effect. The cholesterol levels in patients with chronic kidney disease with Kidney allopattern in patients receiving MHD was similar. A pooled grafts compared to placebo after 6 months of suppleanalysisof10studies249, 250, 255, 265, 268-270, 276-278foundno mentationwith1. 76g/dofEPAwith0. 96g/dofDHAin effect of LC n-3 PUFA supplementation (9 using Fish oil fishoil, Schmitzetal256foundnosuchbenefitinasimilar containing 0. 42-1. 8 g/d of EPA with 0. 24-1. 14 g/d of population. DHA, 1 using 2 g/d of flaxseed oil) on circulating CRP LDL cholesterol. Eight of 12 studies in patients levels as compared to placebo (mean difference, 1. 73; receiving MHD found no benefit of 95%CI, 3. 54to0. 09mg/L). Ewersetal266foundthatfat supplementation, 249, 265, 266, 268, 270-273 while 4 reported supplementation (which also included fats other than LCa reduction in LDL-C levels. 249, 250, 255, 263 Two of the 4 n-3PUFAandspecificn-3PUFAswerenotdescribed)was positive studies supplemented with Fish oil (1.",
    "249, 250, 255, 263 Two of the 4 n-3PUFAandspecificn-3PUFAswerenotdescribed)was positive studies supplemented with Fish oil (1. 5 g total associated with a reduction in CRP levels (P 0. 01) after in Khajehdehi et al263 and 0. 96 g/d of EPA with 0. 6 g/ 12 weeks as compared with nonsupplemented patients. d of DHA in Bowden et al, 255 while the other 2 used Interleukin 6. Six RCTs studied the effect of LC n-3 flaxseed oil or ground flaxseed249, 250 (with both latter PUFAoncirculatingIL-6levels. Neitherofthe2studiesin studies observing a decrease in LDL-C levels). 249, 250 chronic kidney disease patients not receiving Dialysis comparing Fish oil Study quality or duration or type of comparison group supplementation with placebo or at varying doses found a used did not influence the outcome. A pooled analysis significanteffectonIL-6levels(1studyreportedatotalof of all 12 studies noted an improvement in LDL-C levels 1. 8 g/d of n-3 PUFA and 1 reported 1. 4 g/d of EPA with only when excluding the flaxseed-based supplement 1. 0gofDHA), 264, 279nordidapooledanalysisof4studies studies (mean difference, 5. 26 95% CI, 9. 51 to in patients receiving MHD (mean difference, 5. 32; 95% 1. 00 milligrams per deciliter) and even then the result was clinically CI, 5. 637 to 16. 275 pg/mL) in which participants marginal. In chronic kidney disease patients not receiving Dialysis, 4 received 0 to 1. 93 g/d of EPA with 0. 72 to 0. 97 g/d of studies of 8 to 12 weeks length using Fish oil found no DHA. 268, 276, 277, 280 effect on LDL-C levels (1. 8 g/d total in GuebreEgziabher et al264 and 0. 46-1. 44 g/d of EPA with 0. 25Special Discussions 0. 96 g/d of DHA251, 259, 261, 264). In patients with chronic kidney disease The clinical impact of LC n-3 PUFA supplementation in with Kidney allografts, 1 study reported that EPA 9g patients with chronic kidney disease was challenging to assess due to short capsules per day increased LDL-C levels (but a higher study durations, modest sample sizes, and broad heterodose did not), while another study reported negative geneityinthecompositionofthesupplementsanddosing results. 256, 258 strategies. Furthermore, baseline LC n-3 PUFA levels S60 AJKD Vol76Iss3Suppl1September2020 Guideline 5: Micronutrients (either in Blood or tissues) were not typically used to population. This is a High-priority topic and there is target populations that would most benefit. This is an currently an ongoing RCT looking into these outcomes importantbutoftenoverlookedpointbecausetheputative (ISRCTN00691795). 286 benefitsofLCn-3PUFAsupplementationmaybeinversely (cid: 1) The dosage and ratio of LC n-3 PUFA to be related to baseline Blood or tissue concentrations. 248, 281 supplemented, as well as the quality control and purity of the supplement used, should all be Implementation Considerations carefully considered and documented in any study (cid: 1) LCn-3PUFAsupplementationconsiderationswilldiffer design. For example, a recent RCT found that a depending on whether the intervention is diet based or highly purified form of EPA ethyl ester (with no capsule based. ALA or DHA included) at a High dose (4 g/d) (cid: 1) For dietary interventions, the goal of supplementation available only in prescription form was effective must be clearly defined. If it is to increase Blood levels in reducing cardiovascular risk. 287 This is in of α-linolenic acid (ALA), supplementation should contrast to several negative trials in recent years focus on soybean, flaxseed, and other oils, as well as that used different formulations and doses of LC meatanddairyproducts. IfitistoincreaseEPAorDHA n-3 PUFA. Blood/tissuelevels, theprimarydietarysourcesmustbe sardine, mackerel, salmon, and other High-content marine-based foods. 282 Potential limitations to dietary Guideline 5: Micronutrients supplementation include their relatively High cost and 5. 0 Statements for General Guidance difficulty achieving High daily intake.",
    "0 Statements for General Guidance difficulty achieving High daily intake. In addition, the source and processing method will influence LC n-3 Dietary Micronutrient Intake PUFA foodstuff content. For example, farmed Fish 5. 0. 1 InadultswithCKD3-5Dorposttransplantation, itis typically (but not always) have lower LC n-3 PUFA reasonable for the registered dietitian nutritionist content compared with wild Fish, while frying Fish (RDN) or international equivalent to encourage couldalterthen-3ton-6ratio, whichmaybeofclinical eating a diet that meets the recommended dietary significance. 283 allowance (RDA) for adequate intake for all vita- (cid: 1) Capsule-based supplementation involves a set of mins and minerals (OPINION). different considerations. Although dozens of commercial LC n-3 PUFA supplements are available, Micronutrient Assessment and Supplementation quality control is often lacking. 284 This makes precise 5. 0. 2 InadultswithCKD3-5Dorposttransplantation, itis dosing recommendations difficult. An alternative reasonable for the registered dietitian nutritionist route is to have the patient obtain supplements (RDN) or international equivalent, in close collabthrough physician prescription (eg, icosapent ethyl oration with a physician or physician assistant, to and omega-3 ethyl esters). For either option, cost assess dietary vitamin intake periodically and to could be an issue. Achieving High-dose supplemenconsider multivitamin supplementation for intation will be easier with capsules than through didividuals with inadequate vitamin intake etary consumption. Adverse effects of capsule-based (OPINION). supplementation may lead to gastrointestinal side effects such as stomach upset and eructation (though Micronutrient Supplementation, Dialysis the latter can be masked by different formulations). 5. 0. 3 In adults with chronic kidney disease 5D who exhibit inadequate Theoretical risks such as bleeding have not been dietary intake for sustained periods of time, it is borne out in clinical trials. LC n-3 PUFA content is reasonable to consider supplementation with mullisted on the website of the National Institutes of tivitamins, includingallthewater-solublevitamins, Health. 285 and essential trace elements to prevent or treat micronutrient deficiencies (OPINION). Monitoring and Evaluation ThereisnoneedtoroutinelymonitordietaryLCn-3PUFA intake other than in the context of general dietary counseling. An exception could be if the patient is specifically Rationale/Background instructed to consume greater dietary quantities of LC n-3 Micronutrients are essential for metabolic function and PUFA. hence, maintaining an adequate intake of these micronutrients is important. For healthy individuals, many Future Research countries have established dietary reference intakes for (cid: 1) There are no adequately powered studies into whether individual micronutrients. However, there is a paucity of LC n-3 PUFAs reduce cardiovascular risk, and in guidance regarding appropriate intake for people with particular sudden cardiac death, in the High-risk chronic kidney disease chronic diseases. There is some evidence to indicate that AJKD Vol76Iss3Suppl1September2020 S61 Guideline 5: Micronutrients patients with chronic kidney disease are likely to be deficient in certain support that care should be taken to avoid excessive micronutrients. Some of the common reasons for this doses, and there might be some individuals who are at include insufficient dietary intake, dietary prescriptions higher risk for certain micronutrient deficiencies. Taking that may limit vitamin-rich foods (particularly Water-solall these issues into consideration, the expert panel uble vitamins), Dialysis procedures that may contribute to thought that it was important to draft expert opinionmicronutrient loss, improper absorption of vitamins, use based recommendation statements to guide practitioners of certain medications, and illness. Due to these concerns, and to emphasize the need for individualization of multivitamin supplements are routinely prescribed. Findmicronutrient use. ings from the Dialysis Outcomes and Practice Patterns In recent years, there have been a few systematic or Study(DOPPS)indicatethat70%ofMHD patientsin the narrative reviews on the topic of micronutrient suppleUnited States take supplements. However, there is insufmentation in patients with chronic kidney disease.",
    "However, there is insufmentation in patients with chronic kidney disease. The findings from these ficient evidence to indicate whether micronutrients or SRs are in line with findings from the current systematic multivitamin supplementation is beneficial or detrimental review. Tucker et al, 301 in a detailed review of microin this population. nutrients in patients receiving MHD, state that there is insufficient evidence to support routine supplementation; Detailed Justification instead, supplementation should be individualized and based on clinical judgment. Similarly, Jankowska et al302 At present there is a paucity of Good-quality evidence to and Kosmadakis et al303 also state that there is insuffieither support or oppose routine supplementation on cient evidence to support or oppose supplementation and micronutrients, including multivitamins. There is some more Good-quality trials are needed to help clarify evievidencetostatethatpatientswithCKDmightbedeficient dence in this area. in thiamine, 288-290 riboflavin, 291 vitamin B, 292-294 6 vitamin C, 295, 296 vitamin potassium, 297-299 and/or vitamin D. 300 Special Discussions However, most of the supporting evidence on deCertain chronic kidney disease populations might be at higher risk for ficiencies is for the MHD population and not much has micronutrient deficiencies, and this must be taken into been explored in other stages of chronic kidney disease or those treated by consideration. For example, pregnant women, patients peritoneal dialysis or posttransplant. after gastric bypass surgery, patients with anorexia and This systematic review included a comprehensive wasting syndrome with poor intake, patients with search of controlled trials evaluating the effects of malabsorption conditions, patients following vegetarian micronutrient supplementation (both Waterand fat-soldiets, and patients taking certain medications may have uble) in patients with chronic kidney disease. A total of 80 controlled trials different micronutrient needs. were included in the systematic review (folic acid alone, Nutrition Focused Physical Examination should be 14 trials; folic acid B vitamins, 13 trials; vitamin E, 8 conducted with patients to identify whether signs and trials; vitamin potassium, 1 trial; vitamin D, 14 trials; vitamin B, 12 symptoms of certain vitamin and mineral deficiency are 4 trials; vitamin C, 8 trials; thiamine, 1 trial; zinc, 10 present. Thesecanbeusedincombinationwithlaboratory trials; and selenium, 7 trials). Some of the Good-quality measures to get a complete picture of the problem. evidence from these articles led to the development of If patients with chronic kidney disease are not meeting their recomrecommendation statements for specific micronutrients mendedintakeasassessedby24-hourrecallandhavepoor (see specific sections). nutritional status, it is likely that they might be at risk for However, the current evidence in this field has sigmicronutrient deficiencies and appropriate intervention is nificant limitations. A majority of the included studies in required. this systematic review did not report either baseline status of micronutrients examined or dietary intake during the Implementation Considerations trials. Moreover, the outcomes reported by these studies varied significantly across the studies, making it difficult (cid: 1) Gather patient information on whether they are taking to integrate evidence. Also, dosage of supplementation any micronutrient or multivitamin supplements. and duration of intervention varied across studies. (cid: 1) Suggested vitamin intake should be based on recomIncluded studies primarily reported the effect of micromendations for the general population (eg, Recomnutrient supplementation on the serum level of the mended Dietary Allowance RDA) unless there are micronutrient being supplemented. The quality of evispecific considerations requiring modification. dence from these trials ranged from very Low quality to (cid: 1) Assess dietary intake, including consideration of fortimoderate quality for a majority of the micronutrients. fied foods. Due to these significant limitations, it is very difficult to (cid: 1) Review if patients may be at risk for vitamin and minprovide recommendations regarding the exact levels of eral deficiencies.",
    "supplementation or routine supplementation for all pa- (cid: 1) Supplementation dose should be individualized based tients with chronic kidney disease. However, there is some evidence to on each patients needs and risk profile. S62 AJKD Vol76Iss3Suppl1September2020 Guideline 5: Micronutrients Future Research Detailed Justification (cid: 1) Well-designed trials are needed to investigate whether Mortality, Cardiovascular Outcomes, and Vascular Function. Four RCTs did not show any effect of folic acid supplementation improves outcomes. These trials when taken with vitamins B and B on hard outcomes, should limit inclusion to a certain baseline status (eg, 6 12 including all-cause mortality and/or cardiovascular events deficiency/insufficiency) or adjust for baseline status in in patients with stage 5 chronic kidney disease, receiving MHD or peritoneal dialysis, and results. Researchersshouldconsidertheeffectofdietary posttransplant. 304-307 Folic acid and other B-vitamin supintake of micronutrients on findings. (cid: 1) There is a need to determine how dietary interventions plementation ranged from 2. 5 to 40 magnesium/d of folic acid, 1. 4to100mg/dofvitaminB, and150μg/wkto2mg/ targeting micronutrient intake may affect relevant 6 d of vitamin B for a duration of 2 to 5 years. outcomes. 12 Folic acid (alone) intake of 1 to 5 magnesium/d for 4 to 40 weeks showed no effect on flow-mediated dilation. 308, 309 5. 1 Statements on Folic Acid Additionally, folic acid supplementation did not alter the risk for cardiovascular outcomes in 4 RCTs. 310-313 The 4 Folic Acid Supplementation for Hyperhomocysteinemia RCTsincludedpatientswithCKD, stage5nondialyzed, and 5. 1. 1 In adults with chronic kidney disease 3-5D or posttransplantation treated by peritoneal dialysis and MHD. The folic acid supplementation who have hyperhomocysteinemia associated with dose ranged from 1 to 15 magnesium/d and supplementation Kidney disease, we recommend not to routinely duration ranged from 1 to 3. 6 years in these studies. supplementfolatewithorwithoutB-complexsince Supplementation with folic acid in combination with there is no evidence demonstrating reduction in other B vitamins did not improve TC levels, intima media adverse cardiovascular outcomes (1A). thickness, or blood pressure in MHD patients. Doses ranged from 5 to 15 magnesium of folic acid and a B-complex vitamin for 3 to 6 Folic Acid Supplementation for Folic Acid Deficiency and Insufficiency months. 314, 315 5. 1. 2 In adults with chronic kidney disease 1-5D (2B) or posttransplantation (OPINION), we suggest prescribing chronic kidney disease Progression. One RCT examined the effect of folate, vitamin B12, and/or B-complex supplement folic acid supplementation on chronic kidney disease progression. 316 In a to correct for folate or vitamin B12 deficiency/ substudyofalargerprimarystrokepreventiontrial15, 104 insufficiency based on clinical signs and symptoms participantswithCKDstage3diagnosedwithhypertension (2B). and taking the angiotensin-converting enzyme (ACE) inhibitor enalapril were randomly assigned to receive 0. 8 magnesium/d of folic acid or placebo for a median of 4. 4 years. Comparedwiththegroupreceivingenalaprilandplacebo, theenalaprilplusfolicacidgroupsignificantlyreducedthe Rationale/Background adjusted risk for chronic kidney disease progression (heart rate, 0. 45 95% CI, Folicacidisinvolvedinthesynthesisofseveralaminoacids, 0. 27-0. 76; P0. 003), whichwasthesubstudysprimary including serine, glycine, methionine, and histidine. Folic outcome. 316 The limitation of this study was that a plaacidcanbeprovidedbydietarysourcesaswellasover-thecebo-alone group (without enalapril) was not included. counter nutritional supplements. Over-the-counter supTwo other RCTs showed no effect of supplementation plementscomeinvariousforms, suchasfolicacid, methyl with folic acid with vitamins B and B on the risk for folate(alsoknownasL-methylfolate, L-5-methylfolate, or 6 12 Dialysis initiation/end-stage kidney disease in participants with stages 3-5 MTHF), andfolinicacid, amongothers. Folicacidsprimary chronic kidney disease and those posttransplantation. 304, 306 mechanism of action is its role as a 1-carbon donor. Folic acidisreducedtomethylfolate, whichhelpstransfersingle Serum Homocysteine Levels. Fourteen studies methyl groups in various metabolic reactions in the body. examinedtheeffectoffolicacidsupplementationaloneon Folicacidalsoplaysaroleinthefunctioningofthenervous plasma homocysteine levels. 308-313, 316-323 Participants system, inDNAsynthesis, andincelldivision.",
    "examinedtheeffectoffolicacidsupplementationaloneon Folicacidalsoplaysaroleinthefunctioningofthenervous plasma homocysteine levels. 308-313, 316-323 Participants system, inDNAsynthesis, andincelldivision. Foodsources included were those with chronic kidney disease, nondialyzed (4 studies), richinfolicacidincludegreenleafyvegetables, fruits, yeast, receiving MHD (10 studies) and peritoneal dialysis (4 studies), and and Liver. Although intake of foods naturally rich in folic posttransplant (1 study). In the 10 RCTs, folic acid supacid is limited in patients with chronic kidney disease due to their High poplementsrangedfrom0. 8to60mg/danddurationvaried tassium content, folic acid deficiency among this patient from4weeksto4. 4yearsinpatientswithvariousstagesof population seems to be rare. This is especially true since chronic kidney disease. All but 1 study concluded that folic acid supple1996, whenfolicacidfortificationofenrichedcerealgrain mentation significantly decreased homocysteine levels. 309 productswasmandatedintheUnitedStatesandCanada. 301 Thirteen RCTs examined the effect of supplementation Because folate, vitamin B, and vitamin B assist in the with folate and other B vitamins on homocysteine 12 6 conversion of homocysteine to methionine (and thereby levels. 304-307, 314, 315, 324-330 Serum homocysteine level was reduce serum homocysteine levels), they have received a primary outcome of interest in 8 studies. 314, 315, 324considerable attention as a putative treatment for cardiovascular disease in 326, 328-330 Twelve of 13 studies found that folic acid patientswithCKD. with other B vitamin supplementation decreased AJKD Vol76Iss3Suppl1September2020 S63 Guideline 5: Micronutrients homocysteine levels in participants with chronic kidney disease stages 3-5, Because absorption of vitamin B is dependent on 12 treated by MHD or peritoneal dialysis, and posttransplant. Supplementaintrinsic factor and normal gut function and the latter is tiondosesinthesestudiesrangedfrom2. 5to40mg/dof often at least partially impaired in older individuals, folicacid(1studyused3mgofIVfolinicacidperweek), assessmentofserumvitaminB maybenecessaryiffolate 12 1μg/doforalto1, 000mg/wkofIVvitaminB, and1. 4 supplementation is considered. 12 to 100 magnesium of vitamin B and supplementation duration Serum homocysteine, vitamin B, and folate level 6 12 ranged from 8 weeks to 5 years. monitoring may be considered for patients who take certainmedicationssuchasmethotrexate, nitrousoxide, 6CRP and IL-6 Levels. Daily oral folic acid (5 magnesium) azaridine, phenytoin, carbamazepine, and oral contracepwith a B-complex vitamin for 3 months was associated tives and have excessive alcohol intake that can interfere with a decrease in CRP but not IL-6 levels in an RCT that included 121 patients receiving MHD. 310 with folate absorption. FolicAcidandVitaminB Levels. SixRCTsreported Implementation Considerations 12 that supplementation of folic acid alone increased serum (cid: 1) Vitamin B deficiencies may be identified by clinical folic acid levels in participants with stages 3-5 chronic kidney disease and those treated by MHD and peritoneal dialysis. 308, 313, 316, 319, 320, 323 When signs and symptoms. Assessment of serum vitamin B 12 should be considered if folate supplementation is folic acid with vitamins B and B was provided, it is 6 12 administered. worth noting that serum folic acid levels increased with a (cid: 1) High folic acid intake may mask signs of pernicious daily intake of 5 magnesium for 3 months or a daily intake of 2. 5 mgforalongertimeframe. IntheMannetal307studythat anemia and undetected progression of neurologic disease, and thus folate and vitamin B levels should be included patients receiving MHD, serum folic acid levels 12 monitored if folate is being supplemented. significantly increased with an intake of 2. 5 magnesium after 2 (cid: 1) Suggested vitamin intake should be based on recomyears of supplementation as compared with the control group. InChiuetal, 326supplementationof3mgoffolinic mendationsforthegeneralpopulation(eg, RDA)unless therearespecificconsiderationsrequiringmodification. acid weekly IV for 3 months did not result in a significant (cid: 1) Individualizationoftherapy, includingsupplementation increase in serum folic acid levels in participants with dosage, isessentialtothemanagementofanycomorbid stages 3-5 chronic kidney disease or who were treated by MHD and peritoneal dialysis. condition.",
    "condition. Of the 10 studies that examined the effect of supple- (cid: 1) Individualizationshouldincludepatientagebecauseadults mentation of folic acid with B complex, 9 found a significant increase in serum folic acid levels. 305olderthan50yearsmayhaveincreasedneedsduetothe 307, 314, 315, 324, 325, 327, 330 Doses ranged from 2. 5 to 60 magnesium prevalenceofatrophicgastritisinthispopulation. of folic acid and study duration ranged from4 weeks to 5 years. Monitoring and Evaluation Serum/plasma/red blood cell folate and serum vitamin B levels 12 Special Discussions should be assessed as appropriate. Folate status is most often assessed through measurement of folate levels in plasma, serum, or red Blood Future Research cells (RBCs). Serum or plasma folate levels reflect recent (cid: 1) Conduct dose-response studies for folic acid intake, dietary intake, so deficiency must be diagnosed by especially in people undergoing maintenance Dialysis repeated measurements of serum or plasma folate. In and persons who are taking medications that interfere contrast, red blood cell folate levels are more reflective of folate with the intestinal absorption, serum levels, or actions tissue status than serum folate and represent vitamin of folate and/or vitamin B. status at the time the red blood cell was synthesized (ie, longer12 (cid: 1) Assess the recommended daily allowance of folic acid term folate status). Usually red blood cell folate concentrations and other B vitamins in various stages of chronic kidney disease and diminish after about 4 months of Low folate intake, various types of Kidney diseases. reflecting the 120-day life span of RBCs in healthy in- (cid: 1) Examine the prevalence of serum folate deficiency in dividuals. In patients with chronic kidney disease, such concentrations patients with various stages of chronic kidney disease. often decrease more rapidly, reflecting the shorter red blood cell (cid: 1) Given1preliminarypositivereport, conductmoreRCTs life span in chronic kidney disease. Excessive folate intake inhibits zinc to confirm whether folic acid intake may slow down absorption in the gut by forming a complex with zinc chronic kidney disease progression. in the intestinal lumen. High intake of folic acid may mask signs of pernicious anemia, leading to undetected progression of neurologic 5. 2 Statement on Vitamin C disease. Based on the 2015 ultrasound Renal Data System annual Vitamin C Supplementation report, more than two-thirds (38. 9%) of patients who are 5. 2. 1 In adults with chronic kidney disease 1-5D or posttransplantation receiving Dialysis are 65 years or older. Older people have who are at risk of vitamin C deficiency, it is a higher risk for impaired gastrointestinal function. S64 AJKD Vol76Iss3Suppl1September2020 Guideline 5: Micronutrients Nutritional Status Parameters: Serum Albumin, reasonabletoconsidersupplementationtomeetthe Prealbumin, Transferrin, and PNA. Three studies examrecommended intake of at least 90 magnesium/d for men inedtheeffectofvitaminCsupplementationonnutritional and 75 magnesium/d for women (OPINION). status in MHD participants: 1 RCT, 333 1 randomized crossover trial, 296 and 1 comparative study. 336 However, nutritionalstatuswasnottheprimaryoutcomeofinterest. Rationale/Background In Zhang et al, 296 all patients were vitamin C deficient at There are currently limited studies identifying daily baseline, while in De Vriese et al, 336 44% of participants vitamin C requirements for individuals with chronic kidney disease at all were deficient at baseline. In Fumeron et al, 333 vitamin C stages of the disease. Amount of daily intake and optimal deficiency status at baseline was unclear. All outcomes serum level of vitamin C required to maintain nutritional were reported as quantitative values but were not health, reverse deficiency, and avoid toxicity are unclear. comparedtoareferencestandard. Supplementationdosage Studiesincludedforthiscurrentreviewevaluatedtheeffect anddurationrangedfrom750mg/wkfor2months333to of vitamin C supplementation on nutritional status, 1, 500 magnesium/wk for 3 months.",
    "comparedtoareferencestandard. Supplementationdosage Studiesincludedforthiscurrentreviewevaluatedtheeffect anddurationrangedfrom750mg/wkfor2months333to of vitamin C supplementation on nutritional status, 1, 500 magnesium/wk for 3 months. 336 inflammation, anthropometrics, micronutrient levels, All 3 studies reported no effect of supplementation on electrolyte levels, fluid status, serum uric acid levels, lipid albumin levels, as did pooled analysis of 2 of the RCTs. levels, morbidity events, QoL, mortality, and hospitalizaZhang et al296 measured the effect of vitamin C suppletions. Limited data from a very small number of studies mentationonprealbuminlevelsinarandomizedcrossover prohibitdefinitiveevidence-basedconclusionsforallthese trial with MHD participants. Although 1 supplemented surrogate and hard outcomes. Therefore, we suggest that groupexperiencedanincreaseinprealbuminlevelsafter3 individualized decision making is the best clinical months of supplementation with 200 magnesium of vitamin C, approach to determine whether vitamin C supplementaprealbumin levels did not change in the other group after tion, or termination of supplementation, is required for the same intervention. Therefore, the effect of vitamin C adults with chronic kidney disease stages 1-5D and posttransplant. supplementationonprealbuminlevelsisunclear. Fumeron et al333 supplemented MHD participants with 750 magnesium/wk Detailed Justification of vitamin C for 2 months. There were no significant Nine studies examined the effect of vitamin C on nutrichanges in transferrin levels in either group. De Vriese et tion-related outcomes in the chronic kidney disease population, including 5 al336 measured nPNA (nPCR) in an NRCT and found no RCTs, 331-335 1 randomized crossover trial, 296 and 3 effect of vitamin C supplementation on nPNA (nPCR) comparative studies. 336, 337 All studies examined MHD following supplementation with 360 magnesium/wk or 1, 500 patients. Twostudies(Canaveseetal338andSinger335)also magnesium/wk for 9 months in MHD patients. included peritoneal dialysis patients and those with eGFRs 20 milliliters per minute. CRPLevels. Threestudiesexaminedtheeffectoforal vitamin C supplementation on CRP levels in MHD particQoL, Mortality, and Hospitalizations. In adults with ipants296, 333, 336andfoundnosignificanteffectscompared chronic kidney disease, 1 RCT (250 magnesium of oral ascorbic acid 3 times per with the placebo or control groups, but evidence was week for 3 months)335 and 1 comparative study337 (500 limited. magnesium of oral vitamin C per day for 2 years) measured the effectofvitaminCsupplementation, comparedwitheither VitaminCLevels/Deficiency. Four RCTs296, 331, 333, 335 a placebo or control, on hard outcomes, including alland 2 comparative studies336, 337 examined the effect of cause mortality, QoL or hospitalization events. vitamin C supplementation in doses ranging from 360 to Singer335 reported no changes in symptom, cognitive, 3, 500 magnesium/wk and duration ranging from 3 months to 2 or nausea subscales of the Kidney Disease Quality of Life years. In summary, oral vitamin C supplementation Short Form (KDQOL-SF) in either the vitamin increased serum vitamin C levels in MHD patients and Csupplemented or placebo groups in MHD/peritoneal dialysis particidecreased the proportion of participants who were pants. QoL was the primary outcome of interest. vitamin C deficient/insufficient (cutoffs were 11. 44 and Approximately 40% of participants were vitamin C defi23. 0 μmol/L). However, in pooled analysis of 3 RCTS, cient at baseline. In a comparative study by Ono, 337 there the increase in vitamin C levels may not be clinically were no differences in mortality rates or hospitalization significant. The quality of evidence in this regard reevents between vitamin Csupplemented and nonmains Low. Other chronic kidney disease populations such as nondialysis supplemented periods in MHD participants. Mortality was chronic kidney disease 1-5, peritoneal dialysis, and posttransplant participants remain aprimaryoutcomemeasure. BaselinevitaminCstatuswas poorly studied. not reported. These studies did not analyze the effects of vitamin C In summary, vitamin C supplementation did not affect supplementation on optimal dosing or thresholds for QoL, mortality, or hospitalizations in MHD patients, but toxicity. The potential for toxicity was acknowledged evidence was extremely limited.",
    "The potential for toxicity was acknowledged evidence was extremely limited. Evidence-based recomwith dosage ranges maintained at 200 to 250 magnesium daily mendations for the use of vitamin C in this patient popor 3 times weekly in most studies. The study by Ono337 ulation for these end points could not be provided. that dosed MHD patients with 500 magnesium of oral vitamin C AJKD Vol76Iss3Suppl1September2020 S65 Guideline 5: Micronutrients daily for 2 years reported an aggravation of hyperMonitoring and Evaluation oxalemia. De Vriese et al336 had participants dosed at Higher doses of vitamin C supplementation (500 magnesium 360 magnesium/wk for 0 to 3 months followed by 1, 500 magnesium/ daily) have been shown to increase serum oxalate levels. wk dosing for 3 to 6 months and then no supplemenVitamin C is a potent physiologic antioxidant. Lipid tations for 6 to 9 months in MHD patients. This study metabolismmaybeaffectedbyvitaminCsupplementation reported an increase in plasma malondialdehyde and patients receiving vitamin C supplementation should levels. 336 Supplementation with vitamin C increased the have lipid fractions monitored. Vitamin C also affects Low levels, but there is a potential risk for toxicity that immune function and carnitine metabolism. Patients with requires monitoring. any malabsorption or diseases of an inflammatory nature may be more prone to having lower plasma vitamin C Lipid Levels: TC, TG, LDL-C, HDL-C, LDL-C: HDL-C levels than the general population. Therefore, suppleRatio. The results of 3 trials331, 334, 336 demonstrated that mentation dose should take into consideration medical vitamin C supplementation of 125 to 200 magnesium/d for 3 history, comorbid conditions, and concomitant medicamonths may decrease TC and LDL-C levels, but there was tions. Measurementofserumoxalatemaybeconsideredin no effect on TG or HDL-C levels. Vitamin C supplemenpatients prescribed High doses of vitamin C and/or who tation of 125 to 200 magnesium/d decreased the LDL-C: HDL-C are susceptible to calcium oxalate stone formation. ratio or prevented the increase seen in the placebo group. There were several limitations to this evidence, Future Research including a small number of studies, small sample sizes, and Low evidence quality. It is important to note that the (cid: 1) Identify methods to assess vitamin C status. Current study by Khajehdehi et al334 included supplementing pamethodsuseserumlevelsofvitaminC, butreliabilityis tientswithpotentiallytoxicdosesofergocalciferol, 50, 000 unclear. international unit, daily for 3 months. The impact of this amount of (cid: 1) Ascertain the optimal vitamin C status of the chronic kidney disease vitaminDonstudyoutcomeparameters, ifany, cannotbe population, includingCKDstages1-5Dandthosewitha ascertained. Kidney transplant. Treatment of anemia with vitamin C supplementation (cid: 1) Confirm the RDA for vitamin C in various chronic kidney disease popwas beyond the scope of this guideline. ulations and the supplemental vitamin C dose that will preventvitaminCdeficiencywithoutincreasingriskfor Special Discussions toxicity. CurrentnutritionalrequirementsorRecommendedDietary (cid: 1) If feasible, evaluate the effect of vitamin C supplemenIntake of vitamin C for individuals with chronic kidney disease stages 1-5D tation on hard outcomes, including survival, hospitaliand posttransplant are not known and are based on those zation, cardiovascular events, and QoL measures with from the general population. The prevalence of vitamin C RCTs in chronic kidney disease populations. deficiency may vary according to chronic kidney disease stage and Dialysis modality. Toxicity is a possible concern for excessive 5. 3 Statements on Vitamin D vitamin C supplementation. However, these findings do not preclude the imporVitamin D Supplementation for Vitamin D Deficiency and Insufficiency tance of assessing for vitamin C supplementation or when 5. 3. 1 InadultswithCKD1-5D(2C)orposttransplantation to discontinue supplementation. Ongoing monitoring of (OPINION), we suggest prescribing vitamin D overallfoodintakeandnutritionstatusisrequiredtoassess supplementation in the form of cholecalciferol or for vitamin C deficiency.",
    "An individualized approach to ergocalciferol to correct 25-hydroxyvitamin D evaluation and monitoring of vitamin C status is ideally (25(OH)D)deficiency/insufficiency. accomplished by a multidisciplinary care team that includesnephrologist, nursepractitioner, physicianassistant, Vitamin D Supplementation with Proteinuria and RDN. 5. 3. 2 In adults with chronic kidney disease 1-5 with nephrotic range proteinuria, it is reasonable to consider supplementaImplementation Considerations tion of cholecalciferol, ergocalciferol, or other safe and effective 25(OH)D precursors (OPINION). (cid: 1) Initiation and cessation of vitamin C supplementation, as well as supplementation dose, should take into account the individuals nutritional status, dietary intake, comorbid conditions, and Dialysis Rationale/Background modality. Vitamin D (ergocalciferol) and vitamin D (cholecalcif2 3 (cid: 1) Suggested vitamin intake should be based on recomerol) are recognized as prohormones and comprise a mendations for the general population (eg, RDA) group of fat-soluble secosteroids. A unique aspect of unless there are specific considerations requiring vitamin D as a nutrient is that it can be synthesized by the modification. human body through the action of sunlight. These dual S66 AJKD Vol76Iss3Suppl1September2020 Guideline 5: Micronutrients sources of vitamin D (diet and sunlight) make it chalwas moderate heterogeneity in the data (I2 51. 84; P lenging to develop dietary reference intake values. 339 The 0. 08). Additionally, data from 8 studies were pooled to classic actions of vitamin D are the regulation of calcium determine the mean difference in vitamin D levels before mealsand phosphorus homeostasis contributing to bone health. cording to vitamin D supplementation. There was a mean More recently, there has been growing interest in the increase of 21. 06 (95% CI, 17. 46-24. 66) ng/mL in the potential pleiotropic actions of vitamin D on immune, vitamin Dsupplemented groups compared with the placardiovascular, and neurologic systems and on antineocebogroups, butheterogeneitywasmoderate(I267. 3%; plastic activity because extrarenal organs possess the P 0. 003), so results should be interpreted with caution. enzymatic capacity to convert 25-hydroxyvitamin D (calCalcium and Phosphorus Levels. In adults with cidiol; 25OHD) to 1, 25-dihydroxyvitamin D (1, 25 OH D). 340 chronic kidney disease, 12studiesexaminedtheeffectofvitaminDintakeon 2 biomarker levels and/or health outcomes. 267, 350-352, 354Insufficiency/deficiency of vitamin D, assessed by 356, 358-362 Moderate-quality evidence demonstrated no serum concentration 25(OH)D, has been found to be effect of vitamin D supplementation on calcium or phosphatecommon in the general population and even more prevalentinpatientswithCKDstages3-5D. 300, 341, 342Formost phorus levels. In predominantly vitamin Ddeficient participants, experts, vitamin D insufficiency is defined as serum there was no effect of ergocalciferol supplementation on 25(OH)D level between 20 and 29 ng/mL, deficiency is consideredas25(OH)Dlevel20ng/mL, andsufficiency calcium levels in doses of 50, 000 international unit per week or per as serum 25(OH)D level ≥ 30 ng/mL. 343 month or in individualized doses. 350, 351 The effect of cholecalciferol on calcium levels was unclear, with 7 A number of factors or conditions are implicated in studies finding no effect on calcium levels and 3 studies suboptimal vitamin D status in patients with chronic kidney disease, determining that supplementation increased calcium including aging, Diabetes mellitus, obesity, reduced sun levels. In Massart et al, 360 a double-blind randomized exposure, loss of urinary/dialysate vitamin D binding placebo-controlled trial, weekly treatment of 25, 000 international unit Protein, impaired tubular 25(OH) reabsorption, and dietary restrictions. 344-347 Considering the High prevalence of cholecalciferol significantly increased the percentage of hemodialysis patients reaching target levels of 25(OH)D ≥ 30 ng/ of vitamin D deficiency/insufficiency in chronic kidney disease/end-stage kidney disease and mL at 3 months compared to placebo treatment (61. 5% the potential benefits of restoring vitamin D status, the potassium/ DOQI348 (2003) and KDIGO349 (2017) clinical practice vs 7. 4%; P 0. 0001).",
    "However, periodicmeasurement nificant outcomes is yet to be determined. of serum calcium and phosphorus should be considCross-sectional analysis of NHANES III showed a proered, especially for patients who are using calciumgressively higher prevalence of albuminuria with containing phosphate binders and/or vitamin D active decreasing 25(OH)D levels. 365 In a prospective cohort analogues. study, vitamin D deficiency was associated with a higher incidenceofalbuminuria. 366Therearelimitedrandomized Future Research clinical trials investigating the effect of cholecalciferol or There is a need of well-designed trials to determine: calcifediol on proteinuria in chronic kidney disease and the results are inconclusive. 367, 368 (cid: 1) Definition of vitamin D adequacy or insufficiency/ deficiency (cid: 1) 25(OH)D thresholds to initiate 25(OH)D Implementation Considerations supplementation (cid: 1) Theoptimalserum25(OH)Dconcentrationforpatients (cid: 1) Dosing, timingofadministration, andtypeofvitaminD with chronic kidney disease and the concentration at which patients with supplements in the chronic kidney disease population chronic kidney disease are considered deficient/insufficient are not well (cid: 1) Risks and benefits of vitamin D supplementation in the definedbutaregenerallyconsideredtobethesameasin chronic kidney disease population the general population, although there is no absolute (cid: 1) Long-term goals of vitamin D supplementation in the consensusaboutthedefinitionofvitaminDsufficiency. chronic kidney disease population. For most experts, vitamin D insufficiency is defined as serum 25(OH)D level between 20 and 29 ng/mL, deficiencyisconsideredas25(OH)Dlevel20ng/mL, 5. 4 Statement on Vitamins A and E andsufficiencyasserum25(OH)Dlevel≥30ng/mL. 343 Vitamins A and E Supplementation and Toxicity (cid: 1) Both the Kidney Disease Outcomes Quality Initiative and Kidney Disease: Improving Global Outcomes experts recommend 5. 4. 1 In adults with chronic kidney disease 5Don MHD orCKD 5Don peritoneal dialysis, checking and supplementing Low serum 25(OH)D itisreasonabletonotroutinelysupplementvitamin levels in patients with chronic kidney disease and Dialysis patients. 349, 369 A or E because of the potential forvitamin toxicity. In the most recent update of the Kidney Disease: Improving Global Outcomes guideline on However, if supplementation is warranted, care mineral and bone disorder, itissuggestedbasedonlow-qualityevidencethat should be taken to avoid excessive doses, and papatients with chronic kidney disease stages 1-5D have 25(OH)D levels tients should be monitored for toxicity (OPINION). measured, andrepeatedtestingshouldbeindividualized according to baseline values and interventions. However, there was no clear suggestion on how frequently Rationale/Background 25(OH)D levels should be reviewed. 349 Vitamin E is a fat-soluble nutrient recognized for antioxi- (cid: 1) With respect to vitamin D supplementation, current dant properties. There are 8 known naturally occurring guidelines suggest that patients with chronic kidney disease stages 1-5D forms of vitamin E, 339 but alpha-tocopherol is the only and vitamin D insufficiency/deficiency should receive known form of vitamin E that meets human requirements supplementation using the same strategies recomand is the form found in plasma. Therefore, Dietary mended for the general population. However, even for Reference Intake for vitamin E is only available for alphathe general population, the optimal dosage of suppletocopherol. The RDA for vitamin E was determined by mentationvariesamongthemainguidelines. Ithasbeen identifyingserumvitaminElevelsthatprovidedprotection recommended for 1, 000 to 2, 000 international unit/d of cholecalcifto erythrocyte survival when exposed to hydrogen erol for vitamin D repletion for the general population. peroxide. However, KDOQIacknowledges thatpatientswith chronic kidney disease Although vitamin E supplements are typically provided may require a more aggressive therapeutic plan. 369 as alpha-tocopherol, products containing other tocoph- (cid: 1) There is also a debate regarding which form of vitamin erols and tocotrienols have been reported. 339 The potency D should be used, ergocalciferol or cholecalciferol. In of synthetic alpha-tocopherol (RRR-alpha-tocopherol, labeled the general population, there appears to be some as D or d) is not identical to the natural form. This is advantage of using cholecalciferol over ergobecause synthetic alpha-tocopherol contains 8 stereoisocalciferol.",
    "This is advantage of using cholecalciferol over ergobecause synthetic alpha-tocopherol contains 8 stereoisocalciferol. 370 Because in chronic kidney disease there is no clear evidence mers, of which only 4 are found in tissues and serum. about the superiority of cholecalciferol, clinicians Synthetic alpha-tocopherol: all rac-alpha-tocopherol, labeled as S68 AJKD Vol76Iss3Suppl1September2020 Guideline 5: Micronutrients dlorDL, isthereforeonlyhalfasactiveasthenaturalform, cardiovascular causes, unstable angina, Heart failure hostherefore requiring 50% more international units to pitalizations, Heart failure, transient ischemic attack, or receive a dose equivalent to the natural source. 339 Most composite of myocardial infarction, stroke, or death from cardiovascular supplements provide vitamin E as alpha-tocopherol in a causes between groups. 100to 400-magnesium dose. Boaz et al377 examined the effect of vitamin E suppleVitaminEisafat-solublevitamin. Thepotentialriskfor mentation on cardiovascular disease end points (primary outcome) and allvitamin E toxicity is primarily related to the use of supcause mortality. MHD participants with pre-existing cardiovascular disease plements. 339, 372 High doses of vitamin E supplements in weresupplemented with daily oral800 IUof oralvitamin the form of alpha-tocopherol have been reported to cause Eforamedianof519days. Riskforall-causemortalitywas bleeding and/or disrupt Blood coagulation in vivo, and not significantly different between groups. The vitamin E there are some in vivo data that suggest that alphagroup had a significantly decreased risk for experiencing a tocopherol inhibits platelet aggregation. 372 The RDA for cardiovascular disease end point compared with the control group, but the vitamin E for healthy adult men and woman is 15 magnesium per RRs for fatal and nonfatal MIs, ischemic stroke, and physical examinationday (22. 4 international unit). The Food and Nutrition Board has defined ripheral vascular disease were not significantly different anupperlevelofintakeforvitaminEintheformofalphabetween groups. tocopherol and the stereoisomer forms in synthetic Based on these limited data, vitamin E supplementation vitamin E supplements as 1, 500 international unit and 1, 100 international unit/d, did not affect all-cause mortality. Results regarding the respectively. Although not definitive, these levels of intake effects of vitamin E supplementation on cardiovascular disease outcomes appeartobethesafetylimitwithregardtothepotentialof were mixed. Differences may be due to the population vitamin E to confer bleeding risk. studied or vitamin E dosage. In pooled analysis conducted SeveralstudiesevaluatedtheeffectsofvitaminEcoated in the current systematic review, there was no effect of dialyzer membranes on biocompatibility, blood pressure during dialvitamin E supplementation on cardiovascular disease outcomes, though ysis, and oxidative stress. 373, 374 However, results were heterogeneity of results was High. inconclusive. DataregardingtheeffectofvitaminEcoated Anthropometric Measures. Two RCTs examined the dialyzers on hemoglobin level, lipid profile, and nutrieffectofvitaminEsupplementationonnutritionalstatusin tionalstatuswereinconclusive, andstudydesignsforthese MHD participants. 376, 378 Participants received either trials and the meta-analyses were of Low quality. 375 tocotrienols (90 magnesium) and tocopherols (20 magnesium) for16 Studies examining daily vitamin A requirements for weeksor400IUoforalvitaminEperday, 600mgofALA individualswithvariousstagesofCKDarelacking. Optimal per day, or both for 2 months. Although there were no serumvitamin Elevels are not defined forthis population. changes in albumin levels between groups in the former Daily vitamin E required to maintain nutritional health, study (Daud et al378), in Ahmadi et al, 376 SGA score was reverse deficiency, and avoid toxicity in chronic kidney disease populations improved in the vitamin E, ALA, and combined suppleare unclear. Vitamin A was initially investigated in the mentation groups compared with placebo. SGA score was systematic review, but there were no dietary trials availthe primary outcome of interest in this study. Vitamin E able, only trials in which vitamin A was delivered IV, deficiency status at baseline was not described in either which was considered beyond the scope of this guideline. study. Three RCTs examined the effect of oral vitamin E supDetailed Justification plementation on anthropometric measures.",
    "magnesium/888 international unit) after 5 weeks, but no change in the control. Between-group differences were not reported. Boaz et Implementation Considerations al377 found that the vitamin Esupplemented group had (cid: 1) Implementation of vitamin E supplementation should significantly higher vitamin E levels compared with the consider the individual patients nutritional status, diplacebo group when MHD participants with pre-existing CVDweresupplementedwith800IUoforalvitaminEper etary intake, concomitant medications, comorbid conday for a median of 519 days, but between-group differditions particularly with regard to baseline cardiovascular disease, and ences were not reported. In pooled analysis of the 2 RCTs lipid levels. (cid: 1) Oraldoses≥400IUofvitaminEarenotrecommended thatexaminedvitaminEsupplementationalone, therewas without at least intermittent monitoring of serum no significant effect of supplementation compared with vitamin E levels. the placebo/control group. Therefore, available evidence indicates that vitamin E supplementation alone does not affect vitamin E levels. Monitoring and Evaluation Plateletcountshouldbemonitored, asshouldanychanges LipidLevels. Daily oral vitamin E supplementation of 110 magnesium for 4 months378 and 200 magnesium for 3 months in medical status, medications, and nutritional status. (Khajehdehi et al267) did not change serum TG, TC, or Future Research LDL-C levels but demonstrated the efficacy of increasing HDL-C levels. (cid: 1) Identify methods to assess vitamin E status. Current methods use serum levels of vitamin E, but the sensiSpecial Discussions tivity and reliability of this approach are unclear. As a result of the limited number of High-quality studies (cid: 1) Ascertain the optimal vitamin E status of the chronic kidney disease (see study selection criteria) and the variability in the population, including chronic kidney disease stages 1-5, those receiving outcomes reported in these trials, there is insufficient evDialysis, and those who have received a Kidney idence to make recommendations on vitamin E intake for transplant. patients with chronic kidney disease. The nutritional requirements or Rec- (cid: 1) The potential role of vitamin Etreated dialyzer memommendedDietaryIntakeofvitaminEforindividualswith branes on preventing intradialytic hypotension, chronic kidney disease stages 1-5, those undergoing maintenance Dialysis, improving nutritional status, decreasing/preventing and those posttransplant are unknown. Dose-response intradialytic inflammation, and anemia resistance is not studies identifying the relation between vitamin E intake yetdefined. Ongoingstudiesinthisareaareindicatedto and serum vitamin E levels are not available. The prevafurther define the role of vitamin Etreated dialyzer lence of vitamin E deficiency in the chronic kidney disease population is membranes. unclear. The potential of vitamin E toxicity with supple- (cid: 1) Investigate the recommended dietary vitamin E intake mentation is a concern for this fat-soluble vitamin. that will prevent vitamin E deficiency and the recomThere is a potential for toxicity in patients who are mendedsupplementaldoseofvitaminEthatwillcorrect being supplemented. High doses of vitamin E vitamin E deficiency without increasing the risk for S70 AJKD Vol76Iss3Suppl1September2020 Guideline 5: Micronutrients toxicity, including investigation of the effects of larger biliary and pancreatic secretions and occurs in the small doses of oral vitamin E (ie, 800 international unit/d). intestine, where vitamin potassium is incorporated into chylo- (cid: 1) Examine the effects of vitamin E supplementation on microns. The role of the menaquinones in vitamin potassium hard outcomes, including cardiovascular disease, morbidity, and morfunction and nutritional needs is still not completely tality, using RCTs. understood. LargedosesofvitaminEmayinducevitamin potassium deficiency. 384 5. 5 Statement on Vitamin potassium Detailed Justification and Special Discussion Anticoagulant Medication and Vitamin potassium Supplementation TheUSIOMstates thattheadequateintakeof vitaminKis 5. 5. 1 InadultswithCKD1-5Dorposttransplantation, itis 120 and 90 μg/d for adult men and women, respecreasonable that patients receiving anticoagulant tively. 385, 386 These values are based on median vitamin potassium medicines known to inhibit vitamin potassium activity (eg, intakes reported in the NHANES III data.",
    "Globally, dietary warfarin compounds) do not receive vitamin potassium recommendations for vitamin potassium usually vary from 50 to supplements (OPINION). 120 μg/d. 387Theserecommendationsdonotdifferentiate phylloquinone from menaquinone intake. At the time the USIOMrecommendationswereset, thefoodcomposition databases on which these recommendations were made Background contained only the phylloquinone content of foods. VitaminKisafat-solublevitaminthatactsasacofactorfor Hence, these current recommendations are based on gamma-glutamyl carboxylase, which enables the carboxphylloquinone, which is the major form of vitamin potassium in ylation of vitamin potassiumdependent proteins producing Western diets. coagulation factors. Coagulation factors II, VII, IX, and X Increasing age, platelet count, and serum urea and are the most well-known vitamin potassiumdependent proteins, Creatinine levels and lower serum albumin concentrations and deficiency in these factors can lead to impairment in were associated with more severe elevation in prothrombloodclotting. Vitamin potassium alsoenables normalcalcification bin time in patients taking antibiotics. 388, 389 Vitamin potassium processes to proceed in bone and soft tissues. Matrix Gla supplements may return prothrombin time to normal in Protein(MGP)isavitaminKdependentproteinproduced such patients. 389 Patients receiving antibiotics who have by vascular smooth muscle cells that is a powerful inhibpoorintakeandareathigherriskforbleeding(eg, surgical itorofvascularcalcificationinculturemediaandofintimal patients) may be considered for vitamin potassium supplements, atherosclerotic plaque calcification. After carboxylation, particularly if they have acute Kidney injury or chronic kidney disease. 388 MGP binds to calcium crystals, inhibiting further crystal However, the foregoing conclusions were essentially growth. MGP binds to bone morphogenetic Protein 2, based on observational studies of small numbers of thereby blocking the differentiation of vascular smooth patients. muscle cells toward osteochondrogenic type cells. A study of the NHANES data indicated that 72. 1% of VitaminKparticipatesintheenzymaticcarboxylationof adults with mild to moderate chronic kidney disease (estimated glomerular filtration rate by the chronic kidney disease proteins controlling bone calcium deposition (eg, osteoEpidemiology Collaboration chronic kidney disease-EPI equation: 58 mL/ calcin) and plays an important role in normal bone formin/1. 73 m2) had vitamin potassium intake below the recommation and structure. mended adequateintake level(mean, 97. 5; 95% CI, 89. 7HencevitaminK, byfacilitatingcarboxylationofcertain 105. 3μg/d). 390StudiesinItalyconfirmedthatdailyintake proteins, has major effects on Blood clotting, preventing of vitamin potassium in MHD patients is commonly below rec1 softtissuecalcificationincludingvascularcalcification, and ommended levels. 387 Several observational studies in controlling bone calcium crystal formation. advancedCKD(stages3-5)orMHDpatientsindicatedthat Two classes of vitamin potassium compounds are primarily serum vitamin potassium (phylloquinone) and vitamin potassium 1 2 responsible for vitamin potassium activity: phylloquinone (menaquinone) concentrations were frequently Low and (vitamin potassium ) and menaquinones (vitamin potassium ). 383 Phylthat serum levels of other uncarboxylated compounds, 1 2 loquinone is found primarily in foods, especially green whichwhenelevatedindicatedvitaminKdeficiency, were and leafy vegetables (eg, spinach, kale, cabbage, and increased. 391, 392 broccoli), plant-based oils found in many food products, The recommendeddietaryvitamin potassium intake forpatients and cows milk. There are more than 10 menaquinones with chronic kidney disease 1-5, including those with nephrotic syndrome, that differ in the number of isoprenoid units in its side those who are undergoing MHD or peritoneal dialysis, or those who are chain. Most menaquinones are produced by bacteria. posttransplant, were not defined and were based on that Menaquinone4isdifferentandappearstobeproducedin derived for the general population. In MHD patients, vivo from phylloquinone. 383, 384 Menaquinones are vitamin potassium intake and serum vitamin potassium levels are often Low found in dairy products (yogurt), meats, and fermented orundetectable, andserumuncarboxylatedosteocalcinand foods and also synthesized in the intestine by colonic PIVKA-II (Protein induced by vitamin potassium absence/antagobacteria. The intestinal absorption of vitamin potassium requires nist-II) levels are commonly elevated. 310, 311 AJKD Vol76Iss3Suppl1September2020 S71 Guideline 5: Micronutrients Vitamin potassium Levels.",
    "310, 311 AJKD Vol76Iss3Suppl1September2020 S71 Guideline 5: Micronutrients Vitamin potassium Levels. Only 1 short-term randomized Future Research controlled study has been published that examined the (cid: 1) Considering the High prevalence of bone disorders and effects of vitamin potassium supplements on vitamin potassium status in severe atherosclerotic and coronary artery vascular disMHD patients. 392 No such studies have been carried out ease in patients with chronic kidney disease and the relationship of these in other stages of chronic kidney disease or in peritoneal dialysis patients or those postdisorderstocalciumdepositioninthesetissues, thereis transplant. Thestudyinvolvedasmallnumberofpatients agreatneedtomorepreciselydefinethedietaryvitamin who received, by random assignment, supplements of 45, 135, or360μg/dofvitaminK (menaquinone-7)for Krequirementsandtherole, ifany, forroutinevitamin 2 potassium supplementation or increased vitamin potassium intake only 6 weeks. In general, there was a dose-dependent through food sources in patients with different types increase in serum vitamin potassium and decrease in serum 2 and stages of chronic kidney disease and with vascular calcification. uncarboxylated desphosphorylated form of-uncarboxy- (cid: 1) Examine the confounding effects of different comorbid lated dpucMGP (MGP), undercarboxylated osteocalcin, conditions on the dietary requirements for vitamin potassium and PIVKD-II levels. Mean serum vitamin potassium level 2 intake and the need for vitamin potassium supplements and the increased to previously reported normal values with the doseofsuchsupplementsinpatientswithkidneydisease. 45-μg/d dose and to modestly above normal values with (cid: 1) ExaminethephysiologyandmetabolismofvitaminKin the 135and 360-μg/d doses. Serum uncarboxylated people with chronic kidney disease, with particular regard to evaluate desphosphorylated form of MGP, ucosteocalcin, and why vitamin potassium deficiency appears to be more common PIVKD-II levels decreased most with the 360-μg/d dose, in people with advanced chronic kidney disease, including those underbut concentrations still tended to be above normal with going maintenance Dialysis. this dose. (cid: 1) Evaluate the long-term clinical effects including the There are currently several clinical trials of vitamin safety and potential risks, if any, of vitamin potassium potassium supplements in MHD patients, and more informasupplements. tion regarding vitamin potassium supplementation should be (cid: 1) Examine whether there are interactions between available within the near future297, 393, 394 (Clinical vitamin potassium supplements and anticoagulants that are not Trials Identifier: NCT01528800; NCT01742273; warfarin-type compounds. NCT2610933; NCT02870829; UMIN000011490; (cid: 1) Examine whether dietary intake of vitamin potassium and UMIN000017119). In a 2019 study published since 1 vitaminK haveanydifferentclinicallyimportanteffects the systematic review supporting this guideline, when 2 in Kidney diseases. patients receiving hemodialysis received 10 magnesium daily of rivaroxaban, those who received 2, 000 magnesium of menaquinone-7 three times each week after Dialysis had no 5. 6 Statement on Trace Minerals Selenium and difference in calcification outcomes at 18 months. Zinc Though they were secondary outcomes, authors also Selenium and Zinc Supplementation found no difference in all-cause death, stroke, car5. 6. 1 In adults with chronic kidney disease 1-5D, we suggest to not diovascular event rates, or adverse events between groups. 395 There is a paucity of data on the long-term routinelysupplementseleniumorzincsincethereis little evidence that it improves nutritional, inflamsafety of different vitamin potassium intakes and especially of matory, or micronutrient status (2C). vitamin potassium supplements and of the value, if any, of taking different vitamin potassium compounds. Individuals receiving vitamin supplements should not receive anticoagulant medicines that inhibit vitamin potassium activity (eg, warfarin compounds). Rationale/Background Selenium is a trace element that has known antioxidant Implementation Considerations propertiesandplaysaroleinenzymaticactivitiesinsidethe (cid: 1) Patients receiving antibiotics who have poor intake and body. It acts as a cofactor for the reduction in important are at higher risk for bleeding (eg, surgical patients) antioxidant enzymes such as glutathione peroxidase and may be considered for vitamin potassium supplements, particthus protects against oxidation.",
    "reduce the rate of decline of residual Kidney funcHowever, heterogeneity was High. Furthermore, it is not tion. known whether zinc supplementation in deficient patients may affect any health-related outcomes or clinical hard Bicarbonate Maintenance outcomes in patients with chronic kidney disease and Dialysis patients. The 6. 1. 2 InadultswithCKD3-5D, werecommendreducing long-term effects or any toxicity of zinc supplementation net acid production (NEAP) through increased biare also unclear at this stage. carbonate or a citric acid/Sodium citrate solution Therewerenoidentifiedstudiesexaminingtheeffectof supplementation(1C)inordertoreducetherateof zinc supplementation on dysgeusia in patients with chronic kidney disease, decline of residual Kidney function. though this topic has been explored in other 6. 1. 3 In adults with chronic kidney disease 3-5D, it is reasonable to populations. 425 maintain serum bicarbonate levels at 24-26 mmol/ L (OPINION). Implementation Considerations (cid: 1) Suggested intake should be based on recommendations for the general population (eg, RDA) unless there are specific considerations requiring modification. Rationale/Background Acid-base homeostasis is maintained by urinary acidifiMonitoring and Evaluation cation using titratable anions, such as phosphate, to trap There are no specific guidelines for monitoring selenium protons, and trapping ammonium in an acid Urine. As and zinc deficiency or supplementation. However, Kidney function declines, the net acidification requirealthough unlikely, practitioners should be aware of signs ment by residual nephrons increases. This leads to and symptoms of severe selenium and zinc deficiency in increased ammonia production per residual nephron patients with stages 3-5D chronic kidney disease. and requires delivery of glutamine to the residual nephrons as a source of the delivered ammonia. . The Future Research Recommendations increased per-nephron need for increased acidification (cid: 1) Evaluate biochemical testing and thresholds to define and ammonia genesis is in part endothelin controlled zinc and selenium deficiency and whether the same and may increase injury to residual nephrons. Acid thresholds in the general population are applicable to retention also would have the potential to promote patients with Kidney diseases. muscle wasting as part of the homeostatic processes of (cid: 1) Conduct population-based cohort studies to determine normalizing acid-base status. Metabolic acidosis inthe prevalence and importance of selenium and zinc creases skeletal muscle proteolysis by a ubiquitin prodeficiency across different stages of patients with chronic kidney disease teasome pathway that degrades actin, potentially having and Kidney transplant recipients, as well as Dialysis an adverse nutritional impact on the patient accompamodality, and examine whether selenium or zinc definied by an increase in protein-creatinine ratio. ciency may be related to various surrogate and hard clinical outcomes. Detailed Justification (cid: 1) Conduct adequately powered clinical trials of long Eleven studies examined the association between dietary enough duration to evaluate whether selenium or zinc acid load/oral bicarbonate supplements on health outsupplementation in deficient patients with chronic kidney disease and comes in the chronic kidney disease population. Of the included studies, S74 AJKD Vol76Iss3Suppl1September2020 Guideline 6: Electrolytes there were 4 RCTs, 212, 213, 426, 427 1 NRCT, 214 3 nonconcomparable between the 2 groups at baseline and the 1trolled studies, 428-430 2 prospective cohort studies, 431, 432 year follow-up (P 0. 84 and P 0. 32, respectively). This and 1 retrospective cohort study. 433 study does not isolate the effects of alteration in dietary composition and NEAP sufficiently to establish which chronic kidney disease Progression; Effect of Reducing Net Endogeintervention is associated with any biological change nous Acid Production. Studies aimed at evaluating the observed. effect of reduction in net endogenous acid production TheoutcomeofstudiesinpatientswithCKDstages1-2 (NEAP)havebeen2-fold; eitherdirectlyreducingNEAPby are less clear and the outcomes are not as definitive.",
    "This administration of Sodium bicarbonate or by dietary altermay be in part because the per-nephron stress of maination using fruits and vegetables, which both decrease taining acid-base balance is reduced, either decreasing the NEAP and alter the composition and quantity of dietary renal risk of acidification below a critical threshold or by Protein, partially confounding the effect of reduction of reducing the power necessary to measure an effect. NEAP alone. Additionally, studies that alter NEAP by changing dietary InadultswithCKD, 4RCTs, 212, 213, 426, 4271NRCT, 2142 composition are confounded by other variables, such as noncontrolled studies, 429, 430 2 prospective cohort aminoacidloadandquality. Oneoftheoutcomevariables studies, 431, 432 and 1 retrospective cohort study433 exammeasured was urinary albumin excretion. ined the effects of dietary fruit and vegetable or oral biNet Urine albumin excretion was not different among carbonate supplements on chronic kidney disease progression. In patients the 3 groups in patients with chronic kidney disease stage 1 (P 0. 05). withCKDstages2-4(20-65mL/min/1. 73m2inavailable However, in patients with chronic kidney disease stage 2, fruits and vegestudies), higher quartiles of NEAP were associated with tables had a greater decrease in net Urine albumin excregreaterI125iothalamateGFRdecline(P-trend0. 02). 432In tionthanbothbicarbonateandcontrol(P0. 05), andthe chronic kidney disease stages 3-5 not receiving Dialysis (≤60 milliliters per minute/1. 73 bicarbonate group had a greater decrease in net Urine alm2), higherNEAPisassociatedwithCKDprogression(P bumin excretion than control (P 0. 05). 214 It should be 0. 05forallquartilegroups). 433InCKDstages3-4(≥15or noted that a change in diet toward higher intake of fruit 60 milliliters per minute/1. 73 m2) compared with the lowest dietary and vegetables is a different and more complex intervenacid load tertile, the highest dietary acid load had greater tionthanchangeinNEAPbecausetheaminoacidloadand relative hazard of end-stage kidney disease (P 0. 05). 431 composition are changed. This may affect urinary Protein Studies reducing NEAP by the administration of oral loss and have an effect on progression that is independent Sodium bicarbonate are not confounded by alteration in of NEAP if the patient population has significant dietary Protein composition and are easier to study in a proteinuria. randomized controlled prospective manner. In studies involving patients with chronic kidney disease stages 4-5, the oral Sodium Hospitalization. The effects of oral bicarbonate supbicarbonate group had significantly greater Creatinine plements on hospitalization in patients with chronic kidney disease were clearance after 18 and 24 months (P 0. 05). Rapid chronic kidney disease mixed, though evidence is limited. In adults with chronic kidney disease, 2 progression (creatine clearance loss 3 milliliters per minute/1. 73 m2 RCTs426, 427 examined the effects of oral bicarbonate supper year) was lower in the oral Sodium bicarbonate group plements on hospitalization. Among patients treated by (respiratory rate, 0. 15; 95%CI, 0. 06-0. 40). ThedevelopmentofESKD peritoneal dialysis, compared with the placebo group, the intervention was lower in the oral Sodium bicarbonate group (respiratory rate, group had lower hospital admission (trend) and hospital 0. 13; 95% CI, 0. 04-0. 40). 426 In another study of chronic kidney disease length of stay (P 0. 07 and P 0. 02, respectively). 427 In stages 4-5, not receiving Dialysis, there was no significant chronic kidney disease stages 4-5; predialysis, there was no significance differenceincreatinineclearancebetweenbeforeandafter differenceinhospitalizationforheartfailurebetweenthe2 theintervention(P0. 05). 430Arecentstudynotincluded groups (P NS). 426 in the systematic review had similar findings in that parNutritional Status. In patients with chronic kidney disease stages 3-5 ticipants receiving Sodium bicarbonate (0. 4 mEq/kg IBW including those receiving maintenance Dialysis, oral biper day) for 24 months had no difference in change in estimated glomerular filtration rate compared with the placebo group.",
    "05 for both), with no difference between interaction between intake of Protein and net acid. bicarbonate and control. 214 Thus there does not appear to Separating the effect of reduction in acid load and the be a significant effect of reduction in NEAP on nutritional effect of change in dietary Protein amount and distatus in patients with chronic kidney disease 1-2. In chronic kidney disease stage 4 compared etary pattern on outcomes is challenging. with the bicarbonate group, the fruits and vegetables (cid: 1) When increasing fruits and vegetables intake to correct group had lower weight at the 1-year follow up (P acidload, usecautionandmonitorpotassiumlevelsand 0. 01); baselineweightdidnotdifferbetweenthe2groups make sure that energy and Protein intake meet the (P 0. 24). 212 In chronic kidney disease stage 3, fruits and vegetables had nutritional needs. greater net body weight loss than both bicarbonate and control (P 0. 05) and the control group had greater net body weight loss than the bicarbonate group (P Monitoring and Evaluation 0. 05). 213 Clinical trials have demonstrated adherence with expected changesinacid-basestatusasevaluatedbymeasurementof Special Discussions serum bicarbonate. In stage 5 MHD patients, higher bicarbonate concenConsuming fruits and vegetables in the amount that tration in the dialysate Rice is associated with increased could reduce dietary acid by 50% generally had positive mortality in epidemiologic studies. 435 In an analysis of effects on acid-base biomarkers. 212-214 Fruits and vegetaDOPPS data, it was reported that MHD patients with bles increased plasma total CO (though not significant in 2 either very Low bicarbonate (≤17 millimoles per liter) or very High 1 study)214 and decreased potential renal acid load and 8predialysis bicarbonate (27 millimoles per liter) concentrations hour net acid excretion. Except for Goraya et al214 (0. 5 are at the greatest mortality risk. 436 Paradigms that may mEq/kg per day), oral bicarbonate supplements also had apply to patients with residual renal function or those positive effects on acid-base biomarkers by increasing undergoing continuous therapy, such as peritoneal dialysis, do not plasma total CO or bicarbonate levels and decreasing 2 directly apply to hemodialysis patients who are experiencing large potentialrenalacidloadand8-hournetacidexcretionin6 changes in acid-base equilibrium rapidly and/or studies with different supplement combinations and discontinuously. Higher bicarbonate concentrations in dosages. hemodialysis patients may also be reflective of lower Protein No hyperkalemia events were noted in the studies of intake. Goraya et al, 212 who provided a diet rich in fruits and Research on this topic is complicated because the effect vegetables to patients with advanced chronic kidney disease. However, we of acidosis differs with the level of residual Kidney note that inclusion criteria in those studies considered S76 AJKD Vol76Iss3Suppl1September2020 Guideline 6: Electrolytes patients at Low hyperkalemia risk not consuming reninRationale/Background angiotensin system inhibitors. Although no studies have Calcium is a multivalent cation important for many bioformallyevaluatedthecontributionofdietarypotassiumto logicalandcellularfunctions. Approximately99%oftotalhyperkalemia risk in these patients, we recommend body calcium is found in the skeleton and the rest is caution if a fruit and vegetablerich diet is to be recompresent in the extracellular and intracellular spaces. In mendedtocontrolmetabolicacidosis. Closemonitoringof additiontoitsroleinmaintenanceofbonehealth, calcium serum/plasma Potassium levels is encouraged, and fruit/ serves a vital role in nerve impulse transmission, muscular vegetable consumption should be temporarily limited if contraction, Blood coagulation, hormone secretion, and the patient is considered at risk for hyperkalemia. Moniintercellular adhesion.",
    "Moniintercellular adhesion. toring of circulating Potassium level is specially recomCalcium balance is tightly regulated by the concerted mended in patients with chronic kidney disease stage 4 or higher, including action of calcium absorption in the intestine, reabsorption thosereceivingdialysis, becausethisisthekidneyfunction in the Kidney, and exchange from bone, which are all range in which inabilities to compensate for dietary pounder the control of calciotropic hormones triggered by tassium occur. demand for calcium. Serum calcium concentration is maintained in the Future Research normal range until very late in chronic kidney disease, when it decreases (cid: 1) ResearchisneededtoidentifythecontributionofNEAP slightly. 438 However, calcium balance in chronic kidney disease is poorly to that of Protein intake to progression of Kidney disunderstood. Calciumdeficiencyduetodecreasedintestinal ease, as well as to increase urinary Protein excretion. It calcium absorption is a stimulus for the development of is unknown what if any of the injurious effects of secondary hyperparathyroidism and resultant bone disorProtein is contributed by acid load. ders. However, calcium excess may promote extraosseous (cid: 1) Increaseddietaryacidintakeisbelievedtocontributeto calcificationcontributingtotheincreasedriskforCVDand loss of Kidney function and sarcopenia. Further undermortality of these patients. 439 In Kidney transplant, calstandingoftheoptimalthresholdfortranslationofthese cium balance is even more complex and depends on benefits to morbidity and mortality is necessary. several factors, such as posttransplant Kidney function, (cid: 1) With regard to the effects of fruits and vegetables, it is persistenceofhyperparathyroidism, previousbonedisease, important to separate the effect of other aspects of difand immunosuppressive therapy. 440 ferences in dietary composition, amino acid content, and carbohydrate composition from the control diet Detailed Justification from the effects of acid load. Serum calcium levels do not reflect overall body calcium (cid: 1) Increasing pH during intermittent hemodialysis has not been balance and may not be very informative except at exshown to improve clinical outcomes, albeit most tremes. Maintenance of serum calcium level in the normal studies are based on epidemiologic data. It is range in chronic kidney disease depends on several factors, such as bone important to establish the optimal intradialytic biturnover, mineral-regulating hormones, degree of Kidney carbonate concentration and dialytic bicarbonate function, use of vitamin D analogues, dialysate calcium delivery to patients receiving MHD, as well as to concentration, and calcium intake, especially from supunderstand the contribution of reduced Protein plements. A careful medical and nutritional history may intake to higher serum bicarbonate levels in hemodialysis provide some insight into the adequacy of calcium intake. patients. However, due to the multifactorial causes of altered calcium metabolism in chronic kidney disease, the establishment of adequate amounts of dietarycalcium ischallenging and dependson the investigation of calcium balance. 6. 2 Statements on Calcium Theevidencereviewincluded3smallshort-termclinical Total Calcium Intake trialsinCKDpatientsnotreceivingdialysisthatinvestigated 6. 2. 1 In adults with chronic kidney disease 3-4 not taking active vitamin D the effect of calcium intake in food or supplements on analogs, we suggest that a total elemental calcium mineral bone biomarkers and calcium balance. No other intake of 800-1, 000 magnesium/d (including dietary caloutcomes were investigated in these studies. cium, calcium supplementation and calcium-based Calcium Balance and Other Laboratory Measurphosphate binders) be prescribed to maintain a es. In an NRCT, 51 patients in the early stage of chronic kidney disease neutral calcium balance (2B). (Creatinine clearance, 66-82 milliliters per minute) were placed on a 6. 2. 2 In adults with chronic kidney disease 5D, it is reasonable to adjust Low-Protein (40 g/d) and Low-phosphorus (600 magnesium/d) calcium intake (dietary calcium, calcium supplediet supplemented with or without 0. 5 g/d of elemental ments, or calcium-based binders) with considercalcium for 10 days.",
    "5 g/d of elemental ments, or calcium-based binders) with considercalcium for 10 days. 441 A decrease in intact parathyroid hormone level was ation of concurrent use of vitamin D analogs and observed only in the group receiving calcium supplecalcimimetics in order to avoid hypercalcemia or mentation and no changes in serum calcium, phosphorus, calcium overload (OPINION). and calcitriol levels were found in the other groups. AJKD Vol76Iss3Suppl1September2020 S77 Guideline6: Electrolytes Inacrossoverstudy, 6patientswithCKDstages3and4 Implementation Considerations consumed controlled High- (2, 000 magnesium/d) and Low-calHypercalcemia is relatively common in patients receiving ciumdiets(800mg/d)for9days. 442Calciumbalancewas maintenance Dialysis. Evidence has been accumulated slightly negative to neutral in both patients and healthy linking higher serum calcium concentrations to increased controls on the Low-calcium diet (91 ± 113 and 144 ± nonfatal cardiovascular events448 and mortality. 449-452 In 174 magnesium/d, respectively; P 0. 05) and more positive in the event of hypercalcemia, the following adjustments are patients than in controls on the High-calcium diet (759 ± recommended348: 120 and 464 ± 225 magnesium/d, respectively; P 0. 05). Serum (cid: 1) In patientstaking calcium-basedphosphate binders, the calcium and phosphate concentrations were unchanged dose should be reduced or therapy switched to a nonand intact parathyroid hormone and 1, 25(OH) D levels decreased in the 2 calcium phosphate binder. High-calcium diet. (cid: 1) In patients taking active vitamin D analogues, the dose In a 3-week randomized crossover balance study, 8 should be reduced or therapy discontinued until serum patients with chronic kidney disease stages 3 and 4 were randomly concentrations of calcium return to normal. assigned to a controlled calcium intake of 2, 457 magnesium/ (cid: 1) Ifhypercalcemiapersists, considerusingalowdialysate d (1, 500 magnesium of elemental calcium from calcium carcalciumconcentration(1. 5-2. 0mEq/L). Thisshouldbe bonate used as phosphate binder 957 magnesium/d of dietary done with caution because observational studies have calcium) versus placebo (957 magnesium/d of dietary callinked this approach with increased risk for arrhythmia cium). 443 Calcium balance was neutral in the placebo and Heart failure. 453, 454 group and positive in the calcium carbonate group (508 vs 61 magnesium/d, respectively; P 0. 002). Serum calcium, phosphate, and intact parathyroid hormone concentrations were unFuture Research changed in both groups. (cid: 1) Adequatedietarymanagementofcalciumcancontribute Despitethesmallnumberofpatientsinvestigated, these inthecontrolofmineralandbonerelatedcomplications well-performed balance studies showed that dietary calinCKD. However, thereisanurgentneedforadditional cium intake of approximately 800 to 1, 000 magnesium/d may be researchtocovertheexistinggapinthisarea. adequatetomaintaincalciumbalanceinpatientswithCKD (cid: 1) Calcium balance studies are needed to provide data for stages 3 and 4 who are not receiving active vitamin D recommendation of a safe calcium intake threshold for analogues, at least at short term. These values are close to patients with chronic kidney disease in the different stages of the disease, the current estimated average requirement (800-1, 000 including maintenance Dialysis (MHD and peritoneal dialysis) and magnesium/d) and the RDA (1, 000-1, 200 magnesium/d) for healthy inKidney transplant. dividuals proposed by the IOM. 371 (cid: 1) The effect of different sources of calcium (dairy foods, Special Discussions fortified foods, and calcium supplements) on serum calcium concentrations should be studied. In maintenance Dialysis patients, calcium balance is (cid: 1) Defineacceptableserumcalciumthresholdsfordifferent more complex. In addition to dietary calcium load and chronic kidney disease stages. use of vitamin D analogues, calcium concentration in the dialysate and mode of Dialysis also determine the mass balance of calcium. Studies using mathematical 6. 3 Statements on Phosphorus modeling have shown a positive calcium balance mass in patients receiving MHD. 444, 445 According to estimates Dietary Phosphorus Amount 6. 3. 1 InadultswithCKD3-5D, werecommendadjusting and assumptions made, extracellular fluid calcium levels increased with an elemental daily calcium intake 1.",
    "3. 1 InadultswithCKD3-5D, werecommendadjusting and assumptions made, extracellular fluid calcium levels increased with an elemental daily calcium intake 1. 5 g dietary phosphorus intake to maintain serum phosphate levels in the normal range (1B). and were numerically more positive when patients are given active vitamin D analogues. 444 The excess of Dietary Phosphorus Source extracellular calcium is deposited in either osseous or 6. 3. 2 InadultswithCKD1-5Dorposttransplantation, itis extraosseous sites. The extensive soft tissue calcification reasonable when making decisions about phosphatehighly prevalent in MHD patients suggests that extraphorus restriction treatment to consider the osseous sites seem to be the repository for this calcium. 446 bioavailability of phosphorus sources (eg, animal, vegetable, additives) (OPINION). Although calcium balance studies are demanding, they are essential to provide data to make conclusive Phosphorus Intake With Hypophosphatemia recommendation for calcium intake from diet or sup6. 3. 3 For adults with chronic kidney disease posttransplantation with plements for patients receiving maintenance Dialysis. hypophosphatemia, it is reasonable to consider Notably in Kidney Disease: Improving Global Outcomes (chronic Kidney disease-mineral and bone disorder) 2009 and 2017, there prescribing High-phosphorus intake (diet or supare no recommendations for calcium intake for patients plements) in order to replete serum phosphate receiving maintenance Dialysis or with a Kidney transplant. 349, 447 (OPINION). S78 AJKD Vol76Iss3Suppl1September2020 Guideline 6: Electrolytes Rationale/Background recommended to prevent/treat complications related to Phosphorus intake is necessary for bone growth and High phosphate load in patients with chronic kidney disease stages 3-5 and mineralization, as well as for regulation of acid-base homaintenance Dialysis. This can be achieved by intensified meostasis. Phosphorusisanessentialnutrient, occurringin patient educational strategies or individualized dietary most foods both as a natural component and an approved plans. 464 This evidence review included 5 short-term ingredient added during food processing. Because of difclinical trials that evaluated the effect of reduced dietary ficulties of persons with chronic kidney disease to clear excess phosphorus, phosphorus on phosphorus intake, phosphate levels, and additionalmeansofserumphosphatecontrolarenecessary urinary phosphorus excretion, as discussed in the to avoid hyperphosphatemia, which could lead to bone following. and mineral metabolism disorders of chronic kidney disease. Phosphate restriction regimens in nondialysis There are physiologic adaptations in the early stages of chronic kidney disease. Two RCTs157, 441 examined the effects of reduced chronic kidney disease that prevent excessive phosphorus retention, so the dietary phosphorus in patients with chronic kidney disease not undergoing inability to increase phosphorus excretion to avoid phosphateDialysis. These studies evaluated the effect of a Low-phosphatephorus accumulation and hyperphosphatemia is generally phorus diet alone or in combination with an Low protein diet and seen when estimated glomerular filtration rate decreases to 45 milliliters per minute, 455 being less observed significant reductions in serum phosphate levels common in earlier chronic kidney disease stages. In the setting of anuria in and urinary phosphorus excretion postintervention. patients receiving maintenance Dialysis, hyperReducing phosphorus by limiting Protein intake in phosphatemia risks are particularly heightened, 456 with a nondialysis chronic kidney disease. Five RCTs in patients with chronic kidney disease not prevalence as High as 50%. 457 undergoing Dialysis stages 4-5146, 147, 154, 167, 177 evaluated the effect of an Low protein diet or very Low protein diet supplemented with KAs on Detailed Justification serum phosphate levels. All 5 studies reported statistically How much dietary phosphorus/phosphate should be significant147, 154, 167, 177 or borderline-significant146 rerestricted in adult patients with chronic kidney disease is not well estabductions in serum phosphate levels at the end of interlished. Traditionally, chronic kidney disease-specific recommendations sugvention.",
    "Traditionally, chronic kidney disease-specific recommendations sugvention. The interested reader can find more information gest maintaining phosphorus intake between 800 and on this topic in the evidence analysis of dietary Protein 1, 000 magnesium/d in patients with chronic kidney disease stages 3-5 and those restriction in these guidelines. receiving maintenance Dialysis to maintain serum phosphatephate levels in the normal range. 67, 160, 348, 349, 458, 459 Phosphate restriction regimens in maintenance Dialysis. TwoRCTs136, 465examinedtheeffectsoflimiting However, the work group notes that the efficacy of this dietary phosphorus in patients with chronic kidney disease undergoing recommendation has not been established. Further, such a MHD. Lou et al136 tested the effect of a 3-month intensidietaryphosphorusintakerangeishigher thanthecurrent fied dietary counseling to achieve 800 to 900 magnesium/d of recommended dietary allowance for phosphorus in the adult general population (700 magnesium/d). 460 dietary phosphorus and observed a greater decrease in serum phosphate concentrations compared with standard Although dietary intake influences serum phosphate care. Sullivan et al465 tested the effect of patient education levels in patients with chronic kidney disease, factors other than intestinal on identifying foods with phosphorus additives and phosphorus/phosphateabsorption(namelyexchangewith observed, compared with standard care, a significant boneandexcretionbythekidneysinpatientswithresidual reduction in serum phosphate levels after 3 months. No renal function) may be major determinants of serum studies were identified that included peritoneal dialysis patients. phosphate levels. Thus, the work group prefers not sugAlthough dietary phosphorus restriction may be a valid gesting specific dietary phosphate ranges, but to instead stand-alone strategy in patients with chronic kidney disease stages 3-4, the emphasize the need to individualize treatments based on working group notes that collectively, the serum phosphatepatient needs and clinical judgment, taking into considphate reductions achieved solelyby limitingdietary intake eration natural sources of organic phosphorus (animal vs are modest (especially for Dialysis patients) and recomvegetal Protein-based dietary phosphorus) and the use of phosphorus additives in processed foods. 461-463 mend this strategy as only one in the armamentarium of interventions to maintain serum phosphate levels in the With the goal of better understanding the effect of dinormal range. For other nondietary phosphate manageetary phosphate control, the work group decided in this ment strategies, the interested reader can consult recent evidenceanalysistofocusonreportsthataddresseddietary guidelines on the management of the mineral and bone disorder of phosphorus intake/output/balance. This resulted in the chronic kidney disease. 67, 160, 348, 349, 458, 459 Aligning with those guidelines, exclusion of studies reporting solely on serum phosphate we recommend that decisions to restrict dietary phosphatelevels. phorus be based on the presence of progressively or Phosphorus Control. Limiting dietary phosphorus persistently elevated serum phosphate levels (ie, trends intake(perseorincombinationwithrestrictionofdietary rather than a single laboratory value) and after considerProtein, the major source of dietary phosphorus) may be ation of concomitant calcium and parathyroid hormone levels. AJKD Vol76Iss3Suppl1September2020 S79 Guideline6: Electrolytes Clinical Consequences of Dietary Phosphorus Conprobably pointing to a null association. Three studies trol. Whereas many studies have explored the outcome evaluatedthecross-sectionalassociationbetweenmeasures associations with serum phosphate levels throughout the of dietary phosphorus and mortality in individuals with spectrum of chronic kidney disease, the clinical consequences of restricting nondialysisCKD. 466, 470, 471Murtaughetal470evaluatedthe dietary phosphorus are not well studied. association between 24-hour dietary recall estimation of chronic kidney disease progression. Three observational studies evaluphosphorus intake in participants with eGFRs 60 mL/ ated the effects of dietary phosphate restriction on chronic kidney disease min/1. 73 m2 from the community-based ultrasound NHANES III progression. Resultsweremixedandevidencewaslimited. and observed no association between dietary phosphorus Williams et al157 studied the impact of a dietary phosphateintake and mortality.",
    "3 g/kg per day) supplemented and possibly leading to osteomalacia and osteodystrophy. with KAs, each for periods longer than 1 year, Di Iorio et Its pathogenesis has been attributed to increased renal al469 observed that 24-hour proteinuria was reduced phosphateexcretionduetoelevatedlevelsofphosphaturic modestly in patients who maintained relatively higher hormones, the effect of glucocorticoid, persistent elevated serumphosphatelevelsorrelativelyhigherphosphaturiato parathyroid hormone levels, suboptimal recovery of vitamin D activation, be maximal in those who achieved the lowest level of and imbalance in FGF-23. 474-476 serum and Urine phosphate. It has been proposed that dietary intensification of Mortality. In observational studies involving patients phosphorus can solve this complication; 1 small RCT withCKD, theassociationsofdietaryphosphorusintakeon examined the effects of a 12-week dietary phosphorus mortalityare mixed, affectedbyresidualconfoundingand supplementation by means of a neutral phosphate salt S80 AJKD Vol76Iss3Suppl1September2020 Guideline 6: Electrolytes (disodium phosphate) in patients with early postinstance, in bakery products, enhanced meats, and transplantation hypophosphatemia. 477 The authors processed cheeses. 483 observed that compared with Sodium chloride, supple- (cid: 1) Advise choosing natural foods that have a Low amount mentationofphosphorusimprovedhypophosphatemia, as of organic phosphorus versus High amount of Protein. wellasadenosinetriphosphateinthemusclesandtheacid The content of organic phosphorus per 1 g of Protein excretion capacity of the Kidney. No adverse effects on varieswidelyamongfoods. Nutrientcompositiontables serumcalciumandPTHconcentrationswerenotedduring reportingonphosphorustoproteinratiocontentcanbe the intervention. used to recommend food substitutions that can However, the serum phosphate level at which suppleconsiderably reduce the daily intake of organic phosphatementation should be considered in these patients or the phorus while ensuring adequate dietary Protein dose of replacement to be given is not well studied and intake. 481, 484-486 should be decided based on patient needs and clinical (cid: 1) Advise preparing foods at home, using wet cooking judgment. methods such as boiling (and discard the Water). These methods are able to remove about 50% of phosphorus content from foods. 487, 488 Slicing the meat before Implementation Considerations boiling and use of a Hypertension cooker have been shown Recommendations to lower dietary phosphorus intake in to be more effective in terms of achieved Protein to patients with chronic kidney disease have been met with concerns, often phosphorus content. 487 At the same time, these relating to the risk for limiting the intake of other nutrimethodsmayremoveotherminerals(eg, Potassium)of ents, particularly Protein, which is the main source of phosphate in the diet. 473, 478, 479 These concerns are concern for patients with chronic kidney disease. 489 However, such practicesresultinreducedpalatabilityandtextureofthe particularly relevant to patients treated with Dialysis food. because of Protein losses in dialysate and greater Protein catabolism from metabolic stress. 219 Dietary counseling The work group emphasizes to individualize recomthat includes information on not only the amount of mendations after appropriate evaluation of the patients phosphate but also the source of Protein from which the daily intake. It requires nutrition expertise (preferably phosphate derives and suggestion on methods of cooking consultation with a renal dietitian) and should take into phosphate-rich foods can achieve phosphorus intake consideration culturally appropriate food substitutions. withoutcompromisingdietaryqualityorproteinstatus. 480 Nutritional counseling sessions should evolve from the (cid: 1) Advise choosing natural foods that are lower in simpleconceptofphosphaterestrictiontoopportunitiesof educating the patient on differentiation between organic bioavailablephosphorus. Animal-andplant-basedfoods and inorganic sources of phosphate and avoidance of contain the organic form of phosphate. Although aniphosphate additives. 137 Simple educational programs on mal-based phosphate is absorbed in the gastrointestinal how to read food labels and look for phosphate additives tract by 40% to 60%, the absorption of plant-based phosphorusislower(20%-50%). 481Inlinewiththis, a proved to be successful in helping Dialysis patients reduce their serum phosphate levels.",
    "481Inlinewiththis, a proved to be successful in helping Dialysis patients reduce their serum phosphate levels. 464, 465 A meta-analysis sugsmallcrossovertrialincludingpatientswithCKDstage4 gested that nutritional counseling based on structured found that a 7-day vegetarian diet led to lower serum behavioral change are in general successful in controlling phosphate levels and decreased FGF-23 levels than a 7day meat-based diet. 199 Furthermore, foods with only hyperphosphatemia in these patients. 137 However, in this meta-analysis, only about half the studies were randomorganic phosphorus typically are more nutrient dense izedcontrolledinterventionswithashortdurationranging and have higher nutritional value compared with profrom 1 to 6 months, which calls for a need of more cessed foods containing phosphate additives, which dedicated long-term interventional studies on this topic. tendtohavelowernutritionalvalueandareoftenpaired with Sodium and Potassium additives. 482 (cid: 1) Advise choosing commercial food items prepared Future Research Dietary management of phosphorus is an important stratwithout phosphorus-containing food additives. phosphateegy for serum phosphate control in chronic kidney disease. However, as phorus additives are increasingly being added to procomparedwiththemanystudiesexploringpharmacologic cessed and fast foods to preserve moisture or color, management of this electrolyte disorder (eg, use of emulsify ingredients and enhance flavor, and stabilize phosphate binders), the amount of evidence on the foods. However, phosphorus additives contain inoreffectiveness of dietary control is Low. The work group ganic phosphorus with close to 100% intestinal absorption. 480, 481 Meat and poultry products that report recommends future studies to better define the effect of this simple and cost-effective strategy. Examples of still the use of additives have an average phosphate to prounanswered questions are: tein ratio much higher than additive-free products. 462, 463 The most commonly used phosphorus (cid: 1) Study whether dietary phosphorus restriction is able to additives in the food industry can be found, for normalize serum phosphate levels in peritoneal dialysis patients. AJKD Vol76Iss3Suppl1September2020 S81 Guideline6: Electrolytes (cid: 1) Research whether a higher dietary phosphorus intake The consequences of dietary Potassium intake in palevel is associated with worse clinical outcomes such as tients with chronic kidney disease are not known. No clinical trials were cardiovascular events, progression of Kidney disease, or identified that directly examined the relationship between mortality and patient-centered outcomes. dietary Potassium consumption and either serum levels or (cid: 1) Study the benefits and potential adverse nutritional and clinical outcomes. However, several studies used urinary metaboliceffectsofrestrictingdietaryphosphorusand/or Potassium excretion or other surrogates for dietary intake limitingtheintakeofphosphateadditivesinpatientswith to assess the following outcomes. Although we acknowlnondialysisCKDstages3-5andmaintenancedialysis. edge that urinary Potassium excretion may not necessarily (cid: 1) Study the effects of nutritional counseling with a focus represent dietary Potassium in these patients, the studies on organic versus inorganic phosphorus sources on the showed the following results. diet quality and metabolic balance of maintenance Mortality. Dataontheassociationbetweendietaryand Dialysis patients beyond serum phosphate control. urinary Potassium excretion and mortality in adults with 6. 4 Statements on Potassium CKDweremixed. AstudyinpatientsreceivingMHDfound that compared with the lowest quartile of dietary potasDietary Potassium Amount sium intake (879 magnesium or 22. 5 mEq/24 h) as measured 6. 4. 1 InadultswithCKD3-5Dorposttransplantation, itis using the Block Food Frequency Questionnaire, higher reasonable to adjust dietary Potassium intake to quartilesofintakewereassociatedwithastepwiseincrease maintainserumpotassiumwithinthenormalrange in5-yearmortalityrisk(P-trend0. 03). 490Anotherstudy (OPINION). in patients with chronic kidney disease stages 2-4 found no significant associationbetweenquartilesofurinarypotassiumexcretion Dietary and Supplemental Potassium Intake for Hyperkalemia or and all-cause mortality. 491 Compared to the highest Hypokalemia quartile of urinary Potassium excretion (mean, 3, 600 magnesium 6. 4. 2 In adults with chronic kidney disease 3-5D (2D) or postor 92. 1 mEq/24 h), persons in the 3 lowest quartiles had transplantation(OPINION)witheitherhyperkalemia higher all-cause mortality (HRs of 1. 53 95% CI, 1. 15or hypokalemia, we suggest that dietary or sup2. 02, 1.",
    "53 95% CI, 1. 15or hypokalemia, we suggest that dietary or sup2. 02, 1. 7 95% CI, 1. 25-2. 31, and 1. 71 95% CI, 1. 23plemental Potassium intake be based on a patients 2. 38 for quartiles 3, 2, and 1, respectively). Results individual needs and clinician judgment. remained similar even after using time-updated average urinary Potassium excretion. 492 Rationale/Background chronic kidney disease Progression. Data for the association between As the main intracellular cation, Potassium plays a major urinarypotassiumexcretionandCKDprogressioninadults role mediating cellular electrophysiology, vascular funcwith chronic kidney disease were mixed. In patients with chronic kidney disease stages 2-4, tion, blood pressure, and neuromuscular function. High or Low serum urinary Potassium excretion in the highest quartile (≥67. 1 Potassium levels have been associated with muscular mmolor2, 617mg/24h)wassignificantlyassociatedwith weakness, hypertension, ventricular arrhythmias, and chronic kidney disease progression (defined as incident end-stage kidney disease or halving of death. Theinfluenceofdietarypotassiumconsumptionon estimated glomerular filtration rate from baseline; heart rate, 1. 59 95% CI, 1. 25-2. 03) serum Potassium content is therefore of great clinical compared with levels in the lowest quartile (39. 4 mmol relevance. Because the mechanisms involved in Potassium or 1, 541 magnesium/24 h). 491 In another study in patients with homeostasis and excretion (ie, adrenergic system, insulin, stages 2-4, baseline urinary Potassium excretion was not aldosterone, and urinary clearance) are commonly significantly associated with Kidney failure (defined as impaired in patients with chronic kidney disease and end-stage kidney disease, hyperkalemia is dialysistherapyortransplantation)evenwhenusingtimeanespeciallysalientconcern. Dietarypotassiumisthefocus updated average urinary Potassium excretion. 492 of these recommendations (Potassium binders were outside the scope of the current guideline). NerveFunction. Onerandomizedstudyexaminedthe effects of dietary Potassium restriction on progression of Detailed Justification peripheralneuropathy. In42patientswithstages3-4CKD Thereisascarcityofstudiesonthistopicandwefoundno randomly assigned to either dietary Potassium restriction clinical trials on how modifying diet can influence serum versus usual diet (change in dietary Potassium, 854 magnesium Potassium levels in patients with chronic kidney disease. The work group vs 343 magnesium; P 0. 35), Potassium restriction was associemphasizes that factors other than dietary intake influence ated with stabilization of a neuropathy score (difference, serumpotassiumlevels. Theseincludemedications, Kidney 0. 4 ± 2. 2; P 0. 01) and several other nerve-related or function, hydration status, acid-base status, glycemic general health scores over 24 months. 493 control, adrenal function, a catabolic state, or gastrointestinalproblemssuchasvomiting, diarrhea, constipation, Special Discussions and bleeding. All these factors should be consideredwhen Research on this topic is complicated because Potassium formulating a strategy to keep serum Potassium levels handling by the Kidney will vary by disease state and chronic kidney disease within the normal range. stage. InpatientswithpredialysisCKD, theacuteandlongS82 AJKD Vol76Iss3Suppl1September2020 Guideline 6: Electrolytes term effects of dietary Potassium loading are not consis- (cid: 1) There is a need to investigate how Potassium binders tently reflected in serum Potassium levels due to canbeintegratedwithadiettooptimizepotassiumand compensatory mechanisms that are triggered to maintain overall nutritional intake. homeostasis. 494-496 Research and evidence in this area are (cid: 1) In patients receiving MHD, the effect of the Potassium also limited because of difficulties obtaining reliable data Rice concentration on cardiovascular risk, mortality, for dietary Potassium intake and absorption. and other outcomes needs further elucidation. Potassium binders bind Potassium in the gut and preventhyperkalemia. Intheory, thesemedicationscouldlead 6. 5 Statements on Sodium to a more liberalized Potassium-rich diet (ie, fruits and vegetables). However, noneofthepivotaltrialsexamining Sodium Intake and Blood Hypertension Potassium binders evaluated dietary Potassium intake, and 6. 5. 1 In adults with chronic kidney disease 3-5 (1B), chronic kidney disease 5D (1C), or no study investigated how Potassium intake should be posttransplantation (1C), we recommend limiting modifiedinthepresenceofpotassiumbinderuse. Because sodiumintaketolessthan100mmol/d(or2.",
    "Because sodiumintaketolessthan100mmol/d(or2. 3g/ the focus of this guideline was dietary intake rather than d) to reduce Blood Hypertension and improve volume pharmacologic therapy, Potassium binders were outside control. the scope of this guideline. Sodium Intake and Proteinuria Implementation Considerations 6. 5. 2 In adults with chronic kidney disease 3-5 we suggest limiting dietary (cid: 1) Potassium is widely distributed in foods, ranging from sodiumintaketolessthan100mmol/d(or2. 3g/ d) to reduce proteinuria synergistically with availfruits, vegetables, legumes, and nuts, as well as dairy able pharmacologic interventions (2A). and meat products. Notably, Potassium content is available on food labels in many countries and conSodium Intake and Dry Body Weight sumers and practitioners could have a better idea of its 6. 5. 3 In adults with chronic kidney disease 3-5D, we suggest reduced dicontent, especially foods that are processed. Because etary Sodium intake as an adjunctive lifestyle these foods are rich sources of vitamins and minerals modification strategy to achieve better volume and some provide additional dietary fiber, it is essential control and a more desirable body weight (2B). that dietary restrictions of Potassium also consider the overall diet and health goals for the individual patient. (cid: 1) When treating hyperkalemia, clinicians are advised to first try to identify contributing factors that can be corrected, such as a hypoinsulinemic state or certain Rationale/Background medications. This is true in light of the physiologic Sodium is an extracellular cation responsible for fluid benefits that High Potassium intake may confer, such as homeostasis in the body. 501 Normovolemia is maintained putative antihypertensive effects. 497 If hyperkalemia through the action of the renin-angiotensin-aldosterone cannotbereversed, thenextstep istoidentifythemost system. This system acts to adjust the quantity of Sodium important dietary sources of Potassium by interviewing excreted by the body and thereby extracellular fluid volthe patient and using dietary recalls. Clinicians preferumeandarterialBP. Excesssodiumintakeisexcretedinthe ably assisted by a renal dietitian should recommend Urine and serum levels are tightly controlled, requiring fruits, vegetables, and other foods with Low Potassium normalkidneyandbloodvesselfunction. 502However, this contentthatstillcontainhigherlevelsoffiberandother systemmaybecompromisedwithexcessivesodiumintake micronutrients. Published food composition tables can and/orinadequateexcretion, whichmayoccurwith chronic kidney disease. be helpful in this regard. 498 In addition, boiling vegeLong-term High Sodium intake may affect a number of tables can reduce Potassium content in vegetables. Any physiologic functions relating to the vasculature, Heart, reductions in food taste and palatability associated with kidneys, and sympathetic nervous system. 503 Excessive this strategy can be partially improved with the use of Sodium intake is thought to exert toxic effects on Blood aromatic herbs. 499, 500 vessels through mediating factors such as oxidative stress, inflammation, and endothelial dysfunction. 504 Of particular interest in chronic kidney disease is the role of Sodium reduction in Future Research improving the pharmacologic effect of antihypertensive It will be necessary to approach predialysis and Dialysis medication, thereby controlling hypertension. populations separately in light of the large differences in In the general population, short-term intervention Potassium handling. studies show significant reductions in blood pressure (hypertensive (cid: 1) There is a need to study what constitutes an optimal subgroup, reductionsof5. 8mmHgSBPand2. 82mmHg dietarypotassiumintakeaccordingtodifferentstagesof DBP) with a 100-mmol/d reduction in Sodium intake. 505 CKDandhowdietarypotassiumintakeinfluencesblood Indications from a small number of long-term studies (6 Potassium content and clinical outcomes. months)suggestabenefitforcardiovascularmorbidityand AJKD Vol76Iss3Suppl1September2020 S83 Guideline6: Electrolytes mortality, although the studies were underpowered to betweenthelow-andhigh-intakegroups(100mmol/dor adequatelyexaminetheseoutcomes. 506Thefollowingwill 2. 3 g Sodium difference). explore the evidence within chronic kidney disease. One RCT was undertaken in patients postKidney transplantation.",
    "3 g Sodium difference). explore the evidence within chronic kidney disease. One RCT was undertaken in patients postKidney transplantation. 518 This was a parallel RCT of a 12-week Detailed Justification intervention that included counseling by a dietitian for a Overall, the evidence for reducing Sodium intake comes target intake of 80 to 100 mmol/d compared with usual from RCTs of short duration and typically small sample care. This trial demonstrated a significant reduction in size. Asaresult, thereisafocusonclinicalmarkerssuchas sodiumintakeintheinterventiongroup(from190±75to blood pressure, inflammation, body weight, fluid, and proteinuria. 106 ± 48 mmol/d) through dietary counseling, with no There is limited evaluation of hard outcomes, which significant change in the usual-care group (191 ± 117 to thereby rely on observational evidence. In addition, the 237 ± 113 mmol/d). certainty of evidence for Sodium reduction is limited by In the vast majority of trials, the target Sodium restricimprecision and risk of bias, particularly selection, attrition was 80 to 100 mmol/d (or 2-2. 3 g/d). However, bution, and performance bias. therewasalackofconsensusastowhatconstitutesahigh Five RCTs, 1 parallel, 507 and 4 crossover studies508-511 Sodium intake, which was either based on usual intake or examined the effects of reduced dietary Sodium intake in providing supplemental Sodium to ensure a consistently chronic kidney disease (stages 2-5, nondialysis). The crossover studies used High Sodium intake, around 200 mmol or 4 g of Sodium supplemental sodium509-511 or provided meals508 on the per day. background of a Low-Sodium diet to generate consistent intake in the High- (180 mmol to 200 mmol/d, with Mortality, chronic kidney disease Progression, and Cardiovascular about 100-120 mmol/d supplemented) versus Low-soEvents. Thereisinsufficientevidencetomakeastatement diumintakegroup(placebo, total50to0mmolofsodium onreducedsodiumintakeandkidneydiseaseprogression, per day). The parallel RCT was the longest study duration mortality, and cardiovascular events. The evidence for (6 months) conducted in a sample of Bangladeshi immiclinical end points is derived from observational studies grants in the United Kingdom (n 48). 507 Participants because there were no RCTs in Sodium reduction in chronic kidney disease were randomly assigned to a tailored intervention that reported chronic kidney disease progression, cardiovascular event, and including cooking classes modifying traditional cultural mortalityoutcomes. Thisisattributabletothesmallsample recipes together with regular telephone calls with a dietisizes and the longest trial duration of only 6 months. 507 tian. From a baseline Sodium intake of approximately 260 The post hoc analysis of 2 observational cohort studies mmol, the intervention group achieved 138 mmol/d (a showed mixed results investigating the association bereduction of 120 mmol), whereas usual care stayed tween Sodium intake (measured using dietary recall) and largely stable (to 247 mmol/d). subsequent mortality in MHD511 and peritoneal dialysis patients. 520 The Two more recent studies build on this evidence base retrospective cohort study in 303 peritoneal dialysis patients in Japan and include a parallel512 and a crossover trial. 513 Meuleindicated that Low Sodium intake was significantly associman et al512 conducted a 3-month open-label RCT, n ated with higher overall and cardiovascular mortality. 138 adults with chronic kidney disease, hypertension, and High urinary soHowever, this study was open to indication bias because diumexcretion(≥120mmol/d). Theinterventionfocused Sodium intake was also associated with higher LBM, on self-management advice to reduce Sodium (goal, 100 younger age, and higher body mass index. In contrast, in a post hoc mmol/d) and blood pressure monitoring or usual care. In the most analysis of a prospective cohort of 1, 770 MHD patients, recent crossover trial, Saran et al513 evaluated the effect of Mc Causland et al519 found higher dietary Sodium intake sodiumrestrictionof2g/dversususualdietfor4weeks associated with increased mortality. (with a 2-week washout in between) in stages 3 and 4 Moreconsistentresultsweredemonstratedfromalarge chronic kidney disease.",
    "(with a 2-week washout in between) in stages 3 and 4 Moreconsistentresultsweredemonstratedfromalarge chronic kidney disease. This study improved on previous crossover trials High-quality prospective cohort (Chronic Renal Insuffibecause it used dietary counseling, rather than Sodium ciencyCohortCRICStudy)ofCKDpatientsnotreceiving supplementation, to achieve the difference between usual Dialysis with stages 2-4, using urinary Sodium excretion. and Sodium-restricted intakes. In He et al, 491 24-hour urinary Sodium excretion was Four trials were conducted in the maintenance Dialysis associated with greater all-cause mortality and chronic kidney disease propopulation: 1RCTinPD, 5142RCTsinMHD, 515, 516and1 gression (defined as incident end-stage kidney disease or halving of estimated glomerular filtration rate nonrandomizedtrialinbothPDandMHD. 517IntheMHD frombaseline). Sodium excretion wasalsoassociated with study, there was no significant reduction in blood pressure. 516 The composite cardiovascular disease (Heart failure, myocardial infarction, or stroke). 521 difference with this study, compared with all others in Dialysis, is that dietary prescription (rather than suppleBloodPressure. Overall, Sodium reduction probably mentalsodium)wasusedtoachieveamodestreductionof reduces blood pressure in Kidney disease (moderate certainty eviintake (goal, 34 mmol/d lower than usual intake). This dence). Thisevidencereviewincluded9small(n20ton compares to the other interventions in maintenance dial- 52)randomizedclinicaltrials(6werecrossovertrials)of ysis using Sodium supplementation, which achieved a short duration (1 week to 6 months) evaluating the effect much larger gradient of difference in Sodium intake of reducing Sodium intake (typically to a level of 2 g or S84 AJKD Vol76Iss3Suppl1September2020 Guideline 6: Electrolytes 90 mmol/d) on blood pressure. Lower Sodium intake significantly 1-5 nondialysis population (Low-certainty evidence). In decreased SBP in all except 1 study, 516 which reduced the single parallel RCT over 6 months of Sodium restricintake by only 34 mmol/d compared with 90 mmol/ tion, deBrito-Ashurstetal507foundnodifferenceineGFR. dfromtheothertrials. However, thecertaintyofevidence The inconsistency in results may be due to the short-term was limited by risk of bias, particularly risk of selection, crossover trials demonstrating acute hyperfiltration attribution, and performance bias. When evaluating the responsetolow-sodiumintakecomparedwiththelongerevidenceacrossstagesofCKD, thevastamountofevidence term parallel trial reflecting a more clinically stable exists in predialysis chronic kidney disease; however, the blood pressure benefits were circumstance. also apparent in trials in dialysis514, 516, 517, 522 and transRestrictionofsodiumintakemayreduceproteinuria, as plant populations. 518 demonstrated in 3 randomized crossover trials. 509-511, 525 Although this review was unable to derive a summary This evidence is supported by further parallel RCTs and estimate, a Cochrane review on this topic published in observational studies. Meuleman et al512 demonstrated a 2015 showed that dietary Sodium reduction (mean difreduction in proteinuria over 3 months of self-manageference, 105. 9 95% CI, 119. 2 to 92. 5 mmol/d) mentinterventionusingsodiumintake100mmol/dthat resulted in significant reduction in SBP (mean difference, reversed to baseline proteinuria after cessation of the di- 8. 76 95% CI, 11. 35 to 3. 80 mm Hg). These shortetary Sodium restriction. In addition, post hoc analyses of term studies showed clinically meaningful blood pressure reductions clinical trials (REIN I and II) in proteinuric patients with rangingfrom2to12mmHgSBPand1to8mmHgDBP established chronic kidney disease have demonstrated that consuming a in trials 1 week to 6 months in duration. 523 higher Sodium diet was associated with increased risk for progressingtoESKDcomparedwithalowersodiumdiet Inflammatory Markers. Sodium reduction may make 100 mmol/d. 526 little to no difference to inflammation (Low certainty evidence). Two RCTs, a parallel RCT in MHD516 and a crossover in stages 3 and 4, 509 investigated the impact of Implementation Considerations sodiumrestrictiononinflammation, measuredbyCRP, IL- (cid: 1) Achieving a reduced Sodium intake in chronic kidney disease is recom6, andTNF-αlevels. IntheRodriguesTelinietal516study, mended but can be particularly challenging to achthere was a significant reduction in levels of all inflamieve.",
    "IntheRodriguesTelinietal516study, mended but can be particularly challenging to achthere was a significant reduction in levels of all inflamieve. 527 This is a result of the need to navigate a matory markers within the intervention group; however, complex interplay between individual food choice and not reported were between-group differences (and no food supply, together with a range of other dietary difference within control group). The single crossover recommendationsthatcomewithCKD. Becausesodium study in stages 3-4 showed no difference in inflammation is consumed largely from processed foods, the WHO comparing Highand Low-Sodium intake. 509 has initiatives for reducing Sodium content in manufactured foods among the top priorities to combat Body Weight and Fluid. Sodium restriction may noncommunicable diseases. 528 Consuming a Low-soslightly reduce body weight and total-body fluid in nondium diet generally requires education and skill develDialysis chronic kidney disease (Low certainty evidence). However, it is unopment(cookingandlabelreading)andexplicitchoice certain whether Sodium restriction reduces body weight to consume a Low-Sodium diet. Therefore, a concerted and body Water in Dialysis. The evidence from nondialysis and multifaceted intervention strategy is required to chronic kidney disease comes from 2 randomized crossover trials, 1 using support achieving this intake in clinical practice. This Sodium supplementation to compare intake of 60 to 80 mmol/dwith180to200mmol/dfor2weeks509together includes targeting individual behavior change for diwith a more recent investigation by Saran et al513 evaluetary choices, together with a wider public health ating the effect of Sodium restriction 2 g/d versus usual strategytoreducetheavailabilityofsodiuminthefood supply. 528 diet for 4 weeks (with a 2-week washout in between). (cid: 1) Theinterventionsundertakeninclinicaltrialsofsodium Both trials demonstrated a reduction in extracellular volreduction have limited applicability when translating ume. Furthermore, in maintenance Dialysis, 2 RCTS into practice. Many trials to date have used Sodium demonstrated no significant difference in body weight with salt restriction in PD515 or both hemodialysis and peritoneal dialysis. 524 In 1 supplementation or provided foods to enhance adherence in short-term effectiveness studies. 528 Innonrandomized study in hemodialysis, the group advised to restrict Sodium (3 g/d) and fluid (1 L/d) intake demonstrated vestigations of efficacy and behavioral interventions to adopt Low-Sodium intakes in real-life settings are a within-group decrease in interdialytic fluid gain, but limitedintheliterature. Ofthosethatexist, theevidence there was no change in the control group, and betweengroup difference was not significant. 515 is either short term (6 months) or demonstrates that achievingreducedsodiumintakeisonlyapparentwhile Kidney Function (Including Proteinuria). Restriction receiving active intervention. 512 The challenge for the of Sodium intake may slightly reduce Kidney function future is to develop an evidence base to inform sucmarkers of Creatinine clearance508, 510, 511, 522 and eGFR525 cessful strategies to support long-term adherence to demonstrated in short-term crossover trials in the stage dietary Sodium reduction. AJKD Vol76Iss3Suppl1September2020 S85 Guideline6: Electrolytes (cid: 1) Issues with Sodium intake assessment include that topotassiumratiomaybemoreeffectiveinloweringBP measuring Sodium intake and thereby accurately thanloweringsodiumorincreasingpotassiumassingle evaluating adherence to recommendations is interventions. 531 However, there are unknown safety extremely challenging in practice. Sodium intake can aspects in chronic kidney disease, particularly with the risk for hyperbe measured in objective (Urine collection over 24 kalemia. Investigating the relative benefit of Sodium hours or spot sample) and self-report (dietary recall) reduction compared with Potassium intake is beyond or a combination of methods. Urinary Sodium the scopeof the current guidelines but warrants further excretion as a surrogate measure of intake assumes: research. Evidence for Potassium recommendations is 1) a stable intake reflected in a single 24-hour addressed within these guidelines. collection, and 2) Sodium excretion is a direct (cid: 1) Currentlythere istoo much uncertainty inthe evidence reflection of intake.",
    "collection, and 2) Sodium excretion is a direct (cid: 1) Currentlythere istoo much uncertainty inthe evidence reflection of intake. It is this latter assumption that to advise on the effectiveness of Sodium restriction has been recently challenged by Titze, 529 who idenbased on specific thresholds of proteinuria. However, tified a Sodium storage pool in the skin and wide this intervention appears to be effective over a large disparity between Sodium intake and excretion day to range of proteinuria. day. Increasing the number of 24-hour urinary collections may improve the accuracy to partially overFuture Research come these concerns; however, it is not practical in clinical practice. Self-reported dietary assessment (cid: 1) Clinical trials to investigate behavioral interventions methods are prone to reporting bias, can be time using approaches that are patient centered and supconsuming to collect, and require technical expertise port the adoption of long-term strategies for reducing in the analysis. A panel of methods is therefore recSodium intake. In the design of behavioral inommended because no one method is ideal to terventions incorporating less processed foods, adequately assess adherence. 528 including cooking skills, label reading, avoiding (cid: 1) For Sodium relative to Potassium intake, recent obsereating out, and provision of interventions that tailor vational evidence suggests that the ratio of Sodium to to a range of literacy levels. Potassium intake may be as important, if not more (cid: 1) Clinical trials investigating the safety and effectiveness important, than lower Sodium intake alone in chronic kidney disease. 491 oflowsodiumrelativetoincreasedpotassiumintakeon This is the premise of the DASH-Sodium trial and has cardiovascular disease and chronic kidney disease outcomes. demonstrated benefits in the general population, with (cid: 1) Clinical trials to evaluate the long-term effectiveness of Sodium reduction providing additive benefit in blood pressure reduced Sodium intake on hard outcomes. reduction to the DASH diet. 530 In hypertensive adults, (cid: 1) Enhance objective markers of intake and/or improve post hoc analysis of clinical trials indicates that Sodium self-report options with technology advancement. S86 AJKD Vol76Iss3Suppl1September2020 Biographic andDisclosure Information BIOGRAPHIC AND DISCLOSURE INFORMATION Jerrilynn D. Burrowes, PhD, RD, CDN, FNKF Financial Disclosure: Dr Byham-Gray has no relevant DrBurrowesisProfessorofNutritionintheDepartmentof financial interests to disclose. Biomedical, HealthandNutritionalSciencesatLongIsland University Post in Brookville, NY. Dr Burrowes has numerous publications in refereed journals and she has Katrina L. Campbell, PhD, RD been an invited speaker at several professional meetings DrCampbellisanAssociateProfessoratGriffithUniversity, andconferencesonnutritioninkidneydisease. SheisacoBrisbane, Australia, and leads a Health Services Research editorforthe1stand2ndeditionsofthetextbookentitled portfolio in the largest health service in Australia (Metro Nutrition in Kidney Disease, and she is currently the senior North Hospital and Health Service). As a dietitian with a editor for the 3rd edition, which will be published by career spanning clinical practice, teaching, and research, Springer in early 2020. Dr Burrowes has held many leadDrCampbellhasbeendedicatedtoadvancingtheevidence ershipandadvisoryrolesinprofessionalorganizationsand base for the nutrition management in Kidney disease. Her societies, and she has served on numerous association recent research includes roles as a clinical trialist with the committees. She is currently Council Member of the InAustralasian Kidney Trials Network Scientific Committee, ternational Society of Renal Nutrition and Metabolism Associate Investigator on a large research program BEAT- (ISRNM)forthe2018-2020term. Forthepast8years, Dr chronic kidney disease, and the sole dietitian on the landmark DIET-hemodialysis BurrowesservedastheEditor-in-ChieffortheJournalofRenal study, recruiting more than 10, 000 participants worldNutrition. She was also a member of the work group that wide. Her work includes lifestyle interventions in chronic developed the initial Kidney Disease Outcomes Quality Kidney disease (chronic kidney disease), investigating the role of dietary Initiative (Kidney Disease Outcomes Quality Initiative) Clinical Practice Guidelines for Nutripatterns in the trajectory of chronic kidney disease, and nutrition status tion in Chronic Renal Failure.",
    "Dr Burrowes received the assessment and workforce issues, published in more than Recognized Renal Dietitian Award and the Joel D. Kopple 120 peer-reviewed papers. To translate evidence to pracAward from the National Kidney Foundation (National Kidney Foundation) tice, Dr Campbell has led capacity-building workforce Council on Renal Nutrition, and the Outstanding Service initiatives, authored numerous clinical guidelines and Award from the Renal Practice Group of the Academy of systematic reviews, and evaluated the impact of research NutritionandDietetics. DrBurrowesearnedherBachelors translation changing models of care, including co-design degree in biology/pre-medicine from Fisk University in and evaluation for the delivery of lifestyle interventions Nashville, TN; her MS degree in foods, nutrition, and diusing technology. etetics from New York University; and her PhD in nutrition from New York University. Financial Disclosure: Dr Campbell reports no relevant financial relationships. Financial Disclosure: Dr Burrowes reports no relevant financial relationships. Juan-Jesus Carrero, Pharm, PhD (Electrolyte Section Chair) Laura D. Byham-Gray, PhD, RDN, FNKF Dr Carrero is a Professor of Kidney Epidemiology at the Dr Byham-Gray is a Professor and Vice Chair for Research Department of Medical Epidemiology and Biostatistics, in the Department of Clinical and Preventive Nutrition Karolinska Institutet, Stockholm, Sweden. Dr Carrero is Sciences, School of Health Professions at Rutgers Univercurrently the codirector of education outreach program sity. She has received several extramural research grants at the ISRNM and the chair of the European Renal Nutrifromthefederalagenciestoinvestigateenergyexpenditure tion working group at the European Renal Associationand Protein-energy wasting (protein-energy wasting) in patients on renal European Dialysis and Transplant Association (European Renal Associationreplacementtherapies. DrByham-Grayhasheld numerous European Dialysis and Transplant Association). In 2014 he received the Joel Kopple Award from elected and appointed positions at the national, state, and the National Kidney Foundation for his work in Renal Nutrition Research. He has locallevelsofNKF, theAmericanSocietyofParenteraland authored more than 400 peer-reviewed publications and Enteral Nutrition, and the Academy of Nutrition and Di30 book chapters. His research interests include chronic kidney disease epetetics. She has also served as the associate editor for the idemics, pharmacosafety, and protein-energy wasting in chronic kidney disease, with special NKFpublicationtheJournalofRenalNutrition. DrByham-Gray emphasis on body composition, diet quality, and procawas the chief editor for 2 books: Nutrition in Kidney Disease tabolic endocrine disorders. He sits on the board of the (SpringerPublications, 2014), andAClinicalGuidetoNutrition Center for Gender Medicine at Karolinska Institutet, serves Care in Kidney Disease (Academy of Nutrition and Dietetics, as associate editor for Nephrology, Dialysis, and Transplantation 2013) and has more than 100 peer-reviewed articles and andJournalofRenalNutrition, andiseditorialboardmemberat presentations to her credit. Journal of Nephrology. AJKD Vol76Iss3Suppl1September2020 S87 Biographic andDisclosureInformation Disclosures: Dr Carrero reports funding to the Kartheformofjournalarticles, books, andbookchapters. She olinska Institutet for research from AstraZeneca, Viforhas served as a member of the editorial board of Journal of pharma, NovartisAstellas, andMSDfortopicsunrelatedto Renal Nutrition. She presented at various national and interthis guideline. He has performed consultation for Fresenational conferences as an invited speaker. nius, Rubio(cid: 2) laboratories, Astellas, and Baxter and participated as speaker for events organized by Abbott, Nutricia, Financial Disclosure: Dr Cuppari reports no relevant and Dr Schar. financial relationships. Winnie Chan, PhD, RD, FNKF Denis Fouque, MD, PhD DrChanisaPost-DoctoralResearchFellowatUniversityof Birmingham. Shehasmorethan10yearsofexperienceasa Dr Fouque is Professor of Nephrology at the University clinical dietitian specializing in renal nutrition. She was Claude Bernard Lyon, and Chief of the Division of appointed as a Dietetic Research and Postgraduate EducaNephrology at the Hospital Lyon Sud in Lyon, France. He tion Lead, and a Dietitian Representative of Non-Medical is the past Research Vice President (Health Affairs) at the Clinical Academic Research Group at Queen Elizabeth Universit(cid: 2)eClaudeBernardLyon, thelargestmedicalschool Hospital Birmingham. Dr Chan received her Bachelors in France.",
    "Dr Chan received her Bachelors in France. Dr Fouque has published 360 papers, including DegreeinNutritionandPostgraduateDiplomainDietetics reviews, meta-analyses, and 21 book chapters, among from Kings College, University of London. She obtained which are 2 chapters in The Kidney, Brenner and Rector, 2012 herPhDfromtheUniversityofBirmingham, co-fundedby and 2015. His current h factor is 64 and his citations are a National Health Service West Midlands Strategic Health 18, 500. Hisresearchfieldsareinnutritionandmetabolism Authority PhD Research Training Fellowship and a British in chronic kidney disease and Dialysis. Dr Fouque also got training in RenalSocietyresearchgrant. Shehasfosteredkeenresearch Evidence-based Medicine by founding the Cochrane and clinical interests in Kidney transplantation. Her CollaborationRenalGroup. DrFouquewasPresidentofthe research work focuses on investigating the role of nutriISRNM, co-editor-in-Chief of the Journal of Renal Nutrition, tion, body composition, and physical strength on clinical chairman of the European Renal Association-European Dialysis and Transplant Association Nutrition Guideline, and viceoutcomes and quality of life in Kidney transplant rechair of the European Renal Best Practice group of European Renal Associationcipients. She is a multiaward-winning researcher, having European Dialysis and Transplant Association until 2017. He is the past-chair of the European delivered numerous presentations and invited lectures in Nutrition working group of the European Renal Association-European Dialysis and Transplant Association, and the curherareasofacademicandclinicalexpertiseatnationaland rent Editor-in-chief of Nephrology, Dialysis, and Transplantation international conferences. In addition to consistent publijournal. cations in well-respected journals, Dr Chan has authored book chapters and Practice-based Evidence in Nutrition Financial Disclosure: Dr Fouque received honoraria, Knowledge Pathway in the field of renal nutrition. She travel support, and lecture fees from Sanofi, Lilly, Vifor, serves on the editorial board of Journal of Renal Nutrition. She and Fresenius Kabi. isanactiveresearchgrantreviewpanelmemberforKidney Research UK and the British Renal Society. To date, she continues her pivotal role as an Expert Adviser for the Allon N. Friedman, MD National Institute for Health and Care Excellence (NICE) Centre for Guidelines in Renal Disease. Dr Friedman is an Associate Professor of Medicine at Indiana University School of Medicine in Indianapolis and Financial Disclosure: Dr Chan reports no relevant medical director of an affiliated Dialysis unit. Dr Friedman financial relationships. trained at Tufts University and the ultrasound Department of Agriculture-Human Nutrition Research Center in Boston before joining Indiana University. Dr Friedman has pubLilian Cuppari, PhD (Chair) lished dozens of articles, editorials, and book chapters on Dr Cuppari is a dietitian who completed a masters degree topics related to the overlap between nutrition and Kidney in nutrition and PhD at Federal University of Sao Paulo, disease and has received grant funding from the National Brazil. SheiscurrentlyaffiliateprofessorintheDepartment Institutes of Health, National Kidney Foundation, and other institutions. He is on of Medicine/Division of Nephrology at Federal University theeditorialboardoftheJournalofRenalNutritionandFrontiers ofSaoPaulo, andasupervisorofnutritionintherenalunit in Nephrology and has played a leadership role at the Amerof Oswaldo Ramos Foundation-Kidney Hospital in Sao ican Society of Nephrology and the American Association Paulo, serving as the leader of the research and clinical ofKidneyPatients. Heiscurrentlyacouncilmemberofthe practice group on nutrition and Kidney disease. She is an ISRNM. advisor in the Graduation Program of Nutrition and Nephrology at Federal University of Sao Paulo. She has Financial Disclosure: Dr Friedman is a member of the published extensively in the field of nutrition and chronic kidney disease in scientific advisory board for GI Dynamics. S88 AJKD Vol76Iss3Suppl1September2020 Biographic andDisclosure Information Sana Ghaddar, PhD, RDN, RN number of ongoing studies aimed at improving the outDr. Ghaddar recently joined Landmark Health Care as the comes and quality of life in patient populations ranging clinical nurse supervisor. She previously worked as a renal from early Kidney disease, patients receiving maintenance dietitianandaclinicmanageratDaVitaHealthCare. Shehas Dialysis, and patients with acute Kidney injury.",
    "Shehas Dialysis, and patients with acute Kidney injury. He is more than 22 years of experience in the renal and clinical currently an Associate Editor for Kidney International, and he dieteticsfield. DrGhaddartaughtat2privateuniversitiesfor wasthePastPresidentofISRNM2010to2012andNKFof morethan15yearsandmentoredseveralPhDstudentson Middle TN 2002 to 2004, an Associate Editor for Journal of theirresearchstudies. ShehasservedontheAnemiaKDOQI American Society of Nephrology 2006 to 2012, Director of the Guidelinecommittee. ShehasseveralpublicationsinpeerMaster of Science in Clinical Investigation Program at reviewed journals, has served asa member of theeditorial VUSM 2005to 2017, andmember andChair ofAmerican board, andisareviewerforseveralpeer-reviewedjournals, Board of Internal Medicine Nephrology Test Writing including Journal of Renal Nutrition and Archives of Clinical Committee 2008 to 2018. He is the recipient of the National Kidney Foundation Nephrology. Dr Ghaddar is an author of a chapter of the Joel Kopple Award, ISRNM Thomas Addis Award, and textbook entitledNutrition inKidney Disease, 3rd ed (currently VUSM Excellence in Mentoring Translational Scientist under final review). She has been an invited speaker at Award. He has published more than 250 original articles, numerousnationalandinternationalprofessionalmeetings 50 editorial reviews, and 20 book chapters. He is the coand conferences. Dr Ghaddar has a special interest in editor of Handbook of Nutrition in Kidney Disease, 7th ed, and nutrition and metabolism in chronic kidney disease and in cognitive behavChronic Kidney Disease, Dialysis, and Transplantation, 4th ed. ioralcounselingtoimprovepatientoutcomes. Financial Disclosure: Dr Ikizler is a consultant and Financial Disclosure: Dr Ghaddar reports no relevant received honoraria for his consulting work from Abbott financial relationships. Renal Care, Fresenius Kabi, Nestle, and Reata. He is an Associate Editor for Kidney International and received honoraria for his work. D. Jordi Goldstein-Fuchs, DSc, APRN, NP-C, RD Dr Goldstein-Fuchs is a nephrology nurse practitioner and George A. Kaysen, MD, PhD Kidney nutrition specialist with the Pediatric Nephrology DivisionatLucilePackardHospitalStanford. Shehasworked Dr Kaysen is an emeritus professor of Medicine and with adults within all stages of Kidney disease and more Biochemistry and Molecular Medicine at the University of recentlyhasexpandedherexpertisetotherealmofpediatric California(UC)DavisSchoolofMedicine. HewasChiefof nephrology. DrGoldstein-Fuchshasbeenengaged inboth the Nephrology Division for 23 years at UC Davis and basic and clinical research and has an active publication ActingChairofBiochemistryandMolecularMedicinefor6 record pertaining to nutrition and metabolism in renal years. He also served as Chief of Nephrology of the disease. SheisEditorEmeritusoftheJournalofRenalNutrition, DepartmentofVeteransAffairsaffiliatedmedicalcenter, as having served as Co-Editor-in-Chief for 15 years. She has well as Associate Chief of Staff for Research at that instiservedontheCardiovascularandDiabetesKDOQIGuideline tution. HeservedasChairoftheISRNM. Heisstillactively committeesandisaFellowoftheNKF. engaged in research and in-patient care. His research interests are in the relationships between inflammation and Financial Disclosure: Dr Goldstein-Fuchs reports no nutrition and cardiovascular and infectious outcomes and relevant financial relationships. regulation of lipoprotein structure and function in both patients and experimental animals with chronic kidney disease and/or proteinuria, as well as regulation of albumin metabolism and gene transcription and regulation of the serum concenT. Alp Ikizler, MD, FASN (Chair) tration of other both positive and negative acute-phase Dr Ikizler is the Director of Division of Nephrology and proteins both in patients with chronic kidney disease and with nephroticHypertension and Professor of Medicine at the Vanderbilt range proteinuria. He received his MD and PhD at the University School of Medicine (VUSM) in Nashville, Albert Einstein College of Medicine in the Bronx, NY. Tennessee. HealsoholdstheCatherineMcLaughlinHakim Chair in Vascular Biology. He is a member of American FinancialDisclosure: DrKaysenhasnorelevantconflicts Society of Clinical Investigation, Association of American of interest and nothing to disclose. Physicians, and Federation of American Societies for ExperimentalBiologyBoardofDirectors. Hehassignificant research and clinical interest in nutritional and metabolic Joel D. Kopple, MD aspects of acute and chronic disease states.",
    "Hehassignificant research and clinical interest in nutritional and metabolic Joel D. Kopple, MD aspects of acute and chronic disease states. As a clinical investigatorfocusedonmechanismsofdiseaseandpatientDr Kopple is Professor Emeritus of Medicine and Public related outcomes, he is the principal investigator of a Health at the David Geffen UCLA School of Medicine and AJKD Vol76Iss3Suppl1September2020 S89 Biographic andDisclosureInformation UCLA Fielding School of Public Health. He served from Dialysis(ISPD)2006andTravellingLecturerAwardofAsia 1982 to 2007 as the Chief of the Division of Nephrology PacificFederationofClinicalBiochemistry2012. Sheisthe and Hypertension at Harbor-UCLA Medical Center. Dr currentPresidentoftheISRNMandCouncilmemberofthe Kopples research focus has been on amino acid and proISPD. She is also a North and East Asia Regional Board tein metabolism and nutritional and metabolic disorders memberof theInternationalSociety ofNephrology(International Society of Nephrology), and their management, particularly in Kidney disease and Committee member of the International Society of Nephrology-Advancing Clinical Trial Kidney failure. He has authored or coauthored many Core Group, and Executive Committee member of the hundreds of peer-reviewed manuscripts, invited papers, Standardized Outcomes in Nephrology (SONG) Initiative, and chapters. He is an editor of many proceedings and Steering member of the SONG-Peritoneal Dialysis and symposia and an editor of the textbook entitled Nutritional SONG-Hemodialysis Cardiovascular Disease. She was an Management of Renal Disease. He participated in founding the Executive Committee Member of Kidney Disease: ISRNM, the International Federation of Kidney FoundaImproving Global Outcomes (Kidney Disease: Improving Global Outcomes; 2015-2017). She is tions, andWorldKidneyDayandservedaspresidentofthe a work group member of the National Kidney Foundation Clinical Practice National Kidney Foundation, the American Society of Parenteral and Enteral GuidelinesforNutritioninChronicKidneyDisease(2015Nutrition, and other professional and scientific societies. 2019) and Prescribing High Quality Goal-Directed PeriDr Kopple is a Fellow of the American College of Physitoneal Dialysis Practice Recommendations of ISPD (2017cians, the American Society for Clinical Nutrition, the 2019). She chaired the ISPD Adult Cardiovascular and American Society of Nephrology, and the National Kidney Foundation. He has MetabolicGuidelines (2012-2015) and isa Subcommittee received many awards. ChairoftheISPDPeritonealDialysisOutcomesandPractice Patterns Study (PDOPPS). She was a Core member of the Financial Disclosure: In recent years, Dr Kopple has firstKDIGOChronicKidneyDisease-MineralBoneDisease been a consultant for Nephroceuticals and Dr. Schar (chronic Kidney disease-mineral and bone disorder) guidelines (2007-2009) and co-chaired the Company and has received grants from Shire Pharmaceufirst Kidney Disease: Improving Global Outcomes chronic Kidney disease-mineral and bone disorder Guideline Implementation Summit ticals and Affix Health. in Asia in 2018. She currently serves on the editorial boards of Journal of Daniel Teta, MD, PhD the American Society of Nephrology, Kidney International, Clinical JournaloftheAmericanSocietyofNephrology, Nephrology, Dialysis, and Dr. Teta is Professor of Nephrology at the University of Transplantation (Editor of Cardiovascular Section), American Lausanne, andHeadofthemultisiteServiceofNephrology ˇ JournalofNephrology, NephronClinicalPractice(AssociateEditor), at the Hopital du Valais, Sion, Switzerland. Dr. Teta has European Medical Journal-Nephrology (Editor-in-Chief), Renal authored 116 articles, including reviews and case reports, Replacement Therapy (Associate Editor), Journal of Renal Nutrition, and 4 book chapters. His research fields include adipocyJournal of Diabetes, Blood Purification and Kidney Medicine, etc. She tokines in renal disease, nutrition and metabolismin renal was previous Associate Editor of American Journal of Kidney diseases. He has given more than 150 lectures in national Diseases and International Editor of Clinical Journal of the and international meetings/congresses. Dr. Teta is coAmerican Society of Nephrology. She has published more than director of the Total Nutrition Therapy (TNT) Renal 150originalarticlesand10bookchaptersandgivenmore course, an international specialized course for renal spethan 100 invited lectures in international and regional cialists dedicated to nutrition in this setting. He is part of meetings. Her main research interests are on cardiovasthe educational committee of the International Society of cular, metabolic, andnutritionalcomplicationsinCKDand Renal Nutrition and Metabolism (ISRNM). Other leading Dialysis. commitmentsofDr.",
    "Other leading Dialysis. commitmentsofDr. Tetaincludearoleofthemeeditorfor nutrition in the journal Nephrology Dialysis TransFinancial Disclosure: Dr Wang has received speaker plantation, and a role of Vice-Chair of the European honoraria from Sanofi Renal and Fresenius Kabi. She has Nutrition Group of the European Renal Association. received research grants from Sanofi Renal and Baxter Healthcare Corporation. Disclosures: Dr Teta reports no relevant financial disclosures. Evidence Review Team Angela Yee-Moon Wang, MD, PhD, FRCP Mary Rozga, PhD, RDN DrWangwasgraduatedfromtheUniversityofNewSouth Dr Rozga is a Nutrition Researcher for the Evidence Wales, Sydney, Australia, and is an Honorary Associate Analysis Center at the Academy of Nutrition and Dietetics. Professor, Associate Consultant at the University of Hong Inthisrole, sheworksasasystematicreviewandguideline Kong, Queen Mary Hospital, Hong Kong. She was the methodologist and works with expert practitioners, rerecipient of the National Kidney Foundation Joel D. Kopple Award 2018, John F. searchers, and patient advocates on a wide variety of Maher Award of the International Society of Peritoneal nutrition topics to create evidence-based information for S90 AJKD Vol76Iss3Suppl1September2020 Biographic andDisclosure Information dietitians. Before this position, Dr Rozga worked in the Library (EAL). She has methodological expertise in conacademic setting with a focus on breastfeeding research, ducting systematic reviews and quantitative analysis in the includingprovidingpeer-counselingbreastfeedingsupport fieldofnutrition. InherpositionattheAcademyofNutrito Low-income women in the community setting. She has tionandDietetics, shehasledthedevelopmentofanumber served as an Assistant Professor at Bowling Green State of systematic reviews and clinical practice guidelines and University, where she created a masters course on Enviconductedresearchtoimproveevidence-basedmethodsfor ronmentalNutrition. DrRozgahaspublishedbothprimary the EAL. Dr Handu previously has served as the Dietetic and secondary research in peer-reviewed journals such as Internship Director at Edward Hines Jr. VA Hospital, DiThe Journal of the Academy of Nutrition and Dietetics, Public Health rector of the Master of Science in Nutrition and Wellness Nutrition, and the Maternal Child Health Journal. Dr Rozga program at Benedictine University, and Assistant Clinical earned a Bachelors degree in Dietetics from Central ProfessoratLoyolaUniversity. DrHandusresearchinterests Michigan University, a Masters degree in Nutrition lieintheareasofevidence-basedmethods/researchmethResearch from Bastyr University, and a PhD in Human odology, publichealthnutrition, youthoverweight prevaNutrition from Michigan State University, where she also lence and obesity risk, and Diabetes. Her work has been completed her dietetic internship. publishedinrefereedjournals, shehaspublishedabookon Research Methodology, and she has delivered numerous Financial Disclosure: Dr Rozga reports no relevant professional presentations at the local, state, and national financial relationships. level. DrHanduearnedherPhDinHumanNutritionfrom MichiganStateUniversity. Deepa Handu, PhD Dr Handu serves as a Senior Scientific Director for the Financial Disclosure: Dr Handu reports no relevant Academy of Nutrition and Dietetics Evidence Analysis financial relationships. AJKD Vol76Iss3Suppl1September2020 S91 SupplementaryMaterial SUPPLEMENTARY MATERIAL SupplementaryFile1(PDF) EvidenceSummaryTables Guideline1: Assessment TableS1. TechnicalDevicesAnthropometricMeasurementstoMeasureBodyComposition TableS2. LaboratoryMeasurementsofBodyComposition TableS3. HandgripStrength TableS4. MethodstoAssessEnergyRequirements TableS5. CompositeNutritionalIndicestoMeasureNutritionalStatusinCKDPatients TableS6. Tools/MethodsUsedtoAssessProteinIntakeandCalorieIntake Guideline2: MedicalNutritionTherapy TableS7. MedicalNutritionTherapy Guideline3: DietaryProteinandEnergyIntake TableS8. ProteinRestriction(ProteinRestrictionKAA; ProteinRestrictiononly) TableS9. ProteinTypeinCKD TableS10. DietaryPatterns(FruitsandVegetables; MediterraneanDiet) Guideline4: NutritionalSupplementation TableS11. NutritionalSupplementationOral, Enteral, andParentalNutrition TableS12. NutritionSupplementation-Dialysate TableS13. LongChainOmega-3PolyunsaturatedFattyAcids Guideline4: Micronutrients TableS14. Folicacid(withandwithoutBvitamins) TableS15. ThiaminwithvitaminB6 TableS16. VitaminB12 TableS17. VitaminC TableS18. VitaminD TableS19. VitaminE TableS20. VitaminK TableS21. Selenium TableS22. Zinc Guideline5: Electrolytes TableS23. Acid-Base TableS24. Calcium TableS25. Magnesium TableS26. Phosphorus TableS27. Potassium TableS28. Sodium S92 AJKD Vol76Iss3Suppl1September2020 References REFERENCES 1. InstituteofMedicine(ultrasound)CommitteeonStandards forDevel17. Nakao T, Kanazawa Y, Nagaoka Y, et al. Body Protein index opingTrustworthyClinicalPracticeGuidelines, GrahamR, MancherM, based on bioelectrical impedance analysis is a useful new marker MillerWolmanD, etal, eds. ClinicalPracticeGuidelinesWeCanTrust. assessing nutritional status: applications to patients with chronic Washington(DC): NationalAcademiesPress(ultrasound); 2011: 4. https: // renal failure on maintenance Dialysis. Contrib Nephrol. 2007; 155: www. ncbi. nlm. nih. gov/books/NBK209546/. Accessed May 24, 18-28. 2020. 18. AvesaniCM, DraibeSA, KamimuraMA, etal. Assessmentof 2. GuyattG, OxmanAD, SultanS, etal. GRADEguidelines: 11. body composition by dual energy x-ray absorptiometry, skinfold Makinganoverallratingofconfidenceineffectestimatesforasingle thicknessandcreatininekineticsinchronickidneydiseasepatients. outcome and for all outcomes. J Clin Epidemiol. 2013; 66(2): 151NephrolDialTransplant. 2004; 19(9): 2289-2295."
  ],
  "metadatas": [
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 0,
      "content_type": "dietary",
      "content_type_confidence": 5,
      "word_count": 396,
      "entity_count": 5,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,nutrition,micronutrients,monitoring,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 1,
      "content_type": "evidence",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 3,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "calcium,nutrition,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 3,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 600,
      "entity_count": 4,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,nutrition,nutritional assessment,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 4,
      "content_type": "dietary",
      "content_type_confidence": 6,
      "word_count": 598,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "nutrition,energy intake,micronutrients,dialysate,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 5,
      "content_type": "dietary",
      "content_type_confidence": 2,
      "word_count": 600,
      "entity_count": 5,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "potassium,calcium,phosphorus,vitamin D,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 6,
      "content_type": "reference",
      "content_type_confidence": 3,
      "word_count": 564,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,potassium",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 7,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 552,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,end-stage renal disease,creatinine,parathyroid hormone,nutrition,diet,low protein diet,dialysis,hemodialysis",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 8,
      "content_type": "dietary",
      "content_type_confidence": 8,
      "word_count": 574,
      "entity_count": 9,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,acute kidney injury,nutrition,diet,dietary protein,energy intake,dialysis,kidney transplant,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 9,
      "content_type": "dietary",
      "content_type_confidence": 7,
      "word_count": 576,
      "entity_count": 9,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,nutrition,diet,dietary protein,energy intake,nutritional assessment,micronutrients,exercise,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 10,
      "content_type": "dietary",
      "content_type_confidence": 6,
      "word_count": 600,
      "entity_count": 3,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,nutrition,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 11,
      "content_type": "dietary",
      "content_type_confidence": 10,
      "word_count": 595,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,sodium,potassium,calcium,phosphorus,magnesium,nutrition,micronutrients,dialysis,hemodialysis",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 12,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 586,
      "entity_count": 2,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "sodium,phosphorus",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 13,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 600,
      "entity_count": 1,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "guideline",
      "year": "2020",
      "organization": "Unknown",
      "section": "Evidencesummary:"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 14,
      "content_type": "dietary",
      "content_type_confidence": 8,
      "word_count": 590,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,creatinine,nutrition,malnutrition,dietitian,dialysis,peritoneal dialysis,edema,screening,monitoring",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 15,
      "content_type": "dietary",
      "content_type_confidence": 10,
      "word_count": 589,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,proteinuria,potassium,vitamin D,nutrition,diet,dietary protein,supplements,micronutrients,dialysis",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 16,
      "content_type": "dietary",
      "content_type_confidence": 10,
      "word_count": 580,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,proteinuria,sodium,potassium,calcium,phosphate,phosphorus,magnesium,bicarbonate,nutrition",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 17,
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "word_count": 538,
      "entity_count": 7,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,nutritional assessment,dialysis,hemodialysis,peritoneal dialysis,edema,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 18,
      "content_type": "dietary",
      "content_type_confidence": 5,
      "word_count": 596,
      "entity_count": 8,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,creatinine,nutritional assessment,supplements,dialysis,peritoneal dialysis,dialysate,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 23,
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "word_count": 598,
      "entity_count": 7,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,creatinine,nutrition,nutritional assessment,dialysis,screening,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 24,
      "content_type": "monitoring",
      "content_type_confidence": 5,
      "word_count": 582,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,creatinine,serum creatinine,nutritional assessment,supplements,dialysis,hemodialysis,peritoneal dialysis,edema,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 25,
      "content_type": "monitoring",
      "content_type_confidence": 3,
      "word_count": 593,
      "entity_count": 8,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,creatinine,urea,nutritional assessment,dialysis,peritoneal dialysis,dialysate,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 28,
      "content_type": "evidence",
      "content_type_confidence": 3,
      "word_count": 585,
      "entity_count": 9,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,kidney function,creatinine,nutritional assessment,dialysis,peritoneal dialysis,screening,monitoring,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 30,
      "content_type": "dietary",
      "content_type_confidence": 6,
      "word_count": 597,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,nutrition,energy intake,nutritional assessment,malnutrition,dietitian,dialysis,peritoneal dialysis,exercise,physical activity",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 31,
      "content_type": "monitoring",
      "content_type_confidence": 5,
      "word_count": 599,
      "entity_count": 7,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,nutrition,nutritional assessment,malnutrition,exercise,physical activity,screening",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 35,
      "content_type": "dietary",
      "content_type_confidence": 5,
      "word_count": 592,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,creatinine,urea,nutrition,nutritional assessment,malnutrition,dialysis,dialysis adequacy,screening,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 36,
      "content_type": "dietary",
      "content_type_confidence": 11,
      "word_count": 598,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,creatinine,urea,sodium,potassium,nutrition,dietary protein,energy intake,nutrient intake,micronutrients",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 37,
      "content_type": "dietary",
      "content_type_confidence": 9,
      "word_count": 580,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,creatinine,urea,sodium,potassium,blood urea nitrogen,nutrition,dietitian,dialysis,peritoneal dialysis",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 38,
      "content_type": "dietary",
      "content_type_confidence": 7,
      "word_count": 597,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,potassium,phosphate,nutrition,diet,potassium restriction,malnutrition,dialysis,peritoneal dialysis,cardiovascular disease",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 40,
      "content_type": "evidence",
      "content_type_confidence": 5,
      "word_count": 559,
      "entity_count": 7,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,nutrition,diet,low protein diet,patient education,adherence,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 41,
      "content_type": "dietary",
      "content_type_confidence": 6,
      "word_count": 587,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,kidney function,urea,nutrition,diet,energy intake,dialysis,exercise,adherence,quality of life",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 42,
      "content_type": "dietary",
      "content_type_confidence": 5,
      "word_count": 587,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,nephron,diet,dietary protein,energy intake,dialysis,peritoneal dialysis,physical activity,glycemic control,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 49,
      "content_type": "dietary",
      "content_type_confidence": 9,
      "word_count": 566,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,creatinine,nutrition,diet,dietary protein,low protein diet,energy intake,nutrient intake,statins,dialysis",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 50,
      "content_type": "dietary",
      "content_type_confidence": 7,
      "word_count": 594,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,proteinuria,creatinine,urea,sodium,calcium,phosphorus,diet,low protein diet,energy intake",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 52,
      "content_type": "dietary",
      "content_type_confidence": 10,
      "word_count": 592,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,sodium,potassium,calcium,phosphate,phosphorus,nutrition,diet,dietary protein,low protein diet",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 54,
      "content_type": "dietary",
      "content_type_confidence": 9,
      "word_count": 590,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,albuminuria,potassium,bicarbonate,diet,energy intake,dialysis,adherence,monitoring",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 56,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 570,
      "entity_count": 6,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,malnutrition,supplements,dialysis,peritoneal dialysis,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 57,
      "content_type": "dietary",
      "content_type_confidence": 5,
      "word_count": 579,
      "entity_count": 7,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,proteinuria,diet,low protein diet,dialysis,peritoneal dialysis,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 58,
      "content_type": "dietary",
      "content_type_confidence": 8,
      "word_count": 598,
      "entity_count": 9,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,calcium,phosphate,phosphorus,nutrition,energy intake,dialysis,peritoneal dialysis,anemia",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 60,
      "content_type": "dietary",
      "content_type_confidence": 8,
      "word_count": 594,
      "entity_count": 9,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,creatinine,energy intake,insulin,hemodialysis,ultrafiltration,fluid overload,monitoring,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 61,
      "content_type": "dietary",
      "content_type_confidence": 7,
      "word_count": 593,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,phosphate,bicarbonate,nutrition,dietary protein,energy intake,supplements,insulin,dialysis,hemodialysis",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 63,
      "content_type": "evidence",
      "content_type_confidence": 3,
      "word_count": 577,
      "entity_count": 7,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,supplements,dialysis,peritoneal dialysis,fistula,kidney transplant,cardiovascular disease",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 66,
      "content_type": "evidence",
      "content_type_confidence": 3,
      "word_count": 595,
      "entity_count": 3,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,dialysis,physical activity",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 67,
      "content_type": "dietary",
      "content_type_confidence": 4,
      "word_count": 594,
      "entity_count": 5,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,diet,micronutrients,dialysis,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 68,
      "content_type": "dietary",
      "content_type_confidence": 7,
      "word_count": 588,
      "entity_count": 8,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,diet,supplements,micronutrients,dietitian,dialysis,monitoring,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 69,
      "content_type": "dietary",
      "content_type_confidence": 6,
      "word_count": 596,
      "entity_count": 8,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,potassium,vitamin D,nutrition,supplements,micronutrients,dialysis,peritoneal dialysis",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 70,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 584,
      "entity_count": 8,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,magnesium,supplements,micronutrients,dialysis,peritoneal dialysis,stage 5,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 71,
      "content_type": "treatment",
      "content_type_confidence": 5,
      "word_count": 577,
      "entity_count": 9,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,magnesium,micronutrients,dialysis,peritoneal dialysis,anemia,cardiovascular disease,monitoring,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 72,
      "content_type": "evidence",
      "content_type_confidence": 4,
      "word_count": 576,
      "entity_count": 7,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,magnesium,micronutrients,dialysis,anemia,monitoring,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 73,
      "content_type": "evidence",
      "content_type_confidence": 4,
      "word_count": 589,
      "entity_count": 6,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,magnesium,uric acid,dialysis,peritoneal dialysis,quality of life",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 74,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 584,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,calcium,magnesium,vitamin D,micronutrients,dialysis,kidney transplant,anemia,monitoring,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 75,
      "content_type": "dietary",
      "content_type_confidence": 9,
      "word_count": 597,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,proteinuria,potassium,calcium,phosphorus,vitamin D,diet,micronutrients,dialysis,hemodialysis",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 77,
      "content_type": "evidence",
      "content_type_confidence": 7,
      "word_count": 590,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,albuminuria,proteinuria,calcium,phosphate,phosphorus,vitamin D,phosphate binders,supplements,dialysis",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 78,
      "content_type": "evidence",
      "content_type_confidence": 5,
      "word_count": 584,
      "entity_count": 9,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,magnesium,hemoglobin,nutrition,supplements,micronutrients,cardiovascular disease,heart failure,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 80,
      "content_type": "evidence",
      "content_type_confidence": 5,
      "word_count": 581,
      "entity_count": 9,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,potassium,magnesium,micronutrients,dialysis,anemia,cardiovascular disease,monitoring,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 81,
      "content_type": "dietary",
      "content_type_confidence": 6,
      "word_count": 575,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,acute kidney injury,glomerular filtration rate,creatinine,urea,potassium,calcium,supplements,micronutrients,dialysis",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 82,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 589,
      "entity_count": 9,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,potassium,magnesium,supplements,micronutrients,dialysis,hemodialysis,peritoneal dialysis,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 85,
      "content_type": "evidence",
      "content_type_confidence": 5,
      "word_count": 578,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,kidney function,nephron,creatinine,sodium,phosphate,bicarbonate,supplements,dialysis,kidney transplant",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 86,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 578,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,nephron,proteinuria,creatinine,sodium,bicarbonate,diet,dietary protein,supplements",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 88,
      "content_type": "dietary",
      "content_type_confidence": 5,
      "word_count": 541,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,renal function,potassium,calcium,bicarbonate,diet,dietary protein,supplements,dialysis,hemodialysis",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 89,
      "content_type": "dietary",
      "content_type_confidence": 7,
      "word_count": 576,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,kidney function,creatinine,potassium,calcium,phosphorus,magnesium,bicarbonate,vitamin D,diet",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 90,
      "content_type": "evidence",
      "content_type_confidence": 5,
      "word_count": 588,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,calcium,phosphate,phosphorus,magnesium,parathyroid hormone,vitamin D,calcitriol,diet,supplements",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 91,
      "content_type": "dietary",
      "content_type_confidence": 8,
      "word_count": 574,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,calcium,phosphate,phosphorus,vitamin D,diet,low protein diet,dialysis,kidney transplant",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 92,
      "content_type": "dietary",
      "content_type_confidence": 5,
      "word_count": 578,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,renal function,calcium,phosphate,phosphorus,magnesium,parathyroid hormone,dietary protein,dialysis,peritoneal dialysis",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 94,
      "content_type": "dietary",
      "content_type_confidence": 11,
      "word_count": 578,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,proteinuria,sodium,potassium,phosphate,phosphorus,chloride,parathyroid hormone,vitamin D,nutrition",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 95,
      "content_type": "dietary",
      "content_type_confidence": 9,
      "word_count": 597,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,sodium,potassium,phosphate,phosphorus,magnesium,diet,phosphate binders,dialysis,peritoneal dialysis",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 96,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 585,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": false,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,kidney failure,sodium,potassium,magnesium,diet,potassium restriction,insulin,hyperkalemia",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 97,
      "content_type": "dietary",
      "content_type_confidence": 10,
      "word_count": 563,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,proteinuria,sodium,potassium,diet,micronutrients,dietitian,renal dietitian,antihypertensive,dialysis",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 98,
      "content_type": "dietary",
      "content_type_confidence": 8,
      "word_count": 587,
      "entity_count": 8,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,proteinuria,sodium,diet,dietitian,dialysis,peritoneal dialysis,monitoring",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 99,
      "content_type": "evidence",
      "content_type_confidence": 6,
      "word_count": 568,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": true,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,glomerular filtration rate,proteinuria,sodium,diet,sodium restriction,dialysis,cardiovascular disease,heart failure,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 100,
      "content_type": "dietary",
      "content_type_confidence": 8,
      "word_count": 581,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,kidney function,proteinuria,creatinine,sodium,potassium,diet,sodium restriction,dialysis,hemodialysis",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 101,
      "content_type": "dietary",
      "content_type_confidence": 9,
      "word_count": 596,
      "entity_count": 10,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,renal failure,proteinuria,sodium,potassium,nutrition,diet,sodium restriction,dietitian,hemodialysis",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 102,
      "content_type": "dietary",
      "content_type_confidence": 5,
      "word_count": 596,
      "entity_count": 7,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,nutrition,diet,dietitian,renal dietitian,dialysis,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 103,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 594,
      "entity_count": 8,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,acute kidney injury,nutrition,dietitian,dialysis,kidney transplant,quality of life,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 104,
      "content_type": "dietary",
      "content_type_confidence": 3,
      "word_count": 574,
      "entity_count": 5,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,acute kidney injury,proteinuria,nutrition,dialysis",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 105,
      "content_type": "evidence",
      "content_type_confidence": 3,
      "word_count": 595,
      "entity_count": 8,
      "has_ckd": true,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "chronic kidney disease,kidney failure,nutrition,dialysis,hemodialysis,peritoneal dialysis,cardiovascular disease,guideline",
      "year": "2020",
      "organization": "Unknown"
    },
    {
      "source": "PIIS0272638620307265 (1).pdf",
      "chunk_id": 106,
      "content_type": "dietary",
      "content_type_confidence": 11,
      "word_count": 600,
      "entity_count": 10,
      "has_ckd": false,
      "has_gfr": false,
      "has_diabetes": false,
      "has_hypertension": false,
      "has_dialysis": true,
      "medical_entities": "renal failure,sodium,potassium,calcium,phosphorus,magnesium,nutrition,micronutrients,dialysis,dialysate",
      "year": "2020",
      "organization": "Unknown"
    }
  ],
  "ids": [
    "piis0272638620307265 (1)_0",
    "piis0272638620307265 (1)_1",
    "piis0272638620307265 (1)_3",
    "piis0272638620307265 (1)_4",
    "piis0272638620307265 (1)_5",
    "piis0272638620307265 (1)_6",
    "piis0272638620307265 (1)_7",
    "piis0272638620307265 (1)_8",
    "piis0272638620307265 (1)_9",
    "piis0272638620307265 (1)_10",
    "piis0272638620307265 (1)_11",
    "piis0272638620307265 (1)_12",
    "piis0272638620307265 (1)_13",
    "piis0272638620307265 (1)_14",
    "piis0272638620307265 (1)_15",
    "piis0272638620307265 (1)_16",
    "piis0272638620307265 (1)_17",
    "piis0272638620307265 (1)_18",
    "piis0272638620307265 (1)_23",
    "piis0272638620307265 (1)_24",
    "piis0272638620307265 (1)_25",
    "piis0272638620307265 (1)_28",
    "piis0272638620307265 (1)_30",
    "piis0272638620307265 (1)_31",
    "piis0272638620307265 (1)_35",
    "piis0272638620307265 (1)_36",
    "piis0272638620307265 (1)_37",
    "piis0272638620307265 (1)_38",
    "piis0272638620307265 (1)_40",
    "piis0272638620307265 (1)_41",
    "piis0272638620307265 (1)_42",
    "piis0272638620307265 (1)_49",
    "piis0272638620307265 (1)_50",
    "piis0272638620307265 (1)_52",
    "piis0272638620307265 (1)_54",
    "piis0272638620307265 (1)_56",
    "piis0272638620307265 (1)_57",
    "piis0272638620307265 (1)_58",
    "piis0272638620307265 (1)_60",
    "piis0272638620307265 (1)_61",
    "piis0272638620307265 (1)_63",
    "piis0272638620307265 (1)_66",
    "piis0272638620307265 (1)_67",
    "piis0272638620307265 (1)_68",
    "piis0272638620307265 (1)_69",
    "piis0272638620307265 (1)_70",
    "piis0272638620307265 (1)_71",
    "piis0272638620307265 (1)_72",
    "piis0272638620307265 (1)_73",
    "piis0272638620307265 (1)_74",
    "piis0272638620307265 (1)_75",
    "piis0272638620307265 (1)_77",
    "piis0272638620307265 (1)_78",
    "piis0272638620307265 (1)_80",
    "piis0272638620307265 (1)_81",
    "piis0272638620307265 (1)_82",
    "piis0272638620307265 (1)_85",
    "piis0272638620307265 (1)_86",
    "piis0272638620307265 (1)_88",
    "piis0272638620307265 (1)_89",
    "piis0272638620307265 (1)_90",
    "piis0272638620307265 (1)_91",
    "piis0272638620307265 (1)_92",
    "piis0272638620307265 (1)_94",
    "piis0272638620307265 (1)_95",
    "piis0272638620307265 (1)_96",
    "piis0272638620307265 (1)_97",
    "piis0272638620307265 (1)_98",
    "piis0272638620307265 (1)_99",
    "piis0272638620307265 (1)_100",
    "piis0272638620307265 (1)_101",
    "piis0272638620307265 (1)_102",
    "piis0272638620307265 (1)_103",
    "piis0272638620307265 (1)_104",
    "piis0272638620307265 (1)_105",
    "piis0272638620307265 (1)_106"
  ]
}